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 1 General Introduction 
1.1 The liver 
1.1.1 Anatomy and physiology 
The liver is the largest internal organ of the body with an average weight of 1500 g (~ 2.5% of 
body weight). The organ is located below the diaphragm in the upper right quadrant of the 
abdominal cavity, between the organs of the gastrointestinal tract and the heart, linked to 
portal and general circulation, respectively [1]. The portal vein carries the nutrient-enriched 
venous blood from the small intestine, stomach, pancreas, and spleen and constitutes the 
main blood flow entering the liver (~ 75% of blood supply). Additionally, the hepatic artery, 
branching from the celiac trunk and descending aorta, supplies the liver with oxygen 
enriched arterial blood (~ 25% of blood supply). Terminal branches of both vessels join in the 
capillary bed of the liver where the arterial and venous blood is mixed as it enters the 
sinusoids. The blood leaves the sinusoids via central veins, which coalesce into hepatic 
veins and finally empty into the inferior vena cava [2] (Figure 1.1). 
The falciform ligament divides the liver in the right and left lobe, the right lobe being the 
larger (Figure 1.1). Each liver lobe is divided by the right and left hepatic veins into anterior 
and posterior (right lobe) and medial and lateral (left lobe) sections. Finally, the Couinaud 
classification further subdivides the sections into eight functionally independent segments. 
The smaller caudate and quadrate lobes are located posteriorly [2] (Figure 1.1). 
 
Figure 1.1: Gross anatomy of the liver: anterior and posterior views. Encyclopædia Britannica 
Online. http://www.britannica.com/EBchecked/media/68633/Anterior-and-posterior-
views-of-the-liver. 
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The basic functional unit of the liver is the lobule [3] (Figure 1.2). The hexagonal lobule 
largely consists of interconnected plates of hepatocytes, which are separated by the 
sinusoids. At the corner of each lobule, three vessels form the portal triad containing 
branches of the hepatic artery, portal vein, and bile ducts. From a metabolic point of view, the 
liver ascinus is the smallest functional unit. Each ascinus consists of hepatocytes aligned 
around the portal canal and the central veins lying at the corner. Corresponding to the 
distance from arterial blood supply, the ascinus is divided in three zones: the periportal zone 
1 directly around the portal canal, the zone 2 in further distance to the arterial blood supply, 
and the centrilobular zone 3 nearest to the central veins [4]. 
 
Figure 1.2:  Left: The liver lobule with the portal triad, sinusoids, bile canaliculi, and the 
collecting central vein. http://www.dnwalcker.com/Laboratory11and12.html. Right: 
More detailed view of the liver sinusoidal structure with the involved cell types. 
http://www.vetscite.org/publish/articles/000074/index.html. 
Hepatocytes are highly specialized cells, which represent 60% of the liver cells and account 
for about 80% of the liver’s total cell mass [4]. Most of the liver’s metabolic and synthetic 
functions are performed by these cells [5]. They have an average life span of 5 months and 
the ability to regenerate. The radial orientated plates of hepatocytes are separated by 
vascular channels (sinusoids), in which the blood from the portal arteriole and venule flows 
towards the central vein (Figure 1.2). Via the perisinusoidal space of Disse, the surface areas 
of the hepatocytes get in contact to nutrients and toxins that are transported within the blood. 
On the opposite site, the hepatocyte plates line the bile canaliculi. Secreted bile is 
transported back towards the portal canal, drains into a series of bile ducts, and finally 
empties via the common bile duct into the gallbladder to become available for digestive 
processes in the intestine [6]. 
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The sinusoidal endothelial cells separate the sinusoids from the space of Disse. The 
fenestration of these cells allows the exchange of plasma, proteins, nutrients, xenobiotics, 
and oxygen between both sides [7]. 
Kupffer cells are resident macrophages in the sinusoids. They have an important function in 
removing bacteria, virus particles, fibrin-fibrinogen complexes, and damaged erythrocytes 
from circulation by phagocytosis. They also break down heme into bilirubin, which is the main 
pigment of the bile [8]. 
Stellate cells (Ito cells) are located in the perisinusoidal space of Disse. Their major task is to 
store vitamin A in intracellular lipid droplets [9]. Persistent hepatic inflammation leads to 
activation of quiescent hepatic stellate cells transforming them into proliferative, fibrinogenic, 
and contractile myofibroblasts (see chapter 4.1.1). Activated hepatic stellate cells play a 
central role in the pathological process of hepatic fibrosis [10]. 
 
The liver fulfills a multitude of different tasks including synthetic, excretory, metabolic, 
endocrine, and storage functions [11]. Amongst others, the liver is responsible for bile 
production and excretion [6]. Via enterohepatic circulation, 95% of the bile acids are regained 
by recuperation from the terminal ileum, returned to the liver, re-uptaken into hepatocytes 
and excreted into the bile again. Only 400-500 mg of bile acids are produced per day, 
balancing the fecal loss [12]. Cholesterol is the starting molecule in the synthesis of bile 
acids. The formation of bile acids encloses hydroxylation, modification of the sterol ring, 
shortening of the side chain, and conjugation to glycine or taurine. The amphiphilic properties 
of bile acids support the digestion of nutritional components and the excretion of lipophilic 
compounds (such as cholesterol) by the formation of micelles. Therefore, the liver is mainly 
responsible for the cholesterol homeostasis [13]. 
Hepatocytes play a crucial role in the metabolism of drugs and xenobiotics [14]. The 
biotransformation reactions intend to render molecules more hydrophilic and consequently 
facilitate their excretion. The phases of drug metabolism and involved catalyzing enzymes 
are introduced in detail in chapter 5.1.1. 
The liver is also responsible for the metabolism of carbohydrates, lipids, and proteins. 
Maintenance of blood glucose levels (~ 70-100 mg/dL) is a main function of the liver [15]. 
Glycogenesis, glycogenolysis, and gluconeogenesis are hormonally regulated by insulin and 
glucagon. Glycogen is the main carbohydrate store in the liver. After uptake of glucose by 
hepatocytes, the enzyme glucokinase catalyzes the phosphorylation of glucose to form 
glucose-6-phophate. Depending on the energy requirement, glucose-6-phosphate is further 
converted and provided for glycogen synthesis or used for energy production by the 
glycolytic pathway. Also other monosaccharides like fructose and galactose can be 
enzymatically transformed to join the glycolytic pathway. 
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Furthermore, metabolism of lipids, lipogenesis and lipoprotein synthesis are regulated by the 
liver [16]. One the one hand, fatty acids from plasma can be broken down in mitochondria of 
hepatocytes by β-oxidation to provide energy. On the other hand, synthesis of fatty acids is 
carried out in the hepatocellular cytosol. The liver is responsible for the synthesis, secretion, 
and the catabolism of lipoproteins [17]. Most of the circulating proteins are synthesized by 
hepatocytes including cargo proteins such as albumin, immune-related proteins (components 
of the complement system, acute-phase proteins), and coagulation factors [6]. The liver is 
involved in the synthesis and interconversion of nonessential amino acids from essential 
amino acids and in the formation of ketone bodies. 
Moreover, the liver regulates the endocrine function of hormones [11]. As an essential step in 
hormone activation, the liver is the major site of conversion of vitamin D3 to 25-hydroxy 
vitamin D3, and thyroxine (T4) to the biologically more active triiodothyronine (T3). The liver 
modifies the function of growth hormones and constitutes the major organ for the removal of 
peptide hormones. Additionally, it is the main storage site for fat-soluble vitamins (vitamin A, 
vitamin D), vitamin B12, iron, and copper [6]. 
1.1.2 Liver function tests 
Liver function can be determined by means of several blood tests measuring the 
concentration of a variety of proteins and enzymes that are either produced by liver cells or 
that are released after liver cell damage [18]. Assessment of liver function includes the 
determination of prothrombin time (PT) and serum albumin levels. Both prolonged PT and 
decreased serum albumin may reflect liver dysfunction. Elevated alanine amino transferase 
(ALT) and aspartate amino transferase (AST) indicate liver cell damage. Increased bilirubin 
occurs in haemolysis, biliary obstruction, hepatitis, and cirrhosis and becomes apparent in 
form of jaundice. In biliary obstruction, alkaline phosphatase (ALP) levels may be elevated. 
Elevated gamma glutamyl transpeptidase (GGT) can be observed in diseases of the liver, 
biliary system or pancreas, as well as after significant alcohol consumption, and the use of 
several drugs. 
1.1.3 Liver diseases 
The term liver disease (hepatic disease) includes all kind of damage or impairment of the 
liver which leads to restriction or loss of organ function. The duration of liver disorders 
constitutes one way to classify hepatic diseases. Acute liver disease may be displayed in 
acute inflammation provoked by different noxae including intoxication or acute infections [19]. 
Chronic hepatic diseases can be caused by chronic infections with hepatotropic viruses 
(HBV, HCV), alcohol or drug abuse, autoimmune reactions, and metabolic disorders [19]. 
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Hepatitis (hepatic inflammation) can have several causes, virus infections and alcoholism 
being the most common. Hepatitis A virus (HAV) infection induces acute liver inflammation, 
which is usually followed by complete recovery of the organ. Due to improvement of hygiene 
and sanitation coupled with economic and social advancement, the incidence of hepatitis A is 
declining in most European countries [20]. Hepatitis B virus (HBV) and hepatitis C virus 
(HCV) can cause chronic liver infections and constitute main risk factors for the development 
of hepatocellular carcinoma (HCC). According to a recent review, hepatitis B has a 
prevalence of 0.5-0.7%, and hepatitis C of 0.13-3.26% in Europe [20]. To date, vaccines are 
available for HAV and HBV. Interferons (IFN-α2a, INF-α2B) constitute the most established 
anti-viral treatment in hepatitis B and C infections.  
Alcohol is the main cause of liver disease, including liver cirrhosis. In Europe, over 20% of 
the population aged ≥ 15 years report heavy episodic drinking at least once a week [20]. 
Alcoholic liver disease can be differentiated by three major histological stages: alcoholic 
steatosis (fatty liver), acute alcoholic hepatitis, and alcoholic cirrhosis [21]. Steatosis is 
considered as a reversible condition, which is characterized by the intracytoplasmic 
accumulation of triglycerides in liver cells. Alcohol abuse can cause acute and chronic 
hepatitis accompanied by hepatocellular injury, inflammation, and fibrosis. Alcoholic hepatitis 
can be reversed by strictly abstaining from alcohol. Continuous alcohol abuse leads to 
chronic inflammation, fibrogenesis, and alcoholic cirrhosis at late stage [22]. 
Besides of alcohol, other factors such as obesity and insulin resistance can cause fatty liver 
disease. Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of 
liver fat exceeding 5% of hepatocytes in the absence of significant alcohol intake, viral 
infection, or any other defined cause of liver injury [23]. The more severe non-alcoholic 
steatohepatitis (NASH) is accompanied by hepatocellular damage, inflammation, and fibrosis 
[24]. 
Hepatic fibrosis (see chapter 4.1.1) is the most common manifestation of most types of 
chronic liver injury leading to cirrhosis in progressive stages [25]. According to World Health 
Organization (WHO) reports, cirrhosis accounts for 1.8% of all deaths in Europe [20]. 
Complete pictured cirrhosis is considered to be irreversible and is characterized by loss of 
hepatocyte activity, the excessive formation of fibrous scars, and inhibited blood flow leading 
to portal hypertension. 
Persistent hepatocellular damage and chronic inflammation may finally be responsible for the 
development of primary liver cancer. However, most of the liver cancers develop secondarily 
out of metastases from primary tumors of other organs. HCC constitutes the most important 
type of primary liver cancer, representing 70-90% of all cases [26]. In 80% of the patients, 
HCC is associated with liver cirrhosis [20]. HCC is one of the most common cancers 
worldwide with over half a million new cases each year and highest incidence rates in 
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Southeast Asia and Africa. HBV and HCV infections constitute the most prominent risk 
factors for the development of HCC; other risk factors include chronic alcohol abuse, 
metabolic liver disease, aflatoxins, and other cirrhosis-inducing conditions [26]. Liver cancer 
has a high mortality rate because of the lack of efficient therapies (46 801 deaths per annum 
in Europe according to WHO mortality database) [20]. 
Drug-induced liver injury (DILI) is the most common cause of cancelled drug development or 
withdrawal of already approved drugs [27,28]. DILI can be classified into intrinsic/predictable 
hepatotoxicity and idiosyncratic/unpredictable hepatotoxicity. The intrinsic form of injury 
develops in all or most recipients provided adequate up-take of the drug (dose-dependent; 
e.g. acetaminophen). However, a large percentage of DILI occurs as an idiosyncratic toxicity 
underlying immunoallergic mechanisms or metabolic aberrations in individual patients. Risk 
factors, prevalence, and incidence are still only partly known. Gender, age, genetic 
disposition, pre-existing conditions such as diabetes mellitus, and alcohol use are considered 
as probable influencing factors [29]. 
1.2 Herbal hepatoprotectives 
Liver diseases (see chapter 1.1.3) like viral hepatitis, alcoholic liver disease, NAFLD, and 
HCC constitute a major health burden worldwide affecting humans of all ages. Current 
therapies are often limited in efficacy, connected to adverse effects, and they are often very 
expensive. Hence, new therapeutic approaches such as the use of herbal medicine are of 
great common interest. The treatment of liver diseases with medicinal plants or herbal drugs 
has a long tradition, especially in eastern countries [30]. In scientific literature, the list of 
herbal constituents and preparations with claimed hepatoprotective properties is continuously 
getting longer. The mechanisms of hepatoprotection of these compounds include a variety of 
effects such as anti-oxidant, anti-viral, anti-fibrotic, anti-inflammatory, anti-carcinogenic, and 
immunomodulatory activities [31]. However, only for a few standardized extracts or herbal 
compounds, evident data of experimental pharmacology, animal studies or clinical trials are 
currently available. In particular, for most herbal drugs there is a lack of randomized clinical 
trials with well-selected end-points, powerful sample size, and comparison to placebo or 
conventional treatment which proof the efficacy and safety [32,33]. The current status of 
clinically evaluated hepatoprotective herbal remedies has recently been reviewed [34]. 
Standardization of herbal medicines and identification of active constituents is a general 
problem as well. Nevertheless, a number of herbals is quite extensively investigated and 
shows promising effects in vitro and in vivo [30–32,35].The most important hepatoprotective 
herbal “leads” are shortly presented in the following. 
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1.2.1 Silymarin 
Milk thistle (Silybum marianum (L.) GAERTN.) constitutes the most researched plant for the 
treatment of liver diseases and has been already used in the 16th century for this purpose 
[30]. Silymarin, the active principle of the drug, is a mixture of different flavonolignans, mainly 
silibinin (60-70%), silydianin, and silychristin [36] (Figure 1.3). Pharmaceutically used 
extracts are standardized to silibinin, which constitutes the biologically most active 
constituent and is a diastereomeric mixture of silybin A and silybin B (Figure 1.3.). 
Figure 1.3: Structures of silybin A (1), silybin B (2), silydianin (3), and silychristin (4). 
The pharmacological profile of silymarin has been extensively investigated both in vitro and 
in vivo [37]. Its biological activities comprise anti-oxidant, radical scavenging, anti-fibrotic, 
anti-inflammatory, membrane stabilizing, and regenerative effects [38]. In various 
experimental studies, silymarin has shown protective activity against several hepatotoxins 
including carbon tetrachloride (CCl4), acetaminophen, ethanol, and Amanita phalloides toxins 
[33]. Silymarin is clinically used to treat Amanita mushroom poisoning, drug-induced liver 
disease, alcoholic liver disease, and acute and chronic viral hepatitis [39]. The oral dosage 
form is coated tablets or capsules containing standardized extract. Around 20-40% of 
silymarin is excreted via bile in form of glucuronides and sulfates. In human, Cmax is reached 
after 4-6 h and tmax is approximately 6 h [39]. 
Numerous clinical trials of different outcome and quality have been performed to evaluate the 
efficacy and safety of milk thistle in treating liver diseases. Several systematic reviews and 
meta-analyses deal with the evaluation of clinical trial outcomes [40,41]. Treatment with 
silymarin is considered to be safe and well-tolerated. However, the definition of valuable end 
points is considered as major problem. Rating previous data, no reduction of mortality could 
be found with milk thistle treatment. Further randomized, controlled clinical trials with longer 
duration and bigger sample size are required to finally proof the efficacy of silymarin for 
treatment of chronic liver diseases. 
(4) (3) 
(1) (2) 
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1.2.2 Glycyrrhizin 
Glycyrrhizin (Figure 1.4) is a synonym for a mixture of Ca2+ and K+ salts of glycyrrhizic acid 
as well as for an aqueous extract of licorice root (Glycyrrhiza glabra L.) containing 
glycyrrhetic acid, flavonoids, hydroxycoumarins, and β-sitosterol. A Japanese preparation, 
stronger neominophagen C (SNMC), contains glycyrrhizin in combination with cysteine and 
glycine and is used as a parenteral drug for treatment of chronic hepatitis [33]. 
 
Figure 1.4: Structure of glycyrrhizic acid. 
In animal studies, a protective effect against CCl4-induced liver injury could be shown [42]. 
The hepatoprotective activity of glycyrrhizin is mainly attributed to its anti-oxidant, anti-
inflammatory, and immunomodulatory activities [31]. In vitro, glycyrrhizin inhibited CD+-T-cell- 
and TNF-mediated cytotoxicity [43]. Furthermore, it showed membrane-stabilizing effects 
and stimulated the endogenous production of interferon (INF) [33]. Glycyrrhizin altered the 
glycosylation and blocked the sialylation of hepatitis B surface antigen (HBsAg) in cell culture 
experiments [44]. Anti-inflammatory properties could be mediated by inhibition of 11-beta-
hydroxysteroid dehydrogenase activity and prostaglandin E2 (PGE2) production in 
macrophages [45]. Anti-oxidant properties may be attributed to the induction of glutathione-
S-transferase and catalase [45]. Moreover, glycyrrhizin showed anti-fibrotic activities in CCl4 
treated rats by inhibition of NF-κB pathways [46]. Clinical trials have been performed as well 
mainly investigating the effects of SNMC on viral hepatitis B and C infections [32]. Taken 
together, anti-viral activity of glycyrrhizin could not be demonstrated. Beneficial effects 
regarding biochemical reposes (liver function test) may rather be ascribed to its anti-
inflammatory and cytoprotective effects. Other trials evaluated the efficacy of SNMC in 
treatment of subacute liver failure or cirrhosis. For subacute liver failure, survival rate of the 
glycyrrhizin-treated group was higher compared to historical control data [47]. In cirrhotic 
patients, biochemical parameters were mostly improved by glycyrrhizin treatment, however, 
there was no effect on mortality or HBV or HCV clearance [33]. Glycyrrhizin may cause 
mineralocorticoid adverse reactions like high blood pressure, water and salt retention, and 
hypokalemia. To date, treatment of liver diseases with glycyrrhizin is not recommended due 
to the lack of evident benefit. 
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1.2.3 Curcumin 
The yellow-colored curcumin (Figure 1.5) is a major constituent of turmeric rhizome 
(Curcuma spp.). The hepatoprotective effects of curcumin were addressed in several in vitro 
and in animal studies. Curcumin possesses a wide range of biological activities including 
potent anti-oxidant, radical scavenging, and anti-inflammatory effects, to mention just the 
most important ones [31,38,48]. 
 
Figure 1.5: The keto- (1) and enol-form (2) of curcumin. 
As a potent inhibitor of cytochrome P450 enzymes (CYP450), curcumin can prevent the 
metabolic activation of toxic chemicals [49]. Curcumin increases the activity of glutathione-S-
transferase which may support liver detoxification [48]. By inhibition of NF-κB signaling 
pathways, curcumin prevented alcohol-induced liver disease and diet-induced steatohepatitis 
in animals [48]. Furthermore, curcumin demonstrated hepatoprotective effects against liver 
damage induced by toxins like CCl4 [50]. It showed also anti-fibrotic effects by inhibition of 
hepatic stellate cells (HSC) activation and proliferation [51]. Moreover, it altered the 
expression of matrix metalloproteinase and decreased the deposition of extracellular matrix 
(ECM) in hepatocytes [52]. Additionally, curcumin modulated TGF-β signaling and reduced 
levels of pro-inflammatory cytokines such as INF-α, TNF-α, and IL-6 [53]. 
After oral administration, curcumin is poorly absorbed. It is conjugated to glucuronic acid and 
sulfate and is metabolized to tetrahydrocurcumin (active metabolite), hexahydrocurcumin, 
and hexahydrocurcuminol. Conjugated metabolites of tetrahydrocurcumin are found as well 
[38]. Safety studies detected no signs of toxicity in human (100 mg/day) and rats (5 g/day) 
[48]. Curcumin is poorly soluble in water, has a low oral bioavailability, and is sensitive to 
light and temperature which may lower its pharmaceutical use as single component. The 
hepatoprotective activities have not been evaluated in controlled clinical trials yet. 
1.2.4 Phyllanthus 
Plants of the genus Phyllanthus are found in tropical and subtropical regions and are 
traditionally used in Ayurvedic and folk medicine to treat liver disorders. Polyphenols and the 
lignans phyllantin and hypophyllantin are considered as pharmacologically active 
constituents [31] (Figure 1.6). 
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Figure 1.6: Structures of phyllantin (1) and hypophyllantin (2). 
Results of experimental pharmacology imply activity against HBV infection by interference 
with polymerase activity, mRNA transcription and replication [32]. In primary cultured 
hepatocytes, the lignans showed hepatoprotective effects against CCl4 and galactosamine-
induced toxicity [54]. Several clinical trials have addressed the beneficial effects of 
Phyllanthus extracts in patients with chronic HBV infection. A systematic review including 22 
randomized, controlled clinical trials has revealed positive effects on clearance of serum 
HBsAg compared with placebo or no intervention, while there was no significant difference to 
interferon treatment [55]. Noteworthy, a combination of Phyllanthus and interferon seemed to 
enhance the effects. However, other clinical trials found no beneficial effects of Phyllanthus 
treatment in HBV carriers. To date, treatment of HBV patients with Phyllanthus is not 
recommended due to the lack of prospective large-scale controlled trials and long-term 
safety studies. In addition, active ingredients and modes of action have to be further 
elucidated. 
1.2.5 Other herbal hepatoprotectives 
Several herbal preparations form Japanese traditional medicine (Kampo) and Chinese 
traditional medicine (TCM) are used to treat liver diseases [32]. The Kampo-formula TJ-9 
(sho saiko-to), a combination of seven herbs, shows anti-fibrotic activity inhibiting the 
proliferation and transformation of HSC in vitro and in vivo. A long-term prospective study in 
HBV carriers found significant lower development of HCC with treatment of 7.5 g/day of an 
aqueous TJ-9 extract and INF within 5 years [56]. The TCM drug ‘compound 861’, a mixture 
of 10 herbs, exhibits anti-fibrotic activity in vitro [32]. Controlled trials in HBV positive patients 
reported beneficial effects on liver fibrosis and liver enzyme levels, but no clearance of 
HBsAg [32]. The Ayurvetic medicine Liv.52 (combination of herbs) is marked in India for the 
therapy of chronic liver diseases, however, most of the claimed activities are not assured by 
well-planed randomized clinical trials [57]. An alcoholic root extract from Picrorhiza kurroa 
ROYLE EX BENTH (‘Picroliv’) containing the iridoid glycosides picroside and kutkoside is used 
in India as a hepatoprotective drug [31]. In experimental studies, trans-resveratrol (3,4,5’-
trans-trihydroxystilbene) has shown promising anti-fibrotic and hepatoprotective effects due 
to its anti-oxidant and anti-inflammatory properties [38]. The efficacy of resveratrol has not 
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been evaluated in clinical studies yet. Andrographolide, a labdane diterpene lactone from 
Andrographis paniculata (BURM.F.) WALL. EX NEES, exhibits protective effects against toxin-
induced liver damage and choleretic activity in rats [31]. For a huge variety of natural 
compounds and herbal extracts, hepatoprotective effects were demonstrated in hepatocyte 
cultures or in animal studies. Results were compiled in several reviews [31,48,57,58]. 
1.3 Herbal hepatotoxicity 
Worldwide, the popularity of herbal products is increasing, especially with regard to self-
medication, dietary supplements, and life-style products [27,59,60]. In many countries, the 
use of herbal preparations does not underlie prescription regulations and quality standards 
may not be fulfilled due to insufficient labeling or missing regulatory requirement. Several 
herbal drugs have been identified to cause adverse hepatic reactions such as acute and 
chronic hepatitis, hepatic fibrosis, bile duct injury, venoocclusive disease (VOD), cholestasis, 
drug-induced autoimmunity, vascular lesion, and even hepatic necrosis and liver failure [61]. 
Besides direct herbal hepatotoxicity, herb-herb and herb-drug interactions have to be 
considered for a full assessment of adverse effects [62,63]. The identification of the 
responsible toxin in herbal remedies often remains a very difficult issue as preparations often 
contain several ingredients or even represent mixtures of various herbs or herbal extracts. 
Besides, herbal preparations of doubtful origin may be contaminated with microorganism, 
fungal toxins, heavy metals, pesticides, and synthetic drugs. In the last decades, several 
herbal drugs were made responsible for hepatotoxic events [64]. They are shortly presented 
in the following. 
1.3.1 Pyrrolizidine alkaloids 
The dose-dependent hepatotoxicity of plants from Senecio, Heliotropium, Crotalaria, and 
Symphytum species containing pyrrolizidine alkaloids (PA) is known for more than 90 years 
when ‘Senecio disease’ was first reported in South Africa [65]. PA poisoning of children was 
reported in Jamaica after the ingestion of ‘bush tea’ containing Crotalaria species [66]. In 
India [67] and Afghanistan [68] several cases of liver injury were attributed to food 
contamination (e.g. cereals, wheat flour) with toxic weeds (Crotalaria or Heliotropium 
species). PA intoxication was likewise reported in Europe [69] and the US [70,71] (Senecio 
and Comfrey poisoning). The liver injury caused by PA is mainly reflected in the VOD. The 
acute manifestation of VOD (also called sinusoidal obstruction syndrome) may come along 
with abdominal pain, ascites, hepatomegaly, elevated ALT, and jaundice [72]. Pathologically, 
the clinical picture resembles the Budd-Chiari syndrome. Non-thrombolytic obstruction of 
terminal centrilobular veins leads to a post-sinusoidal block and elevated sinusoidal 
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pressure. Damage of sinusoidal endothelial cells contributes to partial obstruction of the 
sinusoids, permitting erythrocytes to enter the space of Disse. Altogether, this results in 
hepatic congestion and centrilobular necrosis leading either to acute liver failure or liver 
fibrosis and cirrhosis. The mechanism of hepatotoxicity was assessed in animal studies. The 
hepatotoxicity of PA probably can be attributed to the biotransformation into reactive pyrrole 
derivatives which act as alkylating agents and hepatocarcinogens [73]. Indeed, the 
hepatotoxicity of PA was enhanced by co-administration of phenobarbital, a potent inducer of 
CYP450 isoenzymes [74]. This further supports the hypotheses that PA’s hepatotoxicity is 
due to metabolic toxification. 
1.3.2 Germander 
Germander (Teucrium chamaedrys L.) has been used as a traditional herbal remedy for its 
choleretic and antiseptic properties for more than 2000 years. Considered as completely 
safe, Germander preparations were approved in France in 1986 as an adjuvant to treat 
obesity and mild diarrhea [60]. In 1992, several cases of germander-associated acute, 
chronic, and even fulminant hepatitis were reported to the French pharmacovigilance 
authorities, which led to the withdrawal of germander preparations from the drug market [75]. 
Usually, hepatitis appeared after a daily intake of 600-1600 mg for 2 months [60]. Mostly, 
signs of acute cytolytic hepatitis were present and reflected in hyperbilirubinemia, elevated 
aminotransferase levels, and impaired synthetic function. However, some patients developed 
chronic hepatitis, fibrosis, and cirrhosis. Most of the patients recovered after the 
discontinuation of germander treatment. Accidental re-exposure caused the recurrence of 
liver injury. Germander contains saponins, glycosides, flavonoids, and a number of furano 
neoclerodane diterpenoids [60]. Loeper et al. evaluated the liver toxicity of germander in 
mice and could show the formation of electrophilic metabolites from furano diterpenoids by 
cytochrome P450 3A [76]. Furthermore, induction of CYP3A and GSH depletion enhanced 
the toxicity. In vitro, the reactive metabolites induced apoptosis of hepatocytes [77]. 
A case of fulminant hepatic failure requiring liver transplantation was reported in a 37-year-
old female after intake of tea made from the Mediterranean plant Teucrium polium L. [78]. 
1.3.3 Kava 
Kava kava (Piper methysticum FORST.) is a traditional psychoactive beverage used for socio-
ceremonial, spiritual, and medicinal purposes in Hawaii, Polynesia, and the Fiji Islands. 
Standardized organic kava root extracts and other kava-containing products were marketed 
for the treatment of anxiety disorders, depression, and as a sleeping aid all over the world. 
Despite of still inconclusive data on this issue, case reports of severe hepatotoxic side effects 
(hepatic necrosis, cholestatic hepatitis, liver failure) led to withdrawal of kava-containing 
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preparations in several countries (for an overview see [64,79,80]). To date, the mechanisms 
and elicitors of the putative hepatotoxic side effects still remain unclear. Kava’s constituents, 
pharmacology, and toxicity are extensively discussed in chapter 3.1 and 3.3.3. 
1.3.4 Chaparral 
Chaparral (Larrea tridentate (DC.) COVILLE) commonly known as ‘creosote bush’ or 
‘greasewood’ originates from Southwestern United States and Mexico and is used as a 
herbal remedy by the Native Americans to treat various conditions like common colds, bone 
and muscle pain, bronchitis, and snakebites [81]. Commercially, chaparral plant extracts are 
available as tablets, capsules, and salves for the treatment of skin disorders, as well as for 
weight-reducing, anti-inflammatory, and ‘blood-purifying’ properties. Chaparral preparations 
are even applied in alternative treatment of AIDS [81]. Since 1990, the Food and Drug 
Administration (FDA) evaluated several reports of chaparral toxicity. Sheikh et al. reviewed 
the chaparral-associated toxicity in 18 patients [82]. Liver injury was evident in 13 patients 
ranging from mild hepatitis to cirrhosis and even fulminant liver failure. Mostly, cholestatic 
hepatitis with elevated serum transaminase and ALP, and hyperbilirubinemia appeared 
within 3 to 52 weeks of intake. Mechanism of toxicity is not fully understood yet. Chaparral 
contains flavonoids, volatile oil, amino acids, lignans, and other compounds [59]. Toxicity 
might be attributed to the active ingredient nordihydroguaiaretic acid, which inhibits 
cyclooxygenase (COX) and CYP450 enzymes [83]. However, also idiosyncratic/immune-
mediated mechanisms are discussed. The causality of chaparral-associated toxicity is quite 
clearly estimated because of temporal correlation between intake and appearance of liver 
injury, and because re-exposure leads to relapse of clinical signs. 
1.3.5 Atractylis gummifera, Callilepis laureola 
In the Mediterranean region, the whitish gummy fluid secreted by the thistle Atractylis 
gummifera L. is used for its antipyretic, emetic, and diuretic activities and it is also enjoyed by 
children as a chewing gum [60]. Few hours after ingestion, acute toxicity can become 
apparent in unspecific symptoms such as nausea, abdominal pain, anxiety, diarrhea, and 
headache [84]. The clinical picture includes hepatorenal failure and hypoglycemia due to 
inhibited gluconeogenesis. Two constituents, atractyloside and gummiferin, were identified 
as fairly toxic compounds impairing mitochondrial functions. In in vitro kidney epithelial as 
wells as hepatocyte cultures, the compounds provoked oxidative stress, depleted glutathione 
levels, and increased lipid peroxidation [85]. 
Atractyloside is also found in Callilepis laureola DC. (Impila), an herbaceous South African 
plant that is used as a traditional multipurpose remedy by the Zulu people. Several cases of 
acute hepato- and nephrotoxicity have been reported since the 1970s [59]. 
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1.3.6 Greater Celandine 
Greater Celandine (Chelidonium majus L.) extracts are used for the treatment of dyspepsia 
and biliary disorders; however, therapeutic efficacy has never been proven in controlled 
clinical trials [60]. The plant contains several alkaloids including berberine, coptisine, 
chelerythrine, and chelidonine. Several cases of acute putative hepatotoxicity were related to 
the intake of commercially available drug preparations in high doses. In 10 female patients, 
signs of hepatotoxicity were reflected in elevated ALT and ALP levels, cholestasis, and low 
titers of antinuclear and smooth muscle antibodies indicating drug-induced autoimmunity 
[86]. Histologically, lobular and portal inflammation and eosinophilic infiltrates were detected. 
The mechanism of toxicity is unknown, but immune-mediated mechanisms are discussed. 
The up-dated recommendation for the daily doses is considered to be safe concerning liver 
toxicity. 
1.3.7 Other hepatotoxic herbs and natural compounds 
Teschke et al. recently compiled case reports of herbal hepatotoxicity and identified 60 
different herbal drugs and herbal supplements which are linked to hepatotoxicity [64]. In 
many cases, however, data acquisition, documentation, and presentation were of rather poor 
quality. Adequate causality assessment was missing in most cases. 
The hepatotoxicity of several Chinese herbs/herbal mixtures e.g. Ma-huang (Ephedra sp.), 
Jin Bu Huan (Lycopodium serratum THUNB.) is quite clearly estimated [59,61,63]. Black 
cohosh (Actaea racemosa, Cimicifuga racemosa (NUTT.) L.) intake was connected to acute 
hepatitis and liver failure in several reports [87,88] but causality assessment revealed 
inconsistencies in most cases. Mechanisms of hepatotoxicity remain as well unidentified. The 
hepatotoxicity of mistletoe (Viscum album L.) is controversially discussed as it is based on 
one single case report although the drug is quite widely used [89]. Noni juice (Morinda 
citrifolia L.) which is rigorously campaigned in European tabloid press for its beneficial health 
effects has been reported to cause severe hepatitis in a 45-year-old man [90]. Liver damage 
has been observed after use of herbal laxatives such as Senna (Cassia angustifolia VAHL.) 
[91]. ‘Prostata’, a combination of herbal ingredients containing Serenoa serrulata 
(W.BARTRAM) SMALL, sold for treatment of benign prostatic hyperplasia, has been reported to 
cause cholestatic hepatitis in a man [92]. Pennyroyal (Mentha pulegium L.) is associated with 
several cases of hepatic and neurologic injury [93,94]. Toxicity is believed to be mediated by 
both (+)-pulegone producing oxidative stress and pulegone’s primary metabolite menthofuran 
that is further oxidized by CYP450, increasing its toxicity [95]. 
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1.4 Aims 
(1) Drug-induced hepatotoxicity constitutes the main reason for a drug not reaching approval 
or for withdrawal of drugs from the market. Kava kava is a prominent example for putative 
herbal hepatotoxicity. For centuries, the plant has been used by the Pacific Islanders for 
ceremonial and medicinal purpose. In Western countries, standardized organic kava root 
extracts were approved for the treatment of non-psychotic anxiety disorders. In 2002, 
German health authorities banned kava-containing products from the market because 
several cases of severe hepatotoxic side effects have been reported which were putatively 
linked to kava-intake. Recently, a reevaluation of case reports stirred up the debate of still 
unknown mechanisms and elicitors of kava-hepatotoxicity. Particularly, there is a lack of 
studies, which address the putative toxicity of single constituents. For this reason, major and 
minor constituents were isolated from an acetonic kava root extract and tested towards their 
hepatotoxic potential in vitro (chapter 3). The study was aimed to uncover the hepatotoxic 
potential of individual constituents and thereby to contribute to the controversial discussion of 
kava-hepatotoxicity. 
 
(2) The anti-Alzheimer’s drug tacrine, an acetylcholinesterase inhibitor, constitutes another 
example for DILI. Despite its clinical efficacy and high potency, tacrine was withdrawn from 
the market due to hepatotoxic side effects. In order to face these therapy limiting side effects, 
a “co-drug” was designed by linking a tacrine-based acetylcholinesterase (AChE)-inhibiting 
part to the hepatoprotective flavonolignane silibinin via a liable ester bond. At first, the 
question should be answered whether this chemical connection is related to beneficial 
pharmacological effects in particular in comparison to a physical mixture of tacrine and 
silibinin. Therefore, the in vitro hepatotoxicity should be evaluated and compared to that of 
tacrine and an equimolar mixture of tacrine and silibinin (chapter 6). Furthermore, the in vitro 
degradation stability and metabolism of the codrug should be studied in different incubations 
systems to obtain valuable information about possible degradation products and metabolites 
of the codrug, which finally may help to identify the active principle of the codrug both in vitro 
and in vivo. In the face of toxification of tacrine to protein-reactive metabolites, the in vitro 
hepatotoxicity of the codrug cleavage products, a tacrine hemi succinamide and silibinin, 
should be addressed as they constitute the primary metabolites and may be rapidly formed in 
vivo. The absence of metabolite toxicity would as well point out the superiority of the codrug 
in terms of the therapy limiting side effects of tacrine. 
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(3) Chalcones represent an interesting substance class for treatment of liver diseases such 
as hepatic fibrosis as they comprise a set of favorable pharmacological properties such as 
anti-inflammatory, anti-oxidant, pro-apoptotic, and immunomodulatory activity. Several 
chalcones, among xanthohumol, have already shown anti-fibrotic effects both in vitro and in 
vivo. Driven by these positive results, this study comprises the testing of a set of structurally 
related prenylated and non-prenylated chalcones towards their anti-proliferative and 
apoptosis-inducing effects against activated human HSC, which have been identified as 
central cellular mediators in the pathogenesis of hepatic fibrosis (chapter 4). Comparing the 
inhibitory effects of the test chalcones, the study was also aimed to identify structure 
elements which enhance or attenuate the inhibitory activity. Chalcones being active may be 
selected for further pharmacological testing. 
 
(4) As the previous chapters deal with the toxicity and biological activity of chalcones, the in 
vitro metabolism of the pharmacologically active flavokawains and alpinetin chalcone were 
investigated in different microsomal incubation systems (chapter 5). Apart from alpinetin 
chalcone, the metabolism of these chalcones has not been studied before. By choosing 
appropriate liquid chromatography–mass spectrometry techniques, the phase I and phase II 
metabolites should be identified. Based on these data, a metabolism scheme might be 
proposed for the test chalcones. Moreover, liquid chromatogryphy–nuclear magnetic 
resonance spectroscopy is applied for structure elucidation of (major) metabolites. For future 
in vitro and in vivo studies, the metabolite profiling might provide helpful information for the 
identification of in vivo metabolites. Moreover, this study might highlight the role of generated 
metabolites and the importance of comprising (conjugated) metabolites to pharmacological in 
vitro testing. 
 2 Materials and Methods 
2.1 Phytochemical and analytical methods 
2.1.1 Plant material and extraction 
Dried Kava Kava rhizome (Piper methysticum FORST., Piperaceae) was kindly provided by 
Martin Bauer GmbH (batch no. 10787/09 96117). The plant material (250 g) was powdered 
and sonicated three times with acetone for 4 h. Due to incompleteness of the extraction, the 
plant material was transferred to a percolation column (Ø 5 cm) and macerated in 500 mL 
acetone overnight. The next day percolation (3 mL/min) was carried out until complete 
exhaustion of the plant material. Overall for the extraction, an amount of 4.2 L acetone was 
used. After rotary evaporation of the acetone, 17.52 g crude extract was obtained. 
2.1.2 Fractionation and isolation of kavalactones 
2.1.2.1 Flash chromatography 
For flash chromatography, the crude extract or the dried fractions were resolved in acetone, 
adsorbed to a part of the stationary phase (silica gel (Si60) or reversed phase 18 (RP18) 
material) by rotary evaporation, and filled in a precolumn for chromatography. The fractions 
(20 mL) were automatically collected and analyzed by ultraviolet/visible spectroscopy at one 
wavelength (λ = 270 nm or 340 nm). 
Table 2.1 lists the used methods and indicates the chromatographic conditions. Collected 
fractions were reasonably combined after thin layer chromatography (TLC) analyses on silica 
plates using solvent system T1 and derivatization reagent D1 (see chapter 2.1.3.1). 
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Table 2.1: Methods for flash chromatography. M method, St stationary phase (column), A and 
B solvent A and solvent B, t time [min], A/B solvent composition, f flow [mL/min]. 
EtOAc p.a., MeOH p.a., H2O ultra-pure. 
M St A B t A/B f 
F1 
 
Precolumn Si60, 20 g 
SVP D40-Si, 15-40 µm, 
90 g 
Hexane EtOAc + 
10% MeOH 
0-5 
5-110 
110-130 
130-140 
100/0 
100/0→60/40 
60/40→0/100 
0/100 
30 
F2 Precolumn LiChroprep 
RP18, 25-40 µM, 5 g 
SVP D40-RP18, 25-
40 µm, 90 g 
H2O/MeOH 
50/50 
MeOH 0-5 
5-70 
70-85 
85-90 
100/0 
80/20→50/50 
50/50→0/100 
0/100 
20 
F3 Precolumn Si60, 10 g 
SVP D40-Si, 15-40 µm, 
90 g 
Hexane Acetone + 
1% EtOAc 
  
0-5 
5-25 
25-55 
55-85 
85-90 
90-100 
100/0 
100/0→80/20 
80/20 
80/20→70/30 
70/30→0/100 
0/100 
30 
F4 Silica Si60 15-40 µm,  
30 g  
Hexane Acetone + 
1% EtOAc 
0-3 
3-23 
23-43 
43-53 
53-55 
55-75 
100/0 
100/0→80/20 
80/20 
80/20→70/30 
70/30→0/100 
0/100 
10 
F5 Silica Si60 15-40 µm,  
30 g 
Hexane Acetone + 
1% EtOAc 
0-5 
5-25 
25-45 
45-55 
55-60 
100/0 
100/0→80/20 
80/20 
80/20→0/100 
0/100 
15 
F6 Silica Si60 15-40 µm,  
30 g 
Hexane Acetone + 
1% EtOAc 
0-2 
2-20 
20-40 
40-60 
100/0 
100/0→80/20 
80/20 
80/20→70/30 
15 
F7 Silica Si60 15-40 µm,  
30 g 
Hexane Acetone + 
1% EtOAc 
0-15 
15-30 
30-50 
50-55 
55-60 
100/0→80/20 
80/20 
80/20→70/30 
70/30→0/100 
0/100 
10 
F8 Silica Si60 15-40 µm,  
30 g 
Hexane Acetone + 
1% EtOAc 
0-2 
2-15 
15-35 
35-55 
55-60 
60-65 
100/0 
100/0→80/20 
80/20 
80/20→70/30 
70/30→0/100 
0/100 
15 
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2.1.2.2 Semi preparative high pressure liquid chromatography 
One fraction (G2.6’) was further purified by semi preparative high pressure liquid 
chromatography (HPLC) (H1). The sample was dissolved in 50% (v/v) methanol (MeOH) to a 
concentration of 2.5 mg/mL and a volume of 1 mL was manually injected. For detection, a 
diode array detector (DAD) was used. HPLC analysis was performed on a Eurosphere-100 
column (C18, 7 µM, 16 x 25 mm, Knauer, Berlin) at ambient temperature with a flow rate of 
10 mL/min. The eluents were H2O and MeOH and following gradient system was used: 
0-5 min 50/50, 5 min 40/60, 5-30 min 40/60→30/70, 30-35 min 30/70→0/100, 35-40 min 
0/100, 40-45 min 0/100→50/50. 
2.1.2.3 Recrystallization 
Yangonin, methysticin, and desmethoxyyangonin (G2.8) were recrystallized in MeOH at 
4 °C. Kawain (G2.4) was dissolved in MeOH and recrystallized by the addition of water. 
Precipitates were sucked off and dried in the exsiccator. 
2.1.3 Analytical methods 
2.1.3.1 Thin layer chromatography / High performance thin layer chromatography 
(High performance) thin layer chromatography ((HP)TLC) analyses were performed using 
aluminum or glass plates coated with silica 60 F254 (Merck, Darmstadt, Germany). 
Substances/fractions were either manually applied or spayed on plates with a Linomat 5 in 
case of HPTLC analysis. The dried plates were developed in a saturated chamber. 
Development of HPTLC plates was performed with an automatic ADC2 Chamber (Twin 
Trough Chamber) to a distance of 7 mm from bottom to the top. Plates were analyzed under 
UV light (254 nm and 365 nm) or daylight after derivatization. The images were recorded on 
a Reprostar 3. 
 
Solvent systems 
T1 Hexane: EtOAc: MeOH (70: 20: 10) 
T1+FA  Hexane: EtOAc: MeOH (70: 20: 10) + 0.1% formic acid (FA) 
T2  EtOAc: Toluene: MeOH: Diethylamine: NH3 (8: 2: 2: 0.5: 1) 
 
Derivatization reagents 
D1 Anisaldehyde reagent  0.5% anisaldehyde, 84.5% MeOH, 10% glacial acid, 
5% H2SO4 conc., heating at 105 °C for 10 min, daylight 
D2 Natural product reagent  1% in MeOH (m/v) / Polyethylene glycol 400 5% in 
MeOH (m/v), heating at 105 °C for 5 min, UV 365 nm 
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2.1.3.2 Nuclear magnetic resonance spectroscopy 
For identification and structure confirmation of isolated kavalactones 1H NMR spectra were 
recorded in deuterated chloroform (CDCl3) at ambient temperature using a Bruker Avance 
spectrometer (300 MHz). Structures of synthesized chalcones were confirmed by Dr. 
Susanne Vogel [96–98]. Hydrogenation of flavokawain C, dihydoxanthohumol C, and 
helichrysetin was executed by Petr Jirásek using an established method [99]. Again, 
molecular structures of hydrogenated compounds were approved by 1H NMR (CDCl3, 
acetone-d6, 400 MHz). Structures of tacrine hemi succinamide (4-oxo-4-(6-(1,2,3,4- 
tetrahydroacridin-9-ylamino)butanoic acid) and the codrug (((2S,3S)-3-(4-hydroxy-3-
methoxyphenyl)-6-((2R,3R)-3,5,7-trihydroxy-4-oxochroman-2-yl)-2,3-
dihydrobenzo[b][1.4]dioxin-2-yl)-methyl 4-oxo-4-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)-
hexylamino)butanoate hydrochloride) synthesized by Dr. Xinyu Chen were confirmed by 
1H NMR (CDCl3, 300 MHz) and 
13C NMR (CDCl3, 75 MHz) spectroscopy [100]. 
2.1.3.3 Analytical high pressure liquid chromatography 
Purity of isolated and synthesized test compounds was evaluated by HPLC–DAD 
(Table 2.2). For P1, P3, and P4 the compounds were dissolved in 50% (v/v) MeOH to a 
concentration of 1 mg/10 mL; for P2, compounds were dissolved in 50% (v/v) acetone to a 
concentration of 10 µM. 
The purity was calculated as percentage of total peak area at indicated wavelengths (λ). 
Purity analysis of method P2 was performed by Dr. Magdalena Motyl [101]; purity analysis of 
P3 and P4 was conducted by Dr. Xinyu Chen [100]. 
Table 2.2: Methods for analytical HPLC. M method, C column 1 Purosphere STAR 250-4 RP 
18e 5 µm, column 2 Purosphere STAR 125-4 RP 18e 3 µm (Merck, Darmstadt) , A 
and B eluents A and B, t time [min], A/B solvent composition, f flow [mL/min], V 
injection volume [µL], λ wavelength [nm], T oven temperature [°C]. FA 98% p.a., 
MeCN for HPLC, TFA p.a. 
M C A B t A/B f V λ T 
P1 1 0.1% FA 95% MeCN 0-15 
15-20 
80/20→0/100 
0/100 
1 10 UVmax 40 
P2 1 0.1% FA 95% MeCN 0-27 
27-30 
30-40 
45/55→15/85 
15/85→45/55 
45/55 
1 20 368 30 
P3 2 0.1% FA 95% MeCN  
+ 0.1% FA 
0-30 
30-40 
40-45 
80/20→0/100 
0/100 
0/100→80/20 
0.4 10 287 
 
40 
P4 2 0.05% TFA 95% MeCN 
+ 0.05% TFA 
0-30 
30-45 
45-55 
55-60 
90/10→10/90 
10/90 
10/90→90/10 
90/10 
0.4 10 247 20 
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2.2 Cell culture 
2.2.1 Chemicals, reagents, supplements 
Alexa Fluor® 488 phalloidin  Molecular Probes, Life Technologies, Carlsbad, USA 
CV crystal violet, Merck, Darmstadt 
CV solution 0.5% (w/v) crystal violet in 20% (v/v) methanol 
Cytochrome C detection kit  Cellomics®, Thermo Fisher Scientific, Waltham, USA 
FCS fetal calf serum, Lot.No. 1050L, Biochrom, Berlin 
L-Glutamine 200 mM, Biochrom, Berlin 
Hoechst33342  bisbenzimide H 33342 trihydrochloride, Sigma-Aldrich, 
 Taufkirchen 
MitoTracker Red CMXRos®  Molecular Probes, Life Technologies, Carlsbad, USA 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide, Sigma-Aldrich, Taufkirchen 
MTT solution  4 mg/mL MTT in PBS, sterile-filtered 
NEA nonessential amino acids, 100x, Biochrom, Berlin 
Paraformaldehyde solution 10% phosphate buffered, Applichem, Darmstadt 
PBS  Dulbecco’s Phosphate Buffered Saline (w/o Mg2+, Ca2+),  
 Sigma-Aldrich, Taufkirchen 
Permeabilization buffer  Triton® X-100, 10x, Cellomics, Pittsburgh, USA 
SDS  sodium dodecyl sulfate, Sigma-Aldrich, Taufkirchen 
SDS solution  10% (w/v) in PBS 
Sodium citrate tri-sodium citrate-2-hydrate, Merck, Darmstadt 
SP sodium pyruvate, 100 mM, Biochrom, Berlin 
Trypan blue  Sigma-Aldrich, Taufkirchen 
Trypan blue solution  0.4% (w/v) trypan blue in PBS, sterile-filtered 
Trypsin/EDTA  10x trypsin/EDTA solution (0.5%/0.2% (w/v)), Biochrom, 
 Berlin 
Trypsin/EDTA solution  10% (v/v) in PBS 
2.2.2 Culture media, cell lines  
2.2.2.1 Heat inactivation of fetal calf serum 
FCS was stored at -20 °C. Initially, 500 mL of FCS were thawed in a water bath at 37 °C. For 
inactivation, FCS was heated to 56 °C in a water bath for 30 min. Aliquots of heat inactivated 
FCS (FCShi, 50 mL) were stored at -20 °C prior to use. 
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2.2.2.2 Culture media 
1) Culture medium (CM 1) Dulbecco’s Modified Eagle Medium (DMEM GIBCO with phenol 
red, 2 mM glutamine, 4.5 g/L glucose, Life Technologies, 
Carlsbad, USA) supplemented with 10% FCShi (Biochrom, 
Berlin, Germany). 
 
2) Culture medium (CM 2)  Dulbecco’s Modified Eagle Medium (DMEM with phenol red, 
1.0 g/L glucose, Biochrom, Berlin, Germany) supplemented with 
10% FCShi, 1% SP and 1% NEA (v/v). 
 
3) Incubation medium  Dulbecco’s Modified Eagle Medium (DMEM GIBCO without 
phenol red, 4.5 g/L glucose, Life Technologies, Carlsbad, USA) 
supplemented with 10% FCShi and 2 mM L-glutamine. 
 
3) Staining medium  Dulbecco’s Modified Eagle Medium (DMEM GIBCO without 
phenol red, 4.5 g/L glucose, Life Technologies, Carlsbad, USA) 
supplemented with 1% FCShi and 2 mM L-glutamine. 
 
4) Freezing medium  70% DMEM, 20% FCShi, 10% DMSO 
2.2.2.3 Cell line data 
Cell name  Tissue Charact.  Source Cell Bank  Cell number 
HuH-7 (CM 1) liver hepatoma human HSRRB JCRB0403 
HepG2 (CM 1) liver  hepatoma human ATCC HB-8065 
HSC (CM 1) liver stellate cells human Univ. Hospital of Regensburg  
Caco-2 (CM 2) colon cancer human ATCC HTB-37 
 
The human hepatoma cell line HepG2 (ATCC®-number HB-8065TM) was obtained from the 
American Type Culture Collection (ATCC), USA. The human hepatoma cell line HuH-7 
(HSRRB-number JCRB0403) was purchased from the Health Science Research Resources 
Bank (HSRRB) of the Japan Health Sciences Foundation (JHSF), Japan. The immortalized 
activated human hepatic stellate cell line (HSC) was provided by the University Hospital of 
Regensburg, Department of Internal Medicine I [102]. The human colorectal cell line (Caco-2, 
ATCC®-number HTB-37TM) was obtained from the Institute of Virology, Helmholtz Zentrum 
München, Germany. 
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2.2.3 Laboratory expendables 
Cell culture flasks (various sizes) TPP, Trasadingen, Switzerland 
Centrifuge tubes (15 and 50 mL)  TPP, Trasadingen, Switzerland 
Cryotubes (2 mL) Greiner, Frickenhausen 
Eppendorf tubes (1.5 and 2 mL) Eppendorf, Hamburg 
Multiwell plates  TPP, Trasadingen, Switzerland 
Pipette tips 200 µL/1000 µL, Sarstedt, Nümbrecht 
 10 µL, Axygen, Union City, USA  
Serological pipettes  TPP, Trasadingen, Switzerland 
Syringe filter units 0.2 µm, Minisart, Sartorius, Göttingen 
2.2.4 Cultivation, handling, treatment 
2.2.4.1 Cultivation of cells 
Cells were cultivated under standard cell culture conditions at 37 °C in a humidified 
atmosphere with 5% CO2 in the appropriate cell culture medium (see chapter 2.2.2.2 and 
2.2.2.3). Medium was changed every 3-4 days and cells were splitted 1-2 times a week when 
about 80% confluence was reached. For this, cells were washed with PBS and detached by 
incubation with trypsin/ETDA solution at 37 °C for 5 min. The trypsin activity was stopped by 
the addition of FCS-supplemented medium (fivefold the amount of trypsin/EDTA solution). 
The cell suspension was transferred to a flacon tube and centrifuged at 700 x g for 5 min. 
The cell pellet was re-suspended in fresh medium. Cells were reseeded in new cell culture 
flasks with a split ratio of 1:5, 1:10 or 1:20 as needed. Cell growth, density and morphology 
were checked periodically using an inverted microscope. 
2.2.4.2 Determination of cell number, seeding of cells 
For determination of cell number, the cell suspension was diluted 1:10 with trypan blue 
solution and transferred to a Neubauer hemocytometer (Brand, Wertheim, Germany). Trypan 
blue only stains cells with impaired cell membranes whereas living cells appear as white 
spots and therefore can be easily distinguished from dead cells. Only living cells were 
counted in four big quadrates of the hemocytometer and cell number was calculated 
according to following equation: 
           
  
                
N: number of counted cells in the four quadrates 
f: dilution factor (10) 
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Depending on the determined cell number, the cell suspension was diluted with medium and 
adjusted to a defined cell concentration in a centrifuge tube. For the experiments, 100 µL/well 
of cell suspension were seeded in 96-well plates with a multichannel pipette (Eppendorf, 
Research); the outer wells were just filled with buffer or medium without cells. The seeding 
density of the cell lines was maintained throughout different experiments to make the results 
comparable. In preliminary tests, the optimal seeding density was determined for the different 
cell lines as shown below: 
________________________________________________ 
HuH-7 1.5 x 105/mL  1.5 x 104/well 
HepG2  1.0 x 105/mL 1.0 x 104/well 
HSC 5.0 x 104/mL 5.0 x 103/well 
Caco-2  2.0 x 105/mL 2.0 x 104/well 
 
Subsequently, the plates were horizontally shaken to evenly distribute the cells inside the 
wells. Prior to treatment, the cells were cultured for 24 h at 37 °C and 5% CO2 in a humidified 
incubator. 
2.2.4.3 Cell treatment 
Concentrations series of the test compound(s) were prepared by diluting the stock solution 
(in dimethyl sulfoxide (DMSO) or ethanol (EtOH)) in the incubation medium (see chapter 
2.2.2.2). The end concentration of the solvents was kept at a maximum concentration of 
0.1% for DMSO and 0.5% for EtOH in the medium as these concentrations lacked significant 
effects in all performed assays. 
Culture medium was carefully aspirated from each well of a plate and cells were treated with 
100 µL of the test solutions. For each concentration, at least three parallels were performed. 
Untreated (pure medium) and solvent-treated (0.1% DMSO or 0.5% EtOH) cells were 
employed as controls. If not mentioned otherwise, the cells were incubated for another 24 h 
at 37 °C and 5% CO2 before cell assays were performed. 
2.2.4.4 Cryopreservation and thawing of cell lines 
For cryopreservation, the cell number was adjusted to 5.0 x 105 cells/mL in freezing medium 
(see chapter 2.2.2.2). Afterward, 2 mL of the cell suspension were transferred into a cryotube 
and immediately frozen at -80 °C. For long-term cryopreservation, the frozen cell suspension 
was finally stored in a liquid nitrogen storage tank. 
Cell thawing was performed quickly in a 37 °C water bath. The cell suspension was mixed 
with 8 mL of fresh culture medium in a centrifuge tube. After re-suspension, cells were 
centrifuged for 5 min at 700 x g. Finally, 2 mL culture medium was added to the obtained cell 
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pellet and the whole cell suspension was transferred to a new culture flask containing 
already 18 mL culture medium. Medium was exchanged the following day. 
2.2.5 Viability and proliferation assays 
2.2.5.1 MTT assay 
For determination of cell viability, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) assay was adapted to previously described procedures [103]. After treatment and 
removal of the incubation medium, cells were incubated with 100 µL MTT solution 
(0.4 mg/mL) per well. The yellow tetrazolium salt is reduced by enzymes of the endoplasmic 
reticulum (ER) of metabolically active cells to a blue insoluble formazan. After 3 h, 
supernatants were removed and 100 µL lysis buffer (10% SDS, pH 4.1) was added to each 
well. The next day the absorbance of the formazan solution was measured with a multiwell 
plate reader at 560 nm. The absorption directly correlates with the number of viable cells. 
Untreated cells were set as 100% values and served as controls. Cell viability was calculated 
using following equation: 
 
               [ ]   
           
             
      
Ax: absorbance treated well 
Actl: absorbance control well 
Ablank: absorbance blank well 
2.2.5.2 Crystal violet assay 
Crystal violet (tris(4-(dimethylamino)phenyl)methylium chloride) also known as Gentian violet 
primarily used for Gram stain, is a basic dye which stains DNA of cell nuclei. Accordingly, the 
photometrically measured absorbance directly correlates with the number of cells and is 
used to determine cell proliferation [104]. 
The incubation medium was carefully removed, and cells were incubated with 50 µL CV 
solution (0.5% in 20% methanol) per well for 10 minutes at room temperature. Staining 
solution was aspirated, and cells were thoroughly washed three times with ultra-pure water. 
After drying plates overnight, 100 µL of sodium citrate buffer (EtOH + 0.1 M sodium citrate 
(1:1, v/v)) was added to each well and absorbance of the solution was determined at 560 nm 
using a multiwell plate reader. To gather information of initial cell number, one 96 well plate 
was already stained 24 h after seeding (before treatment). Untreated cells served as controls 
and were set as 100% values. A significant deviation from 100% values indicates pro- or 
anti-proliferative (cytostatic) effects whereas a drop below the initial cell number suggests a 
cytotoxic effect. 
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2.2.6 Fluorescence microscopic assays 
2.2.6.1 High content analysis 
Nowadays, the development of novel cytotoxicity assays proceeds to multiparameter 
screening methods since conventional cytotoxicity assays often lack sensitivity and only 
detect endpoints without revealing prelethal effects like organelle impairment or 
morphological changes. Hence, a high content analysis (HCA) assay for fluorescence 
microscopy was established applying three different fluorescent dyes staining nuclei, 
mitochondria, and the actin fibers of cells. The used fluorescent dyes and probes showed 
different, non-overlapping excitation and emission spectra (Figure 2.1) what made them 
suitable for multicolor labeling experiments using appropriate filters. 
 
Figure 2.1: Excitation and emission spectra of used fluorescent dyes. Hoechst 33342 (blue) 
352/455 nm, Alexa Fluor 488 (green) 485/581 nm, MitoTracker Red (red) 579/599 nm. 
The HCA assay was established on human HSC which are suitable for fluorescence 
microscopy applications due to their smooth morphology.  
For the staining procedure, stock solutions of fluorescent dyes were diluted in staining 
medium (see chapter 2.2.2.2) to applicable concentrations and kept strictly away from light 
while handling. First, cells were incubated with 50 µL/well of a 1:2000 dilution of MitoTracker 
Red CMXRos® (1 mM stock solution) for 25 min at 37 °C. This mitochondrion-selective, 
rosamine-based probe passively diffuses across the plasma membrane and accumulates in 
active mitochondria. In contrast to tetramethylrosamine and rhodamine 123, the MitoTracker 
is not washed out after fixation and permeabilization steps according to manufacturer. 
Subsequently, 25 µL/well of Hoechst33342 staining solution (bisbenzimide H 33342 
trihydrochloride, 20 mM, 1:1200) was added to the wells for 5 min. Hoechst33342 is a well-
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established intercalating dye for staining cell nuclei. Furthermore, Hoechst33342 staining 
intensity can be used for determination of cellular DNA content (see chapter 2.2.6.3). Next, 
the staining solution was aspirated and cells were washed with 100 µL/well of pre-warmed 
PBS. Afterward, cells were fixed with 100 µL/well of 3% paraformaldehyde (PFA) for 30 min 
at room temperature. Cells were washed again with PBS and then shortly treated with 
50 µL/well of permeabilization buffer (0.1% Triton® X-100 in PBS). After a further washing 
step, the actin skeleton of cells was stained with an Alexa Fluor® 488 labeled phalloidin. 
Bicyclic phallotoxins from Amanita phalloides label F-actin at nanomolar concentrations in a 
stoichiometric ratio, which makes them also suitable to quantify the amount of F-actin in 
cells. The methanolic stock solution (200 units/mL) was diluted 1:50 with staining medium 
and 35 µL were added to each well for 20 min at room temperature. The medium was 
aspirated and cells were washed thoroughly with PBS. At the end, 100 µL of PBS buffer were 
added to each well for image acquisition. 
 
Automatic image acquisition was carried out using a Carl Zeiss AxioObserver.Z1 (Carl Zeiss, 
Göttingen, Germany) with an EC Plan-Neofluar 10x objective, appropriate filters (filter sets: 
49, 43 HE, 38 HE) for the fluorescent dyes, and Software AxioVision 4.8.1 (Carl Zeiss 
MicroImaging, Germany). 
Other default settings for image acquisition: 
 Multichannel: Ch1 Alexa Fluor® 488, Ch2 MitoTracker Red, Ch3 Hoechst33342 
 Fixed exposure times 
 Ch1 Autofocus, Ch2 Channel position +3 µm, Ch3 Channel position -20 µm 
 Positionlist: Three images/well 
 
Image analysis was automatically performed by the ASSAYbuilder Physiology Analyst 
software. Cell nuclei were identified by the software and used to automatically detect and 
count the cells. Besides, Hoechst staining was also used to examine the nuclear area. The 
mean total fluorescence intensity of detected mitochondria spots was measured within a 
defined ring mask over and around the nucleus. The area of actin spots was investigated 
over the complete cellular area defining another ring mask. 
Other default settings for image analysis: 
 Ch1 = Primary Object (nuclei), Ch2 = actin, Ch3 = mitochondria 
 Primary Object Identification:  Threshold Method Isodata (0) 
 Separation Method Peak (8) 
 Primary Object Selection: Gating:  Area 262–2492 pixel2, Shape 1.1–1.7 (1= round), 
reject objects on edge 
 Ch2:  Detection Method Morphological (25) 
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Threshold Method Fixed (mean Isodata ctl cells) 
Circ 3, Ring Distance -20, Ring Width 80 
 Ch3:  Detection Method Box (4) 
Threshold Method Fixed (mean Isodata ctl cells) 
Circ 3, Ring Distance -20, Ring Width 60 
2.2.6.2 Cytochrome c assay 
For the determination of cytochrome c release from apoptotic mitochondria of HSC, the 
Cellomics® Cytochrome C Detection kit (Thermo Fisher Scientific) was applied followed by 
fluorescence microscopic analysis. 
 
Kit contents 
Cytochrome C Primary Antibody 
DyLightTM 549 Conjugated Goat Anti-Mouse IgG (ex/em 550/568 nm) 
Hoechst33342 Dye (ex/em 350/461 nm) 
Wash Buffer (10x Dulbecco’s PBS) 
Wash Buffer II (10x Dulbecco’s PBS with Tween®-20) 
Permeabilization Buffer (10x Dulbecco’s PBS with 1% Triton® X-100) 
Blocking Buffer (10x) 
 
The assay was conducted according to the manufacturer’s protocol with slight modifications. 
After treatment, cells were fixed with 4% PFA (100 µL/well) for 15 min at room temperature. 
Fixation solution was aspirated and cells were washed twice with Wash Buffer. Following, 
cells were incubated with permeabilization buffer (100 µL/well) for 15 min at room 
temperature. Again, the buffer was aspirated and cells were washed twice with Wash Buffer. 
Subsequently, cells were treated with Blocking Buffer (+ 2% FCS, 100 µL/well) for 15 min at 
room temperature. The Blocking Buffer was aspirated and cells were incubated with Primary 
Antibody Solution (1:400 in Blocking Buffer; 50 µL/well) for 1 h at room temperature. After 
removal of the antibody solution, the plate was washed twice with Wash Buffer II and Wash 
Buffer respectively. Staining with Secondary Antibody Solution (1:500 in Blocking Buffer; 
50 µL/well) was performed for 45 min at room temperature under exclusion of light. Finally, 
the staining solution was aspirated, cells were washed twice with Wash Buffer II, Wash 
Buffer, and 200 µL of PBS were added to each well for image acquisition. 
 
Automatic image acquisition was carried out using a Carl Zeiss AxioObserver.Z1 (Carl Zeiss, 
Göttingen, Germany) with an EC Plan-Neofluar 10x objective, appropriate filters (filter sets: 
49, 43 HE) for the fluorescent dyes, and Software AxioVision 4.8.1 (Carl Zeiss MicroImaging, 
Germany). 
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Other default settings for image acquisition: 
 Multichannel: Ch1 DyLight 549, Ch2 Hoechst33342, Ch3 Phase 
Fixed exposure time 
Ch1 and Ch2 Autofocus, Ch3 Current Focus Position 
 Positionlist: Three images/well 
 
Image analysis was automatically done by the ASSAYbuilder Physiology Analyst software.  
In normal cells, cytochrome c is located in the mitochondria, which can be detected as 
cytoplasmic spots. Upon induction of apoptosis, cytochrome c is released from the 
mitochondria and can diffuse into the nucleus. Thus, a reallocation of stained cytochrome c is 
detectable. For image analysis, a circ mask was put over the nucleus area and a ring mask 
over the cytoplasmic area of a cell. The ring mask measures the fluorescence in the 
cytoplasm of cells where unreleased cytochrome c within the mitochondria can be found. The 
circ mask determines the fluorescence in the nucleus area of cells where cytochrome c 
diffuses when it is released from the mitochondria. To determine the reallocation and 
therefore the extent of released cytochrome c, the mean average fluorescence intensity 
between circ and ring mask was analyzed (MEAN_CircRingAvgIntenDiff). 
Other default settings for image analysis: 
 Ch1 = Primary Object (nuclei), Ch2 = cytochrome c 
 Primary Object Identification:  Threshold Method Isodata (0) 
 Separation Method Peak (9) 
 Primary Object Selection: Gating:  Area 351–2406 pixel2, Shape 1.0861–2.065, 
reject objects on edge 
 Ch2:  Detection Method Box (5) 
Threshold Method Isodata (0) 
Circ 3, Ring Distance 3, Ring Width 40 
2.2.6.3 DNA content 
DNA content analysis was performed within the HCA assay system (see chapter 2.2.6.1) 
analyzing the intensity of Hoechst33342 staining. As the fluorescence intensity directly 
correlates with the DNA content, conclusions concerning the actual cell cycle state can be 
drawn. For image analysis, another protocol was developed using the ASSAYbuilder 
Cellcycle Analyst software. 
Following default settings were used: 
 Ch1 = nucleus 
 Nucleus Identification and Selection see settings in chapter 2.2.6.1 
 Settings: Cellcycle Intensity, Peaks_one class for ctl cells 
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2.3 In vitro stability and metabolism 
2.3.1 Human liver microsomes 
Pooled human liver microsomes (HLM) derived from 50 adult donors of mixed gender and 
with a total protein concentration of 20 mg/mL were purchased from Live Technologies 
(HMMC-PL; 0.5 mL). They were stored in aliquots at -80 °C prior to use to avoid frequent 
freeze-thaw cycles. 
2.3.2 Chemicals, reagents 
Potassium dihydrogen phosphate p.a. Merck, Darmstadt 
 
Di-Potassium hydrogen phosphate p.a. Merck, Darmstadt 
 
Magnesium chloride hexahydrate p.a.  Merck, Darmstadt 
 
Nicotinamide adenine dinucleotide phosphate Calbiochem®, Merck, Darmstadt 
reduced tetrasodium salt  
 
Nicotinamide adenine dinucleotide phosphate  Sigma-Aldrich, Taufkirchen 
sodium salt hydrate  
 
Glucose-6-phosphate sodium salt Sigma-Aldrich, Taufkirchen 
 
Glucose-6-phosphate dehydrogenase 100 UN Sigma-Aldrich, Taufkirchen 
 
Uridine 5‘-diphosphoglucuronic acid trisodium salt Sigma-Aldrich, Taufkirchen 
 
Alamethicin from Trichoderma viride Sigma-Aldrich, Taufkirchen 
 
The metabolism studies were carried out in 0.1 M potassium phosphate buffer (PO4 buffer). 
Therefore, 2.76 g of KH2PO4 (A) and 4.56 g of K2HPO4 (B) were dissolved in ultra-pure water 
to a volume of 100 mL (0.2 M) respectively. 19.0 mL of solution A and 81.0 mL of solution B 
were mixed and adjusted to a pH of 7.40 using a pH meter. The adjusted buffer was diluted 
1:1 in ultra-pure water to obtain a concentration of 0.1 M. Afterward, the buffer was sterile-
filtered and stored at 4 °C. 
Stock solutions of glucose-6-phosphate (110 mM, G-6-P), magnesium chloride hexahydrate 
(110 mM, MgCl2), nicotinamide adenine dinucleotide phosphate (43 mM, NADP), reduced 
nicotinamide adenine dinucleotide phosphate (10 mM, NADPH), and uridine 5'-diphospho-
glucuronic acid (40 mM, UDPGA) were prepared in potassium phosphate buffer. The 
glucose-6-phosphate dehydrogenase (G-6-P-DH) was diluted in 5 mM sodium citrate 
solution to a concentration of 40 U/mL. The pore-forming peptide alamethicin (Ala) was 
dissolved in methanol and ultra-pure water (2%, v/v) to a final concentration of 0.5 mg/mL. All 
reagents were stored in aliquots at -20 °C. 
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2.3.3 Microsomal metabolism of chalcones and identification of phase I and 
phase II metabolites 
2.3.3.1 Incubation systems 
The metabolite profiling of flavokawains was conducted in different microsomal incubation 
systems investigating both phase I and II reactions. As only membrane-bound enzymes are 
present in microsomal preparations (see chapter 5.1.1), the set of phase II enzymes is 
limited to UDP-glucuronosyltransferases (UGTs). Therefore, phase II reactions are limited to 
glucuronidation reactions. Phase I and II reactions (Ph I, Ph II) can be studied separately by 
addition of either NADPH or UDPGA equivalents, but also in combination (Ph I+II) by co-
activation of phase I enzymes and UGTs within one system [105]. Suitable negative controls 
without microsomes (w/o micr) or without cofactors (w/o cof) have to be included to the 
sample set to avoid false conclusions because of unspecific reactions or stability problems. 
In addition, stability of the parent compound in the buffer system without any supplements 
has to be proven (stabi). Furthermore in preliminary experiments, 7-ethoxycoumarin (7-EC) 
was used as positive control to check whether the incubations systems and metabolizing 
enzymes are working properly. 7-EC is a commonly used probe for in vitro metabolism 
studies: both oxidative metabolism (deethylation, hydroxylation) and conjugation to 
glucuronic acid can be investigated [106].  
 
Microsomal incubation systems for in vitro metabolism studies are very well established. The 
incubation systems were composed in accordance with literature data and available manuals 
[37]. For phase I metabolism, a NADPH regeneration system was used consisting of 3.3 mM 
MgCl2, 3.3 mM Glc-6-P, 0.4 U/mL Glc-6-P-DH, and 1.3 mM NADP. For phase II metabolism, 
2 mM UDPGA has to be added as activated substrate for UGTs. The pore-forming peptide 
alamethicin (25 µg/mL) helps the substrate to penetrate to the active site of the UGTs, which 
is localized inside the endoplasmic reticulum and thereby facilitates the glucuronidation 
reaction [107]. Stock solution (Stock) of 7-EC was prepared in MeOH (100 mM). The test 
chalcones were dissolved in DMSO (10 mM), again diluted in EtOH (1:10, 1 mM), and stored 
at 4 °C. The end concentration in the incubation system was 250 µM for the positive control 
and 10 µM for the flavokawains. Table 2.3 presents a pipetting scheme for the seven 
different test reactions, exemplarily for an end-volume of 1 mL. 
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Table 2.3: Pipetting scheme for the different incubation systems. Volumes are given in µL. 
 incubation systems 
 matrix stabi w/o micr w/o cof Ph I Ph II Ph I+II 
PO4 buffer 775 990 790 845 865 835 765 
MgCl2 30 - 30 30 30 30 30 
Glc-6-P 30 - 30 30 30 - 30 
Glc-6-P-DH 10 - 10 10 10 - 10 
Ala 50 - 50 50 - 50 50 
Micr 25 - - 25 25 25 25 
Stock - 10 10 10 10 10 10 
NADP 30 - 30 - 30 - 30 
UDPGA 50 - 50 - - 50 50 
 
All reagents were gently defrosted and kept on ice during the experiment. The PO4 buffer 
was pre-warmed to room temperature and the required volume was transferred to 2 mL 
Eppendorf tubes. The reagents were pipetted in descending order. After addition of the 
microsomes, the samples were carefully vortexed and pre-warmed in a stirred water bath at 
37 °C for 5 min. Subsequently, the chalcone stock solution was added and the samples were 
agitated again. By addition of NADP and/or UDPGA the reaction was started. The tubes 
were quickly transferred into the water bath and incubated at 37 °C. At defined time points 
(0-60 min), the metabolic reaction was stopped. Therefore, samples were taken and pipetted 
in another tube already containing the same volume of ice-cold EtOH in case of the 
chalcones or 5% (v/v) HCl (1:5) for 7-EC. The samples were vortexed vigorously for 5 min. 
Precipitated proteins were removed by centrifugation at 14 000 rpm for 5 min. The 
supernatant was used for HPLC and liquid chromatography–mass spectrometry (LC–MS) 
analyses.  
2.3.3.2 Analytical high pressure liquid chromatography 
Metabolized samples of 7-ethoxycoumarin (C1) and flavokawains (C2) were subjected to 
HPLC analysis (Table 2.4). Separation was performed on a C18-column (Hibar® 250-4, 
Purosphere, 5 µm). Temperature was set at 40 °C for the column oven and 4 °C for the 
autosampler. 
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Table 2.4:  Methods for analytical HPLC. M method, A and B eluents A and B, t time [min], A/B 
solvent composition, f flow [mL/min], V injection volume [µL], λ detection 
wavelength [nm]. FA 98% p.a., MeCN for HPLC. 
M A B t A/B f V λ 
C1 0.1% FA 95% MeCN 
(v/v) 
0-20 
20-22 
22-23 
25-30 
90/10→40/60 
40/60 
40/60→90/10 
90/10 
1 10 320 
C2 0.1% FA 95% MeCN 
(v/v) 
0-20 
23-24 
24-25 
25-30 
70/30→0/100 
0/100 
0/100→70/30 
0/100→80/20 
1 10 364 
343 
368 
2.3.3.3 Liquid chromatography–high resolution electrospray ionization mass 
spectrometry 
Samples for liquid chromatography–high resolution electrospray ionization mass 
spectrometry (LC–HRESIMS) analysis (phase I, phase II, phase I+II, negative controls) were 
prepared at two time points (0 min and 60 min) according to the previously described method 
in chapter 2.3.3.1. Matrix samples without test compounds referred as blank controls 
(matrix). All samples were stored in HPLC vials (Wicom, Heppenheim) at -20 °C prior to 
analysis. 
High resolution LC–MS was performed using UHPLC Agilent 1290 infinity, DAD G4212A, MS 
Agilent 6540 UHD Q-TOF with positive and negative electrospray ionization (ESI) using dual 
ion source. For separation, a Thermo Accucore aQ column (C18, 50x2.1 mm, 2.6 µm) and 
the following solvents were used: eluent A was 0.1% formic acid (FA), eluent B 100% 
acetonitrile (MeCN) supplemented with 0.1% FA. A volume of 5 µL (5 µM chalcone solution) 
was injected. An oven temperature of 40 °C and a flow of 0.6 mL/min were set. Separation of 
the sample was conducted using the following gradient system: 
0-10 min 100/0→2/98, 10-11 min 2/98 A, 11-11.1 min 2/98→100/0, 11.1-13 min 100/0. 
Data analysis was performed with MassHunter software (B.05.00, Agilent) using automatic 
mass spectrum integration. The compound tables were manually compared to negative and 
matrix control samples and screened for corresponding metabolite masses. 
2.3.3.4 High pressure liquid chromatography–nuclear magnetic resonance 
spectroscopy 
For structure elucidation of major metabolites by means of high pressure liquid 
chromatography–nuclear magnetic resonance spectroscopy (HPLC–NMR), samples were 
sent to the NMR Group of the Max Planck Institute for Chemical Ecology in Jena. 
Samples (combined phase I and II metabolism) were prepared according to the described 
method in chapter 2.3.3.1. The sample size was increased to 5 mL and the concentration of 
chalcones was raised to 100 µM due to lower detection limit of NMR. A longer incubation 
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time of 4 h was chosen in order to achieve a maximized transformation rate of the initial 
compound and consequently an increased metabolite concentration. Reaction was again 
stopped by the addition of ice-cold EtOH (1:1). Samples were vortexed and centrifuged as 
described before. To improve storage stability, EtOH was carefully evaporated; samples 
were refilled with ultra-pure water, and frozen at –20 °C overnight. After freeze-drying, the 
samples were shipped on dry ice and stored at -20 °C prior to analysis. 
Structure isolation and elucidation were conducted by the working group of Dr. Bernd 
Schneider at the Max Planck Institute Jena. 
 
Isolation and structure elucidation of FKA metabolites 
The provided sample was suspended in ultra-pure water ( 3 mL) and extracted with 5 mL of 
EtOAc by stirring for 30 minutes. The procedure was repeated 5 times. The EtOAc layers 
were joined and the solvent was evaporated under vacuum. The same was done for the 
remaining water fraction. The samples were dissolved in a minimum amount of HPLC 
solvents and HPLC fractionation was performed using an Agilent HP1100 Series equipped 
with binary pump G1312A, degaser G1322A, autoinjector G1367A, column oven G1316, 
and G1315B diode array detector controlled with ChemStation Rev.A.08.04. (1008) software. 
The chromatographic separation was performed on a LiChrospher RP-18 column (5 mm, 250 
× 4 mm; Merck KGaA, Darmstadt, Germany) with a guard column (5 mm, 4 × 4 mm) using a 
linear binary gradient of ultra-pure H2O containing 0.1% (v/v) TFA (solvent A) and MeCN 
(solvent B) with a flow rate of 0.8 mL/min. 
For the EtOAc part the following gradient profile was used: 0 min, 5% B; 10 min, 20% B; 
45 min, 100% B; 55 min, 100% B; 57 min, 5% B. Injection volumes: 10 + 10 + 20 + 30 + 40 + 
40 + 40 μL. Column temperature: 30 °C. 
For the water part the following gradient profile was used: 0 min, 20% B; 30 min, 80% B; 
35 min, 80% B; 37 min, 20% B. Injection volume: 50 μL * 19 times. Column temperature: 
30 °C. 
Isolated samples were dissolved in 100 μL MeOH-d4 and measured in 2 mm capillary NMR 
tubes. 1H-NMR spectra were recorded with a Bruker Avance 500 NMR spectrometer (Bruker-
Biospin, Karlsruhe, Germany) operating at 500.13 MHz and equipped with a 5 mm TCI 
cryoprobe. TMS was used as an internal standard. The manually calibrated spectra were 
phase and baseline corrected by TopSpin 3.1 software. 
 
Isolation and structure elucidation of FKB and FKC metabolites 
An Agilent 1100 chromatography system (quaternary solvent delivery pump G1311A, 
autosampler G1313A; Agilent Technologies, Waldbronn, Germany) and a J&M photodiode 
array detector (DAD, detection 200-700 nm; J&M Analytik AG, Aalen, Germany) was used to 
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separate metabolites from crude assay mixtures and recording UV spectra. The LC system 
was controlled by Bruker software HyStar 3.2 (Bruker-Biospin, Rheinstetten, Germany). 
Column: Nucleodur C18 (5 μm, 250 × 4.6 mm; Macherey & Nagel, Düren, Germany) with a 
flow rate of 1 mL/min. A binary linear solvent system of H2O (solvent A) and MeCN 
containing 0.1% FA (solvent B), was used as follows: 0 min: 20% B, 30 min: 80% B, 35 min: 
80% B, 37 min: 20% B. UV detection was performed at a monitoring wavelength of 254 and 
343 nm for FKB metabolites and of 254 and 368 nm for FKC metabolites. 
NMR spectra (1H-NMR, 1H,1H-COSY, 1H,13C-HMBC, 1H,13C-HSQC) were measured on a 
Bruker Avance 500 NMR spectrometer (Bruker-Biospin, Karlsruhe, Germany), operating at a 
resonance frequency of 500.13 MHz for 1H and 125.75 MHz for 13C. The spectrometer was 
equipped with a TCI cryoprobe (5 mm) and 2 mm capillaries (80 µL MeOH-d4) were used for 
measuring NMR spectra with standard Bruker pulse sequences. 
HRESIMS of FKC-3 was recorded on a LC–MS/MS system consisting of an Ultimate 3000 
series RSLC (Dionex, Sunnyvale, CA, USA) system and an Orbitrap mass spectrometer 
(Thermo Fisher Scientific, Bremen, Germany). HRESIMS data were analyzed using 
XCALIBUR (Thermo Fisher Scientific, Waltham, MA, USA) software. 
2.3.4 In vitro degradation stability and microsomal metabolism of the tacrine-
silibinin codrug 
2.3.4.1 Analytical methods 
For determination of codrug amount in the incubation medium and the microsomal incubation 
systems, two different HPLC methods (Table 2.5) and calibrations (see chapter 2.3.4.2 and 
2.3.4.3) were applied. Separation was performed on a C18-column (Hibar® 250-4, 
Purosphere, 5 µm). Oven temperature was set at 40 °C. 
Table 2.5:  Methods for analytical HPLC. M method, A and B eluents A and B, t time [min], A/B 
solvent composition, f flow [mL/min], V injection volume [µL], λ detection 
wavelength [nm]. FA 98% p.a., MeCN for HPLC. 
M A B t A/B f V λ 
C3 0.1% FA 95% MeCN 
(v/v) 
0-20 
20-24 
24-25 
25-30 
80/20→0/100 
0/100 
0/100→80/20 
80/20 
1 10 287 
C4 0.1% FA 95% MeCN 
(v/v) 
0-3 
3-23 
23-24 
24-29 
29-30 
30-33 
80/20 
80/20→20/80 
20/80→0/100 
0/100 
0/100→80/20 
80/20 
1 20 287 
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LC–HRESIMS was performed using UHPLC Agilent 1290 infinity, DAD G4212A, MS Agilent 
6540 UHD Q-TOF with positive and negative electrospray ionization. For separation, a 
Thermo Accucore aQ column (C18, 50x2.1 mm, 2.6 µm) and the following solvents were 
used: eluent A was 0.1% FA, eluent B 100% MeCN supplemented with 0.1% FA. A volume 
of 7 µL was injected. An oven temperature of 40 °C and a flow of 0.6 mL/min were set. 
Separation of the sample was conducted using the following gradient system: 
0-8 min 95/5→50/50, 8-9 min 50/50→2/98 A, 9-10 min 2/98, 10-10.1 min 2/98→95/5, 10.1-
11 min 95/5. The metabolites were detected at two wavelengths (287 nm and 337 nm). 
2.3.4.2 Stability of the codrug under in vitro assay conditions 
The codrug (50 µM) was incubated for 24 h in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Invitrogen) containing 10% heat-inactivated FCS at standard cell culture conditions (37 °C, 
5% CO2) in 96 well plates as they were used for in vitro assays. After 0, 2, 4, 8, 12, and 24 h, 
100 µL hereof were added to 900 µL ice-cold EtOAc, vortexed for 5 min and centrifuged for 
another 5 min at 14 000 rpm at 4 °C. Afterwards, 720 µL of the upper EtOAc phase was 
evaporated under nitrogen stream to dryness and resolved in 80 µL MeOH + 1% FA for 
HPLC quantification using method C3 (see chapter 2.3.4.1). For calibration the peak areas of 
2.5, 5, 10, 20, 40, and 60 µM codrug in MeOH + 1% FA were determined using the same 
HPLC method. The experiment was conducted three times in triplicates. The recovery rate of 
the codrug was 87 ± 4%. 
2.3.4.3 Microsomal metabolism and metabolic stability in microsomal incubation 
systems 
Microsomal metabolism was investigated in five different incubation systems. Metabolism of 
the codrug (50 µM) was performed in 0.1 M PO4 buffer (pH 7.4) at 37 °C in a water bath. For 
phase I metabolism the incubation system consisted of 0.5 mg/mL HLM (20 mg/mL), 3.3 mM 
MgCl2 (110 mM in buffer) and 1 mM NADPH (10 mM in buffer). For the investigation of 
glucuronidation in phase II metabolism, HLM were incubated together with 3.3 mM MgCl2, 
25 µg/mL alamethicin (0.5 mg/mL in 2% MeOH) and 2 mM UDPGA (40 mM in buffer). 
Finally, both phase I and II reactions, were studied in a combined incubation system 
including NADPH as well as UDPGA equivalents. Furthermore, incubation systems without 
microsomes or cofactors served as negative controls. 
The reaction was stopped at different time points (0, 1, 2, 4, 6 h) by adding 100 µL ice-cold 
MeOH to 100 µL of the incubation solution. The mixture was vortexed 5 min and centrifuged 
at 14 000 rpm for 5 min. The supernatant was used for HPLC (method C4) and LC–MS 
analysis (see chapter 2.3.4.1). For calibration the peak areas of 1, 2.5, 5, 10, 20, 30, 40, 50, 
and 60 µM codrug in a MeOH-buffer mixture were determined in three replicates. The 
recovery rate of the codrug in the microsomal incubation system was 105 ± 5%. 
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2.4 Test compounds, solvents, and other chemicals 
Tested kavalactones_________________________________________________________ 
Desmethoxyyangonin (DMY)   isolated from Kava Kava rhizome  
Dihydrokawain (DHK)   isolated from Kava Kava rhizome  
Dihydromethysticin (DHM)   isolated from Kava Kava rhizome  
Kawain (K)   isolated from Kava Kava rhizome  
Methysticin (M)   isolated from Kava Kava rhizome  
Yangonin (Y)   isolated from Kava Kava rhizome  
 
Tested chalcones____________________________________________________________ 
Alpinetin chalcone (A)   synthesis [96-98] 
4-Acetylxanthohumol (4AcXAN)   synthesis [96-98] 
Dihydroflavokawain C (dhFKC)   synthesis [99] 
Dihydrohelichrysetin (dhHeli)   synthesis [99] 
Dihydroxanthohumol C (dhXANC)  synthesis [96-98] 
Flavokawain A (FKA)   synthesis [96-98] 
Flavokawain B (FKB)   synthesis [96-98] 
Flavokawain C (FKC)   synthesis [96-98] 
Helichrysetin (Heli)   synthesis [96-98] 
3-Hydroxyhelichrysetin (3OHHeli)  synthesis [96-98] 
3-Hydroxyxanthohumol H (3OHXANH)  synthesis [96-98] 
3-Methoxyxanthohumol H (3OMeXANH)  synthesis [96-98] 
4-Methylxanthohumol (4MeXAN)  synthesis [96-98] 
4’-Methylxanthohumol (4’MeXAN)  synthesis [96-98] 
Pinostrobin chalcone 91% (P)   PhytoLab, Vestenbergsgreuth, Germany 
Tetrahydroxanthohumol C (thXANC)  synthesis [99] 
Xanthohumol 98% (XAN)   Nookandeh Institut, Hamburg, Germany 
Xanthohumol C (XANC)   synthesis [96-98] 
Xanthohumol H (XANH)   synthesis [96-98] 
 
Tacrine-silibinin codrug_______________________________________________________ 
Silibinin 98% (S)   PhytoLab, Vestenbergsgreuth, Germany 
Tacrine HCl   99% (T)   Sigma-Aldrich, Taufkirchen, Germany 
Tacrine hemi succinamide (THSA)  synthesis [100] 
Tacrine-silibinin codrug (C)   synthesis [100] 
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Positive controls_____________________________________________________________ 
7-Ethoxycoumarin (7-EC)    Sigma-Aldrich, Taufkirchen, Germany 
Staurosporine   99%    Cell Signaling Technology, Danvers, USA 
 
Solvents 
NMR spectra were recorded in deuterated chloroform (Sigma-Aldrich, Taufkirchen) or 
deuterated acetone (aceton-d6, Deutero, Kastellaun). For HPLC analyses methanol (Merck, 
LiChroSolv), acetonitrile (Merck, LiChroSolv), and ultra-pure water were used as mobile 
phase. If not mentioned otherwise, solvents for fractionation, isolation, (HP)TLC analyses, 
and studies of microsomal metabolism had pro analysi (p.a.) quality and derived from Merck 
or Arcos. For preparing stock solutions for cellular assays and microsomal metabolism, either 
dimethyl sulfoxide (p.a. Merck), ethanol (absolute, Baker), or PBS (Biochrom) was used.  
 
Other chemicals 
Ammonia solution 28-30% p.a. Merck, Darmstadt 
Diethylamine > 99% Merck, Darmstadt 
Diphenylboryloxyethylamine > 97% Sigma-Aldrich, Taufkirchen 
Formic acid 98% p.a.  Merck, Darmstadt 
Glacial acid 100% anhydrous  Merck, Darmstadt 
Lichroprep RP-18 (25-40 µm) Merck, Darmstadt 
p-Methoxybenzaldehyde > 98% Merck, Darmstadt 
Polyethylene glycol 400 Merck, Darmstadt 
Silica gel 60 (40-63 µm)  Merck, Darmstadt 
Sulfuric acid 95-97% p.a.  Merck, Darmstadt 
Trifluoroacetic acid 99% Sigma-Aldrich, Taufkirchen 
2.5 Laboratory instruments 
Analytical balance R 160 P, Sartorius, Göttingen 
 
Cell incubator Nu-5500, Nuaire, Plymouth, USA  
 Cellstar 300 compact, Queue Systems, Ashevill, USA 
 
Cell observer AxioObserver.Z1, Incubator XL-S1 with TempModule S, CO2 
Module S and Heating Unit XL S, motorized stage, stage 
Incubator PM S1, HXP120, AxioCam HRm, 
 AxioVision 4.8.1 software, Carl Zeiss, Göttingen  
 
Centrifuges Megafuge 1.0, Heraeus Sepatech, Osterode 
 BR4i, Thermo electron corporation, Langenselbold 
 
2.5 Laboratory instruments 39 
Flash chromatography  Spot Liquid Chromatography Flash, Armen Glider Flash 
system software V 2.3, Armen, Saint Ave, France 
 
Freeze dryer P 10 with pump PK8D, Ilmvac, Ilmenau 
 
Heating plate Thermoplate S, Desaga, Wiesloch 
 
HPLC system, analytical Elite LaChrom: autosampler L-2200, pump L-2130, column 
 oven L-2350, diode array detector L-2455, EZChromElite  
 3.1.7 software, VWR-Hitachi, Darmstadt 
 
HPLC system, semi-prep ProStar: autosampler 410, pumps 210, detector 335,  
 Galaxie Chromatography Data System, Varian, Darmstadt 
 
(HP)TLC device Linomat 5, Reprostar 3, automatic ADC2 Chamber, 
WinCATS 1.4.2 software, Camag, Muttenz, Switzerland 
 
Inverted light microscope CK X 41, Olympus, Hamburg 
 
Laboratory balance MC 1, Sartorius, Göttingen 
 
Laboratory mill A10, IKA, Staufen 
 
Laminar flow bench HERAsafe KS, Thermo 
 SK 1200, BDK, Sonnenbühl 
 
Magnetic stirrer RCT basic, IKA, Staufen 
 
Mass spectrometer Q-TOF 6540 UHD, Agilent 
 
NMR spectrometer Avance 600 Kryo, Avance 400, Avance 300, Topspin 2.1  
 software, Bruker, Ettlingen 
 
pH meter inoLab pH Level 1, electrode SenTix Mic, WTW, Weilheim 
 
Pipettes Research, Research Pro, Eppendorf, Hamburg 
 
Pipettor Accu jet pro, Brand, Wertheim 
 
 
Plate reader SpectraFluor Plus, Xfluor4 V 4.40 software, Tecan,  
 Crailsheim 
 
Rotary evaporator Laborota 4003 control, Rotavac vario control, Heidolph,  
  Schwabach 
 
Thermometer ETS-D4 fuzzy, IKA, Staufen 
   
Ultrapure water purification  Astacus LS, Membra pure, Bodenheim 
system 
 
Ultrasonic Cleaner USC 1700 TH, VWR, Darmstadt 
 
Vortex mixer Vortex Genius 3, IKA, Staufen 
 
Water bath WB 22, Memmert, Schwabach 
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2.6 Statistical analysis 
If not mentioned otherwise for the data subjected to statistical analysis, experiments were 
conducted in (at least) triplicates and repeated independently not less than three times. The 
results of the assays are presented as the mean ± SD. For cell-based assays untreated 
control cells referred as 100% values. 
Statistical analysis was performed applying either GraphPad Prism 4 or PASW Statistics 18 
software. Gaussian distribution of values was tested prior to statistical analysis. Data were 
subjected to one-way ANOVA followed by appropriate post-hoc tests. P values < 0.05 were 
considered statistically significant. 
 3 Isolation of kava constituents and reevaluation of 
their hepatotoxic potential 
3.1 Introduction 
3.1.1 Botany 
The kava plant (Piper methysticum FORST., Piperaceae) is an up to 7 m high, robust, fairly 
succulent, erect, perennial shrub with heart-shaped, pointed, smooth, on both sides green 
leaves of about 15 cm length. Petioles are up to 6 cm long. At maturity, after 3-5 years of 
growth, the root can reach 60 cm in length and 8 cm in diameter and may eventually occur 
as a heavy knotted mass. Flowers appear in irregular inconspicuous spadices of 3-9 cm 
length (Figure 3.1). 
Figure 3.1: The habitus of kava-kava, Piper methysticum FORST., Piperaceae. 
(http://www.naturepacific.com/contents/en-us/d59_kava.html) 
Kava originates mainly from Western Polynesia. However, it is found und cultivated nearly all 
over the Pacific Islands, from Hawaii to Papua New Guinea, with exception of New 
Caledonia, New Zealand, and most of the Solomon Islands. Its widespread cultivation, 
attended by various morphological characteristics of the kava plant, led to classification of 
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different varieties of Piper methysticum by the native people with vernacular names, i.e. apu, 
makea, liwa, mo’i, or papa. These varieties also differ in traditional use [108]. 
The herbal drug consists of the dried (and peeled) rhizomes (Piperis methystici rhizoma; 
DAC 1998) from which roots are mostly removed. The drug is unregularly cut in transverse 
and longitudinal pieces of varying size and shape. Fractures are coarsely fibrous. The outer 
surface appears light yellowish or greyish brown with thin bark. The inner surface is colored 
yellow-white [109]. A kavalactone content of at least 3.5% was demanded by the German 
monograph (DAC 1998). 
3.1.2 Chemical constituents 
The major constituents and pharmacologically active compounds of kava are the 
kavalactones (also called kavapyrones). They possess a typical arylethylene-α-pyrone 
skeleton (Figure 3.2). 
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 R1 R2 R3 R4 C5-C6 C7-C8 
7,8-Dihydrokawain       
Hydroxykawain    OH  ═ 
Kawain      ═ 
11-Hydroxy-12-methoxydihydrokawain OCH3 OH     
11-Methoxy-12-hydroxydehydrokawain OH OCH3   ═ ═ 
7,8-Dihydro-5-hydroxykawain    β-OH   
11,12-Dimethoxydihydrokawain OCH3 OCH3     
Methysticin OCH2O    ═ 
Dihydromethysticin OCH2O     
5,6-Dehydromethysticin OCH2O   ═ ═ 
Desmethoxyyangonin      ═ 
Yangonin OCH3    ═ ═ 
5,6,7,8-Tetrahydroyangonin OCH3      
5,6-Dihydroyangonin OCH3     ═ 
7,8-Dihydroyangonin OCH3    ═  
10-Methoxyyangonin OCH3   OCH3 ═ ═ 
11-Methoxyyangonin OCH3  OCH3  ═ ═ 
11-Hydroxyyangonin OCH3  OH  ═ ═ 
11-Methoxy-5,6-dihydroyangonin OCH3  OCH3   ═ 
Figure 3.2: Kavalactones in kava kava rhizome (modified according to [110]). 
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The content of kavalactones in dried rhizomes varies from 3-20%. Six major kavalactones 
account for 96% of the kavalactone content in extracts namely (+)-kawain (K), (+)-
methysticin (M), desmethoxyyangonin (DMY), yangonin (Y), (+)-dihydrokawain (DHK), and 
(+)-dihydromethysticin (DHM) [111].  
The first isolated compound was reached by Gobley (1860) and Cuzent (1861) and has been 
later identified as M. In 1874, a further crystalline substance was isolated, which was named 
Y by Lewin in 1886. Winzheimer succeeded in isolating DHM in 1908 [108]. More extensive 
investigations by Brosche and coworkers in the first half of the 20 th century yielded the 
isolation of K and DHK together with structure elucidation of previously isolated compounds 
[112]. Moreover, synthesis routes for kavalactones and derivatives were investigated [113]. 
DMY was finally isolated by Klohs et al. in 1959 [108]. Achenbach recorded NMR spectra of 
kavalactones and contributed to structure elucidation and configuration [114]. To date at 
least 19 kavalactones have been isolated and/or identified by various working groups (Figure 
3.2). 
 
In addition, several chalcones (Figure 3.3) and flavanones can be found in Piper 
methysticum. Hänsel et al. were the first who isolated two yellow pigments from a chloroform 
extract [115]. These compounds were identified as methoxylated chalcones and named 
flavokawain A (FKA) and flavokawain B (FKB) due to their color. In 1972, the orange colored 
flavokawain C (FKC) was isolated from a benzene extract [116]. The total content of 
flavokawains in an ethanolic kava extract was determined at 1.1% [117]. 
 
 
 
 
Figure 3.3: Chalcones in kava kava rhizome. 
Flavanones like pinostrobin and 5,7-dimethoxyflavanone are present in kava root extracts as 
minor constituents [118]. C-glycoside flavonoids were identified in kava leaf extracts [119]. 
 
Furthermore, different alkaloids are found in kava as minor constituents. Cepharadione A 
[120] and two pyrrolidine alkaloids [121] have been isolated from kava roots. Investigating 
aerial parts of the plant, the piperidine alkaloids pipermethysticine [122], 3α,4α-epoxy-5β-
pipermethysticine, and awaine [123] were discovered in leaves and stems. 
 
Besides, steroids like stigmasterol, long-chained alcohols [124], derivatives of cinnamic acid 
[125], little essential oil, and starch is present in Piper methysticum. A tabulation of 
constituents is compiled in [126]. 
 R 
Flavokawain A OCH3 
Flavokawain B H 
Flavokawain C OH O
R
H3CO
OHH3CO
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3.1.3 Traditional use 
Kava (kava kava, kawa, ava, awa, yagona) is the term given by the Pacific Islanders to both 
the plant and the psychoactive beverage made from the rhizome. The meaning of the name 
kava is quite broad and ranges from ‘bitter’, ‘sour’, ‘acidic’, ‘salty’, ‘sharp’ or ‘pungent’ to just 
‘beverage’ [108]. 
The origin of kava drinking dates back centuries and is not exactly known. Kava is used as 
intoxicating beverage for many sociocultural or religious aspects by the natives of Oceania 
perhaps comparable to the use of other psychoactive drugs like the peyote by the Native 
Americans. In the 18th century, European discoverers first got in contact with the Oceanic 
plant and the ceremony of kava drinking. 
The preparation of the beverage requires the dried kava root (particles or powder), a bowl, a 
drinking cup, a strainer, and water. The plant material is either mechanically pulverized with a 
mortar and a pestle or it is chewed by young men or women prior to preparation of the 
infusion. The powdered or chewed material is put in the bowl, doused with water, macerated 
some time, and finally strained. The beverage is handed in special cups for ceremonial 
drinking. 
Mostly, kava is used for social ceremonial reason e.g. as a welcome drink for honored 
guests. Besides, it is employed for magico-religious purpose out of respect to gods or spirits. 
Additionally, it plays an important role in traditional medicine. In general, kava drinking is 
thought to have beneficial effect on health. More precise, kava is applied to soothe the 
nerves, induce relaxation and sleep, combat fatigue, reduce weight, and treat asthma, 
common cold, headaches, urinary and fungal infections, and gonorrhea. 
3.1.4 Experimental pharmacology 
Kava extracts and in particular the biologically active kavalactones are extensively analyzed 
toward their activity on central nervous system (CNS) receptors (especially γ-aminobutyric 
acid (GABA) receptors) and neurotransmitters as well as toward the modulation of voltage-
dependent Na+ and Ca2+ channels. An overview of biochemical mechanisms and possible 
molecular targets is given in [127,128]. 
 
Due to similar pharmacological properties of kavalactones and benzodiazepines, the GABA 
receptors as possible targets were investigated. Enhanced binding of the GABA receptor-
agonist [3H]muscimol to GABAA receptors has been described for kavalactones with 
EC50 values ranging from 200 to 300 µM using membrane fractions from different rat brain 
regions [129]. Kavalactone-binding to GABA receptors was discussed and investigated in 
brainstem models [130]. However, isolated kavalactones showed only week binding to 
GABAA receptors and lacked any binding to GABAB [131]. Dinh and coworkers tested 
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methanolic kava extracts from different cultivars on several CNS receptors and found as well 
only week binding to benzodiazepine binding site of GABAA. In contrast to previous findings, 
a potent binding inhibition was observed for the GABA binding site [132]. In summary, the 
modulation of GABAergic activity seems to contribute in any case to the overall 
pharmacological effects of kavalactones. 
 
Alterations in noradrenaline (NA) uptake and monoamine oxidase B (MAO-B) inhibition seem 
to be involved in the psychotropic activity of kava. Inhibition of [3H]NA uptake was observed 
for K (70-80% vs. control) and less distinct for M [133]. One in vitro study examined the 
inhibition of MAO-B in comparison to established antidepressants. Kava extract reversibly 
inhibited MAO-B in intact platelets (IC50 24 µM) and disrupted platelet homogenates (IC50 
1.2 µM). The most potent kavalactone was DMY (IC50 28 µM and IC50 0.12 µM) [134]. 
 
For kava, also anticonvulsive and local anesthetic activities are postulated. Indeed, 
kavalactones exhibit an effect on ion channels and neuronal transmission similar to approved 
mood stabilizers like lamotrigine [135]. The influence of (±)-K on voltage-dependent Na+-
channels was investigated. By veratridine elevated [Na+]i concentrations were rapidly 
reduced to 30% by K with an IC50 of 86 µM [136,137]. (±)-K’s effect on voltage-dependent 
Ca2+ and Na+ channels was further investigated using rodent dorsal root ganglion cells. A 
pronounced decrease of both Ca2+ and Na+ currents was observed [138]. In hippocampal 
neurons, (+)-M and (±)-K showed a voltage-dependent inhibition of Na+ channels by 
interaction with closed and inactivated states of Na+ channels [139]. Isolated guinea-pig 
ileum was used to examine the Ca2+ channel blocking (spasmolytic) properties of K on 
evoked contractile activity. K inhibited dose-dependently the contractile response induced by 
carbachol, but not by caffeine. After nifedipin and pertussis toxin pretreatment of carbachol 
induced ileum contractions, K was able to block the remaining response in high 
concentrations (400 µM). However, K showed no effect on Ca2+ elicited contractions [140]. 
Moreover, kava’s pharmacological properties may as well be mediated through additive 
effects on serotonin 5-HT1A receptors and activation of glutamate (NMDA, N-methyl-D-
aspartate) receptors [141]. 
Compounds of kava root extracts showed COX inhibitory activities. Major kavalactones and 
FKA were tested for COX-I and COX-II inhibition. All compounds demonstrated similar or 
even better COX-I and COX-II inhibition activity than ibuprofen, naproxen, and acetylsalicylic 
acid with DHK and Y being the most potent inhibitors at 100 µg/mL. Moreover, for Y and M, 
free radical-scavenging capacity against stable DPPH radicals was found [142]. A bornyl 
ester of cinnamic acid derivative and FKB, both isolated from a methanol extract, exhibited 
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the strongest COX-I enzyme inhibition at 100 µg/mL. Also, a moderate COX-II inhibitory 
activity was found for extracted compounds [118]. 
 
K and DHK were positively screened for their ability to inhibit tumor necrosis factor alpha 
(TNF-α) secretion by lipopolysaccharide (LPS)-stimulated THP-1 cells and to reduce levels of 
the p65 subunit in cell lysate. In vivo, K pretreated mice were rendered immune to lethal 
doses of LPS [143]. Folmer at al. investigated the influence of kava compounds on the 
nuclear factor NF-κB signaling pathway and discovered a dose-dependent inhibition of TNF-
α induced NF-κB-DNA binding for K, DHK, and the chalcones FKA and FKB. The latter also 
inhibited various protein kinases [144]. In contrast, another working group identified M as a 
potent and non-toxic NF-κB inhibitor (IC50 0.19 ± 0.01 µg/mL) by assay guided fractionation 
[145]. 
 
The kavalactones’ influence on P-glycoprotein (Pgp) was investigated in a fluorescent 
calcein uptake assay. All kavalactones increased intracellular calcein concentration at two 
digit micromolar IC50 values among DMY being the most potent (17.1 µM ± 0.6 µM) [146]. 
Weiss et al. observed an inhibition of Pgp in a Pgp-overexpressing cell line by kava extracts 
(80% inhibition at 170 µg/mL) and by individual kavalactones over a concentration range of 
17-90 µM [147]. 
 
Recently, kavalactones were tested for cannabinoid (CB) receptor affinity and inhibitory 
activity of two major metabolic enzymes of the endocannabinoid system, fatty acid amine 
hydrolase and monoacylglycerol lipase. No inhibitory activity of these enzymes could be 
observed for the test compounds. Y exhibited selective CB1 receptor affinity with Ki of 
0.72 µM (CB2 Ki > 10 µM). These results suggest that the endocannabinoid system might 
also be involved in pharmacological activity of kava [148]. 
3.1.5 Preclinical studies 
Neurological and sedative effects, and anticonvulsive, muscle relaxing, and spasmolytic 
activity of kava extracts or kavalactones have been examined in several in vivo studies, 
mainly in rats and mice. A dichloromethane extract of kava rhizome (150 mg/kg) decreased 
motility and reduced motor control in mice. Besides, at this dose hypnosis and analgesia 
were observed [149]. Apomorphine induced hyperactivity was reduced in rats after 
intraperitoneal administration of an aqueous or dichloromethane extract of the rhizome 
(120 mg/kg) [150]. Administration of kava extract (50-100 mg/kg) or (±)-K (10-50 mg/kg) led 
to reduce muscle tone in cats [151]. A depression of the CNS occurred in rodents after 
intraperitoneal administration of an aqueous rhizome extract [152]. Modulatory effects of 
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kava extracts and kavalactones on the dopaminergic system of rats were detected by Baum 
et al. [153]. Co-administration of kavalactones and pentobarbital in mice potentiated their 
sleeping-time up to 400% for DHM [154]. Neuroprotective effects of kavalactones were 
investigated in a model of focal cerebral ischemia in mice and rats and compared to 
memantine. The kava extract, M, and DHM showed protective effects against ischemic brain 
damage [155]. Analgesic activity of an aqueous and a dichloromethane extract of kava 
rhizome was observed in mice measured by tail-flick reaction times [156]. Also 
anticonvulsant activity of kava extracts on strychnine-induced convulsions was investigated 
in mice [154]. DHM and DHK reduced electroshock-induced seizures in mice and rats [157]. 
3.1.6 Clinical pharmacology 
Several double-blind, randomized, controlled trials have been conducted to proof the efficacy 
of kava extracts in treatment of anxiety disorders. Warnecke et al. performed a study in two 
groups of 20 women with anxiety due to climacteric syndrome [158]. Patients were treated 
with kava WS 1490 extract 300 mg/day (210 mg kavalactones) or placebo for 8 weeks. The 
Hamilton Anxiety scale (HAM-A) was used as rating target. A significant improvement of 
anxiety symptomology associated with very god tolerance was found in the kava group.  
Kinzler et al. investigated the clinical efficacy of kava extracts in patients with non-psychotic 
anxiety syndrome in a double-blind, placebo controlled study (two groups à 29 patients) over 
a period of 4 weeks [159]. Again, the HAM-A score was significantly reduced in the drug 
receiving group. No adverse reactions were observed within the 4 weeks of treatment with 
kava WS 1490 extract. 
A placebo-controlled, double-blind study with 101 patients suffering from anxiety of non-
psychotic origin was conducted by Volz et al. with kava extract WS 1490 over a period of 
25 weeks [160]. There was a significant improvement of anxiety symptoms in the kava group 
starting from week 8. After 24 weeks the HAM-A score of WS 1490 group was 9.7 compared 
to placebo with a value of 15.2. 
Malsch et al. investigated the efficacy of kava WS 1490 extract in benzodiazepine pretreated 
patients with non-psychotic anxiety disorders [161]. Patients received either 300 mg/day of 
kava extract or placebo while benzodiazepine dose was tapered off over 2 weeks followed by 
3 weeks of monotherapy with drug or placebo. The outcome was measured with the HAM-A 
scale, and again WS 1490 was superior to placebo associated with high tolerance of the 
drug.  
Gastpar et al. examined the efficacy and tolerability of 150 mg/day (105 mg kavalactones) of 
kava WS 1490 in 141 patients suffering from neurotic anxiety [162]. The post-treatment score 
of the Anxiety Status Inventory (ASI) observer rating scale did not significantly differ between 
the two groups. However, there was a significant difference between treatment end and 
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baseline, with a superiority of the herbal extract over placebo. Compared to previous studies 
investigating higher doses of kava extracts, the beneficial effects of kava remained relatively 
small. WS 1490 was well tolerated and did not impair liver functions.  
Lehrl et al. tested the clinical efficacy of kava WS1490 extract in 61 patients with anxiety 
associated sleeping disturbances [163]. Patients were treated with either 200 mg/day 
(140 mg kavalactones) of extract or placebo for 4 weeks. Efficacy was measured by a sleep 
questionnaire (SF-B) and by HAM-A. After 4 weeks, significant differences between the two 
groups were observed with superiority of herbal treatment for both the quality and 
recuperative effect of sleep and the HAM-A score.  
Geier et al. investigated lower doses of WS 1490 (150 mg/day) in 50 patients in a placebo-
controlled, double-blind trial for 4 weeks and found a relevant reduction in anxiety versus 
placebo [164]. 
A recent study of Sarris et al. compared effects of a standardized aqueous kava extract 
(60 mg kavalactones) to oxazepam treatment in a randomized, placebo-controlled, double-
blind study [165]. Patients received kava extract (3 x 60 mg/day), oxazepam (30 mg), or 
placebo for one week. For oxazepam there was a significant reduction in anxiety, which was 
not found for kava treatment under applied conditions. 
 
Pittler and Ernst compiled 12 double-blind, randomized, controlled trials and performed a 
meta-analysis of data using total score on the HAM-A [166]. The results suggest significant 
reduction of the HAM-A score in patient receiving kava extract (total of 197 patients) 
compared with patients receiving placebo (total of 183 patients) although the effect seems to 
be weak. Within the 1-24 weeks of treatment, data imply safety of kava extracts. However, 
authors recommend long-term safety studies with larger sample sizes. 
Another meta-analysis was conducted in 2005, investigating the efficacy of acetonic kava 
WS 1490 extract in patients with non-psychotic anxiety disorders [167]. Individual patient 
data of 6 placebo-controlled, randomized trials were included. HAM-A score was used as 
endpoint parameter. Data analysis showed an improvement on the HAM-A scale with WS 
1490 extract, on average achieving 5.49 points less than the placebo. Therefore, the authors 
suggest acetonic kava extracts to be effective and to constitute a therapeutic alternative to 
benzodiazepines and antidepressants in the treatment of non-psychotic anxiety disorders. 
3.1.7 Pharmacokinetic studies 
Bioavailability of kavalactones in ethanolic and aqueous extracts was studied in vitro using 
Caco-2 cell monolayers [168]. The extracts showed only minor differences in ratio of 
kavalactones (in contrast to investigations of Coté [111]) but there was a difference in total 
amount (204 mg/mL in ethanolic and 103 mg/mL in aqueous extracts). Good bioavailability 
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was found for kavalactones as they rapidly crossed the Caco-2 monolayers. Apparent 
permeability (Papp) calculated from uptake data from 10 to 90 min was for all > 40 x 10
-6 cm/s. 
Complete intestinal absorption is considered for Papp > 1 x 10
-6 cm/s. Y was potentially 
retained in Caco-2 cells as recovery on the apical side was only 40%. Permeability of purified 
K was significantly lower compared to K uptake from extracts. Bioavailability was not 
affected by the extraction method. 
 
Pharmacokinetics of K has been investigated in rats [169] and humans [170]. Tarbah et al. 
studied kinetics after administration of a single oral dose of 800 mg K in a self-medication 
study. K metabolites were detected in serum and urine samples. The main metabolite of K is 
p-hydroxykawain, which was found in serum and urine in its free (~ 10% in serum) and 
conjugated forms (glucuronide and sulfate). Further metabolization takes place to p-hydroxy-
7,8-dihydrokawain, which was only detected in urine in form of its conjugates. Opening of the 
lactone ring, demethylation, decarboxylation and oxidation leads to 6-phenyl-5-hexene-2,4-
dione which was detected in urine after 24 h. K is furthermore dehydrated to form 5,6-
dehydrokawain (DMY). The latter molecule is hydroxylated and demethylated to o-
desmethyl-hydroxy-5,6-dehydrokawain. Serum concentrations within 1-4 h after oral uptake 
ranged between 40 and 10 ng/mL for K, 300 and 125 ng/mL for p-hydroxykawain, and 90 
and 40 ng/mL for o-desmethyl-hydroxy-5,6-dehydrokawain. The major metabolite p-
hydroxykawain appears in serum in free and conjugated forms with a lag time of 0.25 h and 
peaks after 0.75 h. The half-lives of free and conjugated forms range between 0.7 and 1.9 h 
indicating that K metabolites can be found up to 10 h in serum samples. 
Mathews and coworkers dealt with K pharmacokinetics in rats [169]. After intravenous 
administration of 7 mg/kg K, an initial plasma concentration of 7.2 µg/mL was determined. K 
was rapidly eliminated with a mean half-life of 0.63 h. Oral administration of 100 mg/kg K 
resulted in ~ 50% bioavailability, Cmax of 2.6 µg/mL, and a mean half-life of 1.3 h. They could 
also show that K bioavailability is improved with co-administration of kava extract. Cmax 
doubled to 5.4 µg/mL. This is in accordance to findings of Matthias et al. [168]. 
 
Fu et al. studied the microsomal metabolism of kavalactones [171,172]. A HPLC quantitative 
assay was established and validated for K, M, and DMY. P-hydroxykawain, m,p-
dihydroxykawain, and p-hydroxyyangonin were identified as primary metabolites [171]. 
Moreover, cytochrome P450 isoforms responsible for kavalactone metabolism were 
examined [172]. CYP3A1/3A23 was found to be responsible for kavalactone metabolism in 
female rats, CYP3A2 in male rats. For DMY, CYP2C6 and CYP2C11 were involved in males 
and CYP2C12 in females. Kavalactone metabolism was also investigated in the isolated 
perfused rat liver [173]. The rat livers were exposed to K, M, and DMY for 120 min. 
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Metabolism was found to be of first-order nature with similar half-lives of decay (1.2 – 3 h). P-
hydroxykawain and m,p-dihydroxykawain were found as metabolites. Biliary excretion of 
kavalactones was negligible. 
3.1.8 Adverse reactions and drug interactions 
An observatory study involving 4049 patients consuming orally 105 mg kavalactones per day 
(standardized extract of Piperis methystici rhizoma) for seven weeks revealed 61 cases 
(1.5%) of adverse reactions [174]. The major reactions were gastrointestinal disturbances or 
allergic skin reactions. Another study with 3029 patients taking 240 mg of a standardized 
kava extract orally for four weeks reported similar side effects in 2.3% of patients. Chronic 
administration of kava rhizome preparations may cause a transient yellow discoloration of the 
skin and nails. Furthermore, disturbances in visual accommodation occurred after ingestion 
of large doses of kava [109]. Anti-dopaminergic side effects were reported in 4 patients with 
symptoms similar to Parkinson’s disease [175]. 
 
Aqueous kava kava extracts have been used for centuries for medicinal, ceremonial and 
sociocultural purpose by different ethnic groups from Pacific Islands (see chapter 3.1.3). In 
1990, standardized acetonic or ethanolic kava rhizome extracts were established on the 
German market (e.g. Kavasedon®, Laitan®, Kava ratiopharm®) for symptomatic treatment of 
mild states of anxiety and nervous disorders. The pharmacology of kava extracts is 
extensively investigated. Numerous data of experimental pharmacology as well as clinical 
studies are available, which proof the efficacy of the drug (see chapters 3.1.4 and 3.1.6). 
Longtime, Kava was also considered to be safe with a very favorable risk profile and 
kavalactone extracts were estimated as valuable drugs in rational phytotherapy.  
Since 1998, several cases of severe hepatotoxic side effects arose that were connected to 
kava intake [79,176–184] (an overview of case reports is given by Teschke and Stickel 
[64,79,80]). As a consequence, kava containing drugs were banned from the German market 
by the BfArM in 2002. Other European countries, Canada and Australia reacted equally, 
even so a reevaluation of the case reports of the Commission E [185] and the Society of 
Medicinal Plant Research [186] revealed some inconsistencies like double reports of 
identical cases, probable influence of co-medication, and alcohol abuse or over-dosage. 
Pursuant to Schmidt and Nahrstedt [185], only 4 of 78 originally reported cases could be 
reasonably connected to adverse events against kava and only one could be attributed 
directly to kava intake in conform dosages (120 mg/d) recommended by the monograph of 
the German commission [176]. However, authors only consider direct hepatotoxicity of kava 
although indirect mechanisms may lead to toxic effects as well [187,188]. Putative 
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hepatotoxicity of kava, kava extracts and kava constituents and possible mechanisms are 
extensively discussed in chapter 3.3.3. 
 
Drug interaction potential of kava is extensively treated in literature [189,190]. Kava extracts 
and the active principle, the kavalactones, have shown to be potent inhibitors of cytochrome 
P450 enzymes [169,191–193]. 
Mathews et al. investigated the inhibition of cytochrome P450 enzymes of a kava extract 
normalized to 100 µM kavalactones as well as the effect of individual kavalactones [191]. 
The kava extract (100 µM) markedly inhibited CYP2C9, CYP2C19, and CYP3A4 about 78% 
to 92%. An effect was already present at a kavalactone concentration of 10 µM. CYP1A2 
(56% inhibition), CYP2D6 (73%), and CYP4A9/11 (65%) were also significantly affected. 
Kavalactones were tested in concentrations of 1 and 10 µM. With exception of K, cytochrome 
inhibition was detected for all assayed kavalactones at 10 µM: CYP2C9 was inhibited by 
DMY (42%), M (58%), and DHM (69%); CYP2C19 by DHM (76%); CYP2D6 by M (44%); and 
CYP3A4 by DMY (40%), M (27%), and DHM (54%) [191]. An extended study by Mathews et 
al. revealed inhibition of CYP2C9, CYP2C19, CYP2D6, and CYP3A4 by a composite 
formulation of kavalactones. They investigated the inhibition kinetics of M, DHM, and DMY 
with regard to the mostly affected isoforms CYP2C9 and CYP2C19. K i values for CYP2C9 
inhibition were 5 µM for M and 9 µM for DMY, and 7 µM for DHM inhibiting CYP2C19 [169]. 
Furthermore, the influence of kava extracts and sub-fractions on CYP3A4 was analyzed. The 
fraction containing kavalactones was identified as major inhibitory principle with 60% 
inhibition [192].  
Zou and coworkers examined the influence of the six major kavalactones on recombinant 
human CYP isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, the most 
important isoforms involved in drug metabolism. A distinct inhibitory activity (IC50) was found 
for CYP1A2 by DMY (1.70 µM), for CYP2C19 by DHM (0.43 µM), DMY (0.51 µM), M 
(0.93 µM), and K (4.86 µM), and for CYP3A4 by M (1.49 µM) and DHM (2.69 µM). Partly, 
enzyme inhibitory activity was equal to or even more pronounced than that of used positive 
controls (furafylline for CYP1A2 1.65 µM; tranylcypromine for CYP2C19 5.46 µM). Y could 
not be investigated due to its native fluorescence [193]. In summary, collected data suggest 
a high potential for pharmacokinetic herb-drug interactions as a number of CYP enzymes is 
significantly affected by kava extracts and especially kavalactones. 
 
Additionally, several putative pharmacodynamic drug interactions have been reported for 
kava and are listed in [189]. The impact of a simultaneous intake of kava extract and ethanol 
was evaluated in two volunteer clinical studies [194,195]. Whereas Herberg et al. did not 
detect any effect of kava in combination with alcohol, Foo et al. found a potentiated sedation, 
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intoxication, and impairment of cognition/coordination. The interaction potential of kava with 
bromazepam was examined in a double-blind, randomized, cross-over trial on 18 volunteers 
receiving either 800 mg of a kava extract, 9 mg bromazepam, or both for 14 days. No 
significant differences between groups were observed. In contrast, a human case report was 
published connecting kava and alprazolam intake, which led to a comatose state in a 54-
year-old man [196]. 
Schelosky et al. reported a possible interaction of kava with levodopa in a 76-year-old man 
suffering from Parkinson’s disease. Frequency and duration of “off-periods” were increased 
[175]. 
Rhabdomyolysis was observed in a 29-year-old man who took a herbal product containing 
caffeine, Ginkgo biloba, and kava extract. A putative interaction between the methylxanthine 
effects and the antidopaminergic activities of kava were discussed [197]. However, this is the 
only case report suggesting an interaction between kava and caffeine.  
3.1.9 Kava extracts, approved indication, posology 
In contrast to traditionally used water infusions, most commercially available kava extracts 
are prepared by ethanolic or acetonic extraction of rhizomes. Whereas no qualitative 
differences of traditional and industrial kava extracts were detected by TLC [198], aqueous 
and organic kava extracts differ in total amount and ratio of kavalactones [111]. The 
kavalactone content of extracts ranges from 30 to 70%; 96% of kavalactone content is 
contributed to the six major constituents.  
Kava extracts were approved for treatment of mild states of anxiety or insomnia due to 
nervousness, stress, or tension. The daily dosage advised by the German monograph was 
60-120 mg of kavalactones (commission E). 
In 2002, all kava containing drugs were banned from the German market due to argued 
hepatotoxic side effects. 
3.2 Aim of the study 
Standardized acetonic kava root extracts have widely been used as approved herbal 
remedies for treatment of non-psychotic anxiety disorders. In recent years, several cases of 
hepatic necrosis have been reported as severe side effects in connection to intake of 
commercially available kava products.  
Hence, this study was aimed to isolate and identify major constituents of an acetonic extract 
of rhizome of Piper methysticum. Since the ban of kava in Germany in 2002, kava 
hepatotoxicity has been extensively reviewed [187,188,199–205], albeit it still remains a 
controversial issue: possible mechanisms as well as different constituents responsible for 
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hepatotoxic effects are discussed. However, above all there is a lack of novel experimental 
data investigating the toxic potential of individual major and minor constituents. With regard 
to still incomplete data, the study should give a comparative insight into the in vitro 
hepatotoxicity of major kavalactones and chalcones in order to identify putative toxic 
compounds and estimate the overall hepatotoxicity of kava. 
3.3 Results and discussion 
3.3.1 Fractions and isolated structures 
The extraction method is described in chapter 2.1.1. The fractionation and isolation was 
carried out mainly by medium pressure liquid chromatography (MPLC) / flash 
chromatography (see chapter 2.1.2). The complete fractionation scheme is presented in 
Figure 3.4. One part of the crude extract (≈ 5 g) was used for establishment and optimization 
of the flash chromatographic methods (see chapter 2.1.2.1). First, 11.86 g of the crude 
extract was separated into eight fractions (A-H) using method F1. Fraction B (0.11 g, Rt ~ 36-
43 min) contained mainly a chalcone, which was identified as FKB. Fraction D and E 
contained a further chalcone, namely FKA (0.1 g and 0.2 g, Rt ~ 56-61 min). The 
kavalactone fraction (fraction G, 7.91 g, Rt ~ 62-84 min) was separated from most other 
constituents. Thereby, two compounds already precipitated in the tubes: the yellow needles 
(0.49 g) and white crystals (0.69 g) were sucked off and dried in an exsiccator. The 
precipitates were further purified by recrystallization (see chapter 2.1.2.3) and pure Y (0.41 g) 
and M (0.45 g) were finally obtained. Fraction G, containing all kavalactones, was further 
separated in seven sub-fractions (G1-G7) using method F2. Mainly, fraction G2 (5.46 g, Rt ~ 
25-35 min) and G4 (1.33 g, Rt ~ 47-68 min) had considerable contents. In fraction G2, DHK, 
K, DHM, and M were separated from DMY and Y in fraction G4. Moreover, DMY (0.35 g) 
partly precipitated in the tubes and was carefully sucked off and dried. Subsequently, 
fractions G2 and G4 were subjected once again to flash chromatography using methods F3 
and F4 respectively. Separation of G2 resulted in eight sub-fractions. Quite pure isolates 
were obtained for G2.2 (DHK, 1.14 g, Rt ~ 40-43 min), G2.4 (K, 1.83 g, Rt ~ 47-55 min), and 
G2.6 (DHM, 0.24 g, Rt ~ 60-61 min). Part of the fraction G2.4 was recrystallized in methanol 
due to still present impurities (see chapter 2.1.2.3). Additionally, methods F5-F7 were used 
for purification and yielded in 0.45 g pure DHK (Rt ~ 33-37 min) and 0.31 g K (Rt ~ 33-
40 min). For fraction G2.6’, the HPLC method H1 (see chapter 2.1.2.2) was applied to finally 
obtain pure DHM (0.17 g, Rt = 18 min). Finally, fraction G4.2 and precipitated DMY were 
purified using method F8. At the end, 0.16 g of DMY (Rt ~ 47-57 min) was isolated.
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Figure 3.4: Fractionation scheme. Used methods are describe in chapters 2.1.2.1 and 2.1.2.2. 
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Figure 3.5: Chemical structures of isolated kavalactones. 
The six major kavalactones (Figure 3.5) were isolated in sufficient amounts with a very high 
degree of purity using flash techniques. FKB and FKA were identified in fraction B and 
fractions D/E, respectively. FKC was not found, probably due to a kavalactone like 
chromatographic behavior. Fractionated chalcones were not further purified as they were 
synthesized by our working group for pharmacological testing. 
3.3.2 Analytical characterization of isolated kavalactones 
Identity of isolated compounds was confirmed by 1H NMR spectroscopy (see chapter 
2.1.3.2). Chemical shifts were compared to literature [206]. Purity of isolated kavalactones 
was determined by HPTLC (1 mg/mL, 7.5 µL) with solvent system T1 (see chapter 2.1.3.1) 
and HPLC (1 mg/10 mL; 10 µL) using method P1 (see chapter 2.1.3.3).  
Table 3.1: HPTLC and HPLC analysis of kavalactones. 
 HPTLC HPLC 
 365 nm AA/H2SO4 Rf λ [nm] Rt [min] purity [%] 
K - red 0.23 244 11.75 99 
DHK - brown 0.25 236 11.93 99 
M - grey 0.17 264 11.29 95 
DHM - blue 0.21 235 11.39 98 
Y blue green 0.24 356 12.57 100 
DMY - violet 0.30 255 12.63 98 
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Figure 3.6: HPTLC of isolated kavalactones. On the left: 254 nm, on the right: daylight after 
derivatization with anisaldehyde reagent. 
The results of the HPTLC (Figure 3.6) show no detectable impurities at 254 nm, 365 nm, and 
daylight. All kavalactones quench fluorescence at 254 nm; Y exhibits a blue fluorescence at 
365 nm. After derivatization with anisaldehyde reagent, the kavalactones react to bright 
colored products. Due to similar chemical structures of the kavalactones, their 
chromatographic behavior resembles as can be seen from Rf and Rt values. Therefore, DMY 
is estimated to be the most lipophilic and M the most hydrophilic of the compounds. LogP 
values confirm these findings and were calculated for M as 1.51, for DHM as 1.81, for K as 
1.65, for Y as 1.99, and for DMY as 2.05 [207]. The purity of the isolates was confirmed by 
HPLC (Table 3.1). For all compounds, a purity of at least 95% was found. 
The analytical characterization of the synthesized kavachalcones (FKA-C) is described in 
chapter 4.3.1. 
3.3.3 In vitro cytotoxicity of kavalactones and chalcones, major and minor 
constituents in kava rhizome extract 
Since in 2002 kava containing products were banned by German health authorities, a 
controversial dispute broke out concerning putative culprits and possible mechanism of kava 
hepatotoxicity. Despite the necessity of novel approaches, still quite little new experimental 
data are available which evaluate and compile the toxic potential of individual kava 
constituents. Thus, the hepatotoxic potential of the six kavalactones and three chalcones, 
major and minor constituents of the acetonic kava rhizome extract, was (re)assessed using 
two human hepatoma cell lines (HepG2, HuH-7), and for comparative evaluation of 
potentially liver-specific effects, an intestinal cell line (Caco-2, see chapter 2.2.2.3). Cells 
were cultivated and treated as described in chapter 2.2.4. Used cell culture reagents and 
expendables are listed in chapters 2.2.1, 2.2.2 and 2.2.3. The influence of the individual 
compounds on viability or metabolic activity and cell proliferation was investigated with MTT 
(see chapter 2.2.5.1) and CV (see chapter 2.2.5.2) assay, respectively. The test 
concentration ranged from 10 to 100 µM and the incubation period was 24 h.  
DHM M DHK K DMY Y DHM M DHK K Y DMY 
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The question of suitability of the test concentration range can be answered by a theoretical 
approach and in vivo pharmacokinetic data. Maximum daily oral dose of kavalactones is 
120 mg, resulting in an average dose of 20 mg for each kavalactone. After a single oral dose 
of 200 mg (±)-K in human, a maximum plasma concentration of 18 µg/mL was detected [24]; 
thus, bioavailability was approximately 50%. Other experiments in rats have shown 
increased absorbance of K in presence of other kavalactones [168] so that at least 50% 
bioavailability can be assumed for kavalactones ingested with kava extracts. Assuming an 
average molecular weight of 250 g/mol, a blood volume of 6 L, and a minimum bioavailability 
of 50%, blood concentrations of 2 µg/mL (~ 8 µM) might be reached. In tissues like the liver, 
concentrations may even be higher. As short-term toxicity of kavalactones in liver cells is 
addressed, the concentration range of 10-100 µM is considered adequate. 
Table 3.2 shows the results of the MTT and CV assay for all tested kavalactones indicating 
all concentrations with significant effects on cell viability and proliferation. The two hydrated 
compounds DHK and DHM had no significant influence on viability and cell number up to the 
highest concentration tested. K and M decreased viability of HepG2 cells significantly already 
at low concentrations (10 µM and 30 µM respectively). Interestingly, the effect seemed to be 
dose independent as viability remained constant at around 70-80% even at 100 µM. There 
was no measurable influence on cell proliferation. DMY exhibited a slight but significant 
effect on both viability of HepG2 and HuH-7 and cell proliferation of HuH-7 and Caco-2. 
Viability of DMY treated cells remained at around 70% for HepG2 (50-100 µM) and 80% for 
HuH-7 (100 µM). Cell number of HuH-7 decreased to 80% starting at 80 µM, and to 80% at 
100 µM for Caco-2. A pronounced and dose-dependent impact on cell viability of HepG2 and 
HuH-7 was found for Y starting already at 10 and 30 µM with higher concentrations being 
more toxic. Calculated IC50 values for HepG2 were 60 ± 13 µM and for HuH-7 52 ± 9 µM 
(Table 3.3). Loss of cell viability was also observed for Caco-2. As it was less distinct and 
leveled off at 70% (50-100 µM), no IC50 value could be calculated. Y also impaired cell 
proliferation of HepG2 and HuH-7 already at low concentrations (10 µM). Cell number was 
decreased to 70% and 80% of control, respectively, unchanging over the whole 
concentration range. In comparison, cell number of Caco-2 was only affected at the highest 
test concentration. 
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Table 3.2: Toxicity of kavalactones on HepG2, HuH-7, and Caco-2 cells determined by MTT 
and CV assay. Concentrations [µM] are indicated for significant effects (p < 0.05): 
v [%] remaining viability, p [%] remaining cell number, referred to untreated control 
cells (100%); (-) no significant effect. Values are indicated as the means ± SD (n = 
3). Statistical analysis (one-way ANOVA followed by Dunnett’s multi-comparison 
post-hoc test) was performed using GraphPad Prism 4 software. 
 MTT and CV assay 
  HepG2 HuH-7 Caco-2 
 c [µM] v [%] p [%] v [%] p [%] v [%] p[%] 
DMY 10 
30 
50 
60 
70 
80 
90 
100 
- 
- 
78 ± 11 
67 ± 10 
69 ± 7 
72 ± 10 
80 ± 6 
73 ± 11 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
81 ± 4 
- 
- 
- 
- 
- 
82 ± 11 
82 ± 11 
81 ± 17 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
80 ± 4 
Y 10 
30 
50 
60 
70 
80 
90 
100 
76 ± 15 
62 ± 5 
50 ± 4 
46 ± 7 
44 ± 7 
43 ± 2 
44 ± 5 
52 ± 9 
72 ± 5 
69 ± 9 
72 ± 4 
70 ± 4 
67 ± 6 
70 ± 3 
71 ± 4 
75 ± 5 
- 
70 ± 6 
46 ± 10 
40 ± 8 
40 ± 8 
39 ± 8 
39 ± 9 
40 ± 10 
86 ± 14 
85 ± 6 
81 ± 4 
80 ± 4 
83 ± 5 
76 ± 5 
83 ± 6 
79 ± 4 
- 
- 
75 ± 11 
69 ± 10 
69 ± 8 
71 ± 7 
70 ± 8 
70 ± 6 
- 
- 
- 
- 
- 
- 
- 
81 ± 1 
DHK - - - - - - - 
K 10 
30 
50 
60 
70 
80 
90 
100 
76 ± 3 
76 ± 6 
71 ± 2 
70 ± 3 
74 ± 4 
70 ± 6 
77 ± 5 
82 ± 8 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
DHM - - - - - - - 
M 10 
30 
50 
60 
70 
80 
90 
100 
- 
84 ± 12 
83 ± 7 
75 ± 4 
74 ± 6 
72 ± 8 
76 ± 6 
76 ± 2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
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Direct hepatotoxicity of kavalactones and kavalactone rich extracts has been assessed in 
numerous in vitro studies yielding different and partly inconsistent results. Tang et al. studied 
the in vitro toxicity of Y, M, and K in HepG2 cells using lactate dehydrogenase (LDH) release 
and ethidium bromide assay [208]. Toxic effects were observed for M and K at 100 and 
200 µM, respectively. For Y, pronounced decrease of cell viability to 40% at 25 µM in the 
ethidium bromide assay was detected. Thus, these results are in good accordance to 
findings of the present study where Y also showed distinct cytotoxicity in HepG2. 
Furthermore, the mode of cell death was elucidated using acridine orange/ethidium bromide 
dual staining. Early and late apoptotic cells were detected after a treatment with 200 µM M 
and 25 µM Y but not with 200 µM K. Glutathione levels were not decreased by kavalactone 
treatment so glutathione depletion may not be the cause for observed toxicity.  
These findings differ from other in vitro studies, which analyzed the effect of individual 
kavalactones on ATP levels in primary human hepatocytes [209]. M and DMY were found to 
be the most toxic and, surprisingly, Y the least toxic kavalactone.  
Nerurkar et al. investigated the toxicity of DMY and DHM in HepG2 and found no increased 
LDH release up to 200 µM and 24 h of treatment [210]. In preliminary experiments individual 
kavalactones failed to show any toxic potential in HepG2 at concentrations less than 0.5 µM 
for up to two weeks. DHM and DMY exhibited no toxicity at 50 and 100 µM up to 8 days of 
treatment. Unfortunately, authors did show any data of long-term toxicity.  
Gebhardt et al. examined the cytotoxicity of kava extracts and kavalactones in rat 
hepatocytes and HepG2 [211]. No cytotoxic effects of kavalactones were detected in HepG2 
(IC50 > 200 µg/mL ~800 µM). K and M were the most toxic constituents in rat hepatocytes 
with IC50 values of 45 µg/mL (~ 200 µM) and 63 µg/mL (~ 230 µM). A native ethanolic kava 
extract was toxic in concentrations above 250 µg/mL, and the acetonic extract at 
concentrations above 125 µg/mL, whereas the commercial extracts did not exhibit any 
toxicity. Used assay systems were only insufficiently indicated.  
Another study also identified Y as most hepatotoxic kavalactone in HepG2 (IC50 ~ 100 µM). 
However, no toxicity was observed in an immortalized human hepatocyte cell line L-02 [212]. 
Commercial kava extracts and kavalactones were also tested for mutagenicity and toxicity in 
L5178Y mouse lymphoma cells [213]. DMY and Y appeared to be the most toxic 
components. However, both extracts and individual kavalactones lacked any mutagenic 
response in the mutation assay with addition of human liver S9 activation. 
Lüde et al. compared the hepatocellular toxicity of kava leaf and root extracts in HepG2 and 
isolated liver mitochondria [214]. Methanolic and acetonic root extracts contained 
approximately 80% kavalactones and 0.011% pipermethysticine whereas the methanolic leaf 
extract had 24% kavalactones and 1.34% pipermethysticine. The kava leaf extract showed 
lower cytotoxicity and less mitochondrial impairment compared to root extracts. The authors 
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draw the conclusion that rather the kavalactones than the alkaloid pipermethysticine can be 
considered as the toxic principle in kava extracts. These results contradict the findings of 
Nerurkar et al. who found more pronounced toxicity of pipermethysticine compared to 
individual kavalactones [210]. 
One reason for the huge differences in assay results could be the use of different assay 
systems with different sensitivity degrees. Furthermore, findings in HepG2 and primary 
hepatocytes (also the use of hepatocytes from different species) are not necessarily 
comparable. For example, cytochrome P450 enzymes are highly down-regulated in HepG2 
whereas primary hepatocytes normally possess the whole range of metabolizing enzymes. 
Primary human hepatocytes - if available - still remain the “gold-standard” in any in vitro 
hepatotoxicity approach. Nevertheless, a re-evaluation of toxicity especially of Y in primary 
hepatocytes compared to liver cell lines would be a very interesting issue. 
 
Not only the in vitro findings but also in vivo toxicity testing leads to different results 
concerning kavalactone or kava extract toxicity. Both aqueous and organic extracts as well 
as single kavalactones have been investigated. Sorrentino et al. assessed the long-term 
toxicity of an ethanolic kava extract (daily 73 mg kavalactones/kg) in rats over 6 month and 
found no signs of hepatotoxic effects [215]. Singh et al. investigated the effects of an 
aqueous kava extract on liver function in rats (daily 200-500 mg kavalactones/kg) for up to 4 
weeks and detected no altered levels of ALT, AST, ALP, or LDH [216]. Clayton et al. 
examined the effects of an organic kava extract in concentrations from 0.25 up to 2 g 
extract/kg/day in rats [217]. Time- and dose-dependency of hepatotoxicity was revealed. No 
hepatotoxic effect was observed with doses of 0.25 g/kg/d. Toxicity of 1 g/kg/d appeared 
after 93 days of treatment and after 4 days with 2 g/kg/d. Another study from 2006, 
investigating the effect of an acetonic and an ethanolic extract at three different oral doses 
from 31 to 133 mg/kg in rats, observed no liver injury based on serum markers and serum 
lipid peroxidase status [218]. K’s effect on hepatic ultrastructure was tested by infusing 10 
µg/mL K solution for 2 h in rats [219]. Histological analysis revealed severe vascular and 
endothelial damages in the livers of K treated rats compared to control. A recent study 
investigated the hepatotoxicity of K and M in perfused livers of rats, which were either 
pretreated with the macrophage intoxicant gadolinium chloride or not [220]. An extensive 
damage was observed in kavalactone-perfused livers whereas the damage was significantly 
lower with a gadolinium chloride pretreatment. These results indicate that the activation of 
liver macrophages may be a factor for observed hepatotoxicity of kavalactones. 
In general, kavachalcones (Figure 3.7) exhibited a more pronounced cytotoxicity compared 
to kavalactones with exception of Y (Table 3.3). The most cytotoxic compound was FKB, 
followed by FKC and then FKA. The latter compound significantly reduced cell viability of 
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HepG2 and HuH-7 but not of Caco-2 cells. For HepG2, an IC50 of 73 ± 10 µM (Table 3.3) 
was determined. Viability of HuH-7 cells was significantly decreased to 80% at 80 µM and to 
67% at 100 µM. Cell proliferation was impaired in all cell lines. For FKA, an IC50 of 71 ± 8 µM 
was calculated for HepG2 and an IC50 of 90 ± 12 µM for HuH-7. Cell number of Caco-2 was 
only affected at high concentrations and decreased to around 70% at 100 µM. For FKC, a 
higher toxicity was observed in liver cell lines. IC50 values determined by MTT assay were 55 
± 7 µM for HepG2 and 58 ± 5 µM for HuH-7. In Caco-2 cells, FKC effects on viability were 
less pronounced and completely absent regarding cell proliferation. Viability at 100 µM was 
still 75% in comparison to only 28% in HepG2 and 19% in HuH-7. Cell number of HepG2 
was significantly reduced at 60 µM and determined as 53% at 100 µM; for HuH-7 an IC50 of 
92 ± 11 µM was found. FKB was by far the most toxic of all tested kava compounds in all 
three cell lines herein again the liver cell lines being more sensitive. IC50 values assessed by 
MTT assay were 33 ± 1 µM, 42 ± 2 µM, and 70 ± 4 µM for HepG2, HuH-7, and Caco-2. 
Moreover, the compound exhibited a strong anti-proliferative and in higher concentrations 
also a cytotoxic effect. IC50 values in the CV assay were 35 ± 3 µM, 42 ± 3 µM, 91 ± 17 µM 
for HepG2, HuH-7, and Caco-2, thus ranging in the same concentrations as IC50 values of 
cell viability. Accordingly, toxic potential of FKB is rather explainable due to decrease of cell 
number than due to enzymatic impairment. 
Table 3.3: IC50 values of toxic kava constituents determined by nonlinear regression using 
GraphPad Prsim 4 software. (-) IC50 value was not determinable in the test 
concentration range (10-100 µM). Calculated values are presented as mean ± SE.  
 IC50 [µM] 
 HepG2 HuH-7 Caco-2 
 MTT CV MTT CV MTT CV 
Y 60 ± 13 - 52 ± 9 - - - 
FKA 73 ± 10 71 ± 8 - 90 ± 12 - - 
FKB 33 ± 1 35± 3 42 ± 2 42 ± 3 70 ± 4 91 ± 17 
FKC 55 ± 7 - 58 ± 5 92 ± 11 - - 
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Figure 3.7: Toxicity of kavachalcones: A = FKA; B = FKB; C = FKC; 1 = MTT; 2 = CV; black bars 
HepG2; grey bars HuH-7; white bars Caco-2. Values are presented as means ± SD 
(n = 3) referred to untreated control cells (ctl/ctl2 = 100%); ctl1 = initial cell density 
(before treatment). Statistical analysis (one-way ANOVA followed by Dunnett’s 
multi-comparison post-hoc test) was performed using GraphPad Prism 4 software. 
Levels of significance *p < 0.05; **p < 0.01. 
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FKB has been previously identified as cytotoxic constituent of a methanolic kava root extract 
by bioassay-guided fractionation [221]. The finally isolated compound exhibited pronounced 
cytotoxic effects on HepG2 in MTT (IC50 8.4 µg/mL ~ 30 µM), LDH, and AST assay 
comparable to the findings of our present study. FKB has also shown to be a potent COX-I 
and moderate COX-II inhibitor [142]. It is discussed whether this might contribute to the 
hepatotoxic potential [200]. A recent study investigated the molecular mechanisms of FKB 
toxicity in HepG2 and human hepatocytes L-02 and also evaluated the toxicity of FKA and 
FKC [212]. In accordance with our present study, FKB was found to be the most toxic 
compound in HepG2 (IC50 15 µM; 48 h incubation). FKA and FKC were also toxic in test 
concentrations of 10-50 µM. In L-02 cells, an IC50 of 32 µM was determined for FKB and 
70 µM for FKC, whereas FKA was not toxic. Further investigations of cell morphology in L-02 
cells and caspase-3 activation in HepG2 revealed apoptotic activity of FKB (30 µM). 
Caspase-3 was not cleaved with FKA and FKC treatment at same concentrations. 
Furthermore, FKB inhibited TNF-α induced activation of NF-κB (IC50 10 µM) and activated 
mitogen-activated kinases (MAPKs) signaling pathways in HepG2. Transient activation of 
MAPKs like JNK leads to proliferation, whereas prolonged activation of JNK has been link to 
hepatocytic death. FKB also depleted glutathione (GSH) levels, and exogenous 
supplementation of GSH reduced FKB-induced hepatotoxicity. In vivo, hepatotoxic potential 
of FKB was investigated in mice that received daily oral doses of 25 mg/kg FKB over one 
week. Histological analysis revealed massive liver damage with hepatocellular swelling and 
vesiculated cytoplasm indicating inflammatory infiltration. AST and ALP levels were 
significantly increased in FKB treated mice. Additionally, LPS induced NF-κB activation was 
greatly reduced by FKB also in vivo. Taken together, this study emphasizes the overall 
hepatotoxic potential of FKB. In vivo toxicity of FKA and FKC has not been addressed yet, 
although they might also contribute to the observed liver toxicity, as they are also present in 
kava extracts. 
FKB is only a minor constituent of Piper methysticum with an amount of < 1% of dry weight 
[200]. HPLC analysis of an ethanolic kava extract quantitated a total chalcone content of 
1.1% [117]. However, flavokawain content seems to be highly dependent on the kava cultivar 
[201]. Different amounts of FKB were found in organic kava extracts varying from 0.54-
7.06 mg equated to 120 mg kavalactones. In the worst case, 7.06 mg of FKB would be 
ingested with daily kava extract dose. Assuming complete oral absorption and an average 
blood volume of 6 L, blood/plasma concentrations of 1.2 µg/mL (~ 4 µM) may be predicted. 
In vitro hepatotoxicity was observed starting at 20 µM (Figure 3.7), a five-fold higher 
concentration. Nevertheless, it has to be kept in mind that only short-term toxicity (24 h) has 
been investigated yet. Further assays should examine the long-term toxicity of 
kavachalcones choosing longer incubation times (72 h) which may lead to much lower IC50 
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values that might be dose-relevant then. To date, there are neither data available that 
address toxicity of kava-chalcones in primary human hepatocytes nor in vivo studies (except 
FKB in mice [212]) that take in account their hepatotoxic potential. 
 
Another kava constituent, the alkaloid pipermethysticine has also been suspected to be the 
culprit of hepatotoxic events. Pipermethysticine was isolated from aerial parts of the plant 
(leaves, stem peelings) [123]. Nerurkar et al. compared the toxicity and apoptotic potential of 
pipermethystine to that of DHM and DMY in HepG2 cells [210]. The alkaloid significantly 
increased LDH release at 50 µM (65%) and 100 µM (90%) within 24 h whereas the 
kavalactones showed no alterations. Furthermore, pipermethysticine depleted ATP levels at 
same concentrations by 70-90% and increased caspase-3 activity by 250 and 575%. A 
decrease of mitochondrial membrane potential and increased ROS production was observed 
as well at 50 and 100 µM, respectively. In contrast to these findings, a methanolic kava leaf 
extract containing 1.34% pipermethysticine was less toxic than an acetonic and methanolic 
root extract containing only 0.011% pipermethysticine [214]. These results suggest rather the 
kavalactones than pipermethysticine being the toxic principle. An in vivo study in F-344 rats 
investigated the short-term toxicity (2 weeks) of pipermethysticine (10 mg/kg) and an 
acetonic kava rhizome extract (100 mg/kg) [222]. Both lacked significant changes in liver 
function tests (ALT and AST levels, lipid peroxidation) or severe hepatotoxic injury. 
Pipermethysticine treatment, however, led to increased markers of oxidative stress such as 
elevated glutathione levels, and enhanced cytosolic superoxide dismutase activity and TNF-α 
mRNA expression. Alteration of CYP2E1 and 1A2 was also reported, which may lead to drug 
interactions. It is discussed whether pipermethysticine can be found in raw material of kava 
rhizomes and roots [201]. Pipermethysticine could not be detected in commercially available 
kava products from Germany. However, it may be present in kava products of poorer quality 
or due to adulterations with aerial parts. In summary, the evidence for pipermethysticine as 
culprit of kava’s hepatotoxicity remains unclear.  
 
Beside the direct hepatotoxicity of kava constituents, also indirect mechanisms may cause 
kava’s hepatotoxicity. Indeed, several models of indirect kava toxicity are discussed. Kava 
extracts and kavalactones possess a high potential of cytochrome P 450 enzyme alteration 
(see 3.1.8 drug interactions). A set of important drug metabolizing cytochrome enzymes is 
significantly inhibited [169,191–193]. As kava extracts were sold as over the counter drugs 
and have been likely used in combination with other remedies, a high potential of 
pharmacokinetic drug interactions theoretically exists, which may have led to intoxicative 
complications in certain combinations. In addition, these toxic drug interactions are not likely 
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detected in a clinical test surrounding where co-medication is strictly monitored. On the other 
hand, surveillance studies neither did reveal toxic events due to drug interactions. 
Moreover, metabolic interaction of kava and alcohol is suggested as possible mechanism of 
kava hepatotoxicity [223]. Ethanol is partly metabolized by the hepatic cytochrome P450 
enzymes, especially CYP2E1, which was found to be inhibited in a test group consuming 
kava. 
Due to two case reports in patients with a deficiency in CYP2D6, it is discussed weather 
genetic polymorphism of CYP2D6 is responsible for hepatotoxicity of kava in the Caucasian 
population (~ 10% of poor metabolizers) [203]. 
Another assumption attributes COX inhibitory activity to possible hepatotoxicity of kava [204]. 
Kava constituents like Y and DHK have been shown to be COX-II inhibitors [142]. COX-II is 
known to mediate hepatoprotective factors, and other COX-II inhibitors (e.g. NSAIDs) have 
shown hepatotoxic potential as well [224]. 
Whitton and coworkers postulated that observed hepatotoxic side effects might arise from 
different extraction process of commercial kava extracts compared to traditional ones [225]. 
Aqueous extracts contain glutathione, which is absent in standardized organic extracts. In 
vitro experiments showed that glutathione binds irreversibly to kavalactones by a Michael 
type reaction, due to opening of the lactone ring. This might also be the detoxifying phase II 
reaction in vivo. Whitton et al. argue that glutathione depletion after intake of standardized 
kavalactone extracts might be the reason for observed hepatotoxic effects. This theory is 
critically questioned by Schmidt et al. [202], doubting the in vivo relevance as kavalactones 
are absorbed intact from intestine, and because they are undoubtedly the carries of 
pharmacological actions.  
Differences between traditional and commercial kava extracts were also discussed in 
another context. Since aqueous kava extracts have been longtime used by the Pacific 
Islanders without reports of liver toxicity and necrotic hepatitis appeared in Western countries 
after intake of ethanolic and acetonic kava extracts, different composition of traditional and 
commercial extracts might be the reason for hepatotoxicity. Actually, differences in total 
kavalactone amount, in kavalactone distribution, and inhibitory activity of cytochrome 
enzymes was detected for organic and aqueous extracts [111]. Generally, aqueous extracts 
contained less kavalactones, above all less Y. However, Teschke et al. composed clinical 
data of 5 patients with suspected liver disease in association with the use of traditional 
aqueous kava extracts [226]. This data rather suggest that kava hepatotoxicity is 
independent from extraction procedure. In fact, a recent German case of toxic hepatitis in a 
42-year-old man was reported after consumption of traditional kava beverage during his stay 
in Samoa [183]. 
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Johnson and coworkers identified electrophilic o-quinone metabolites of M and DHM via 
GSH trapping and LC–MS after incubation of a kava extract with liver microsomes. These 
electrophilic metabolites, however, could not be detected in vivo [227]. Zou et al. tested the 
toxification of kavalactones in MCL-5 cells, which were transfected with 5 human P450 
enzymes, and a control cell line (cH2) without these metabolizing enzymes. They detected 
that both cell lines were equally sensitive to the test compounds. These results suggest that 
kavalactones are not activated to toxic metabolites [228].  
Teschke et al. proposed that poor kava cultivar (export of substandard cultivars) or plant part 
quality (root peelings, aerial parts), adulterants, or mold hepatotoxins (due to insufficient 
drying and inaccurate storing) may be responsible for observed hepatotoxic side effects 
[188,229–231]. 
 
Summing up, there is a broad spectrum of possible explanations for kava hepatotoxicity. 
Probably, not only one single toxic principle or mechanism can explain all cases of 
hepatotoxic side effects. Nevertheless, there is evidence that direct hepatotoxic potential of 
kava constituents, above all Y and kava-chalcones, is present in human HepG2 and HuH-7. 
This fact should be considered for an over-all evaluation of hepatotoxic potential of kava. 
Furthermore, cytotoxicity was significantly more pronounced in the liver cell lines compared 
to Caco-2 cells. This finding suggests a certain liver specificity of toxic effects.  
Further studies are needed that assess long-term toxicity and mechanism of toxicity of Y and 
flavokawains as well as their pharmacokinetics. In any case, the role of these potential 
hepatotoxins should be considered in further investigations. 
3.4 Conclusion 
Six major kavalactones were isolated in high purity degrees from an acetonic kava rhizome 
extract using mainly flash techniques. FKA and FKB, but not FKC, were identified in sub-
fractions of the extract. 
The evaluation of the in vitro hepatotoxicity of kavalactones and chalcones in human HepG2 
and HuH-7 identified Y and flavokawains as toxic compounds. For comparison, the well-
known hepatotoxine tacrine showed higher IC50 values in the MTT assay under same 
conditions (IC50 (HepG2) 64 µM and IC50 (HuH-7) 94 µM; see chapter 6.3.4 Table 6.2). 
Toxicity in descending order was found to be FKB > FKC~Y > FKA. While FKA and FKB 
affected cell viability and proliferation in nearly same extents, FKC and Y reduced mainly the 
metabolic activity of cells and less pronounced the cell number. This could be due to different 
mechanisms of toxicity. K and M showed a weak, dose-independent decrease of cell viability 
in HepG2 already at low concentrations. Toxicity was completely absent for the two hydrated 
3.4 Conclusion 67 
compounds DHK and DHM in all cell lines. This could be an indicator that the 7,8-double-
bond triggers kavalactone toxicity. 
The toxicity of FKB (which was also the most toxic compound in this study) is quite clearly 
estimated. Physiological relevance of test concentrations has to be integrated in the 
discussion as FKB is only a minor constituent in kava extracts. However, in account of and 
combination with FKA and FKC, the chalcones could contribute to kava hepatotoxicity. 
Further studies should be conducted concerning in vivo hepatotoxicity and pharmacokinetics 
(microsomal metabolism see chapter 5.3.2). FKA and FKC should attract more interest as 
they showed distinct toxicity in HepG2 and HuH-7 cells. Studies could be repeated in human 
primary hepatocytes with longer incubation times and lower concentrations to augment the 
physiological relevance.  
Results concerning kavalactones remain contradictory. The toxicity and apoptotic potential of 
Y was detected in HepG2 before [208], however, it was completely absent in another study in 
HepG2 and primary cultured rat hepatocytes [211]. Some findings indicate hepatotoxicity of 
K, M, and kava extracts. Results of in vivo testings are as well ambiguous. The overall 
estimation of kavalactone toxicity stays a difficult issue. However, this study reveals the 
explicit toxicity of Y in comparison to other kavalactones. At least in vitro, toxicity of K and M 
should be considered as well.  
A full evaluation of kava hepatotoxicity is still not possible. In summary, it seems to be very 
likely that not only one factor is responsible for the observed hepatotoxic side effects. Direct 
toxicity of constituents - as also shown in this study - as well as indirect mechanisms may be 
involved. Albeit very laborious, a case by case evaluation might be more suitable. 
Additionally, long-time safety studies of kava extracts are required. Taking in account the 
high hepatotoxic potential of flavokawains in vitro together with lacking pharmacological 
benefits, strict analytical characterization of kava extracts with respect to chalcone content or 
even the usage of chalcone-free extracts can be highly recommended. 
 4 Inhibitory activity of structurally related chalcones on 
activated human hepatic stellate cells 
4.1 Introduction 
4.1.1 The role of hepatic stellate cells in liver fibrosis 
Liver fibrosis is considered as a wound-healing response to chronic liver injury, which is 
attended by exceeding production and deposition of extracellular matrix (ECM) proteins 
leading to disorganization of the normal liver architecture, portal hypertension, and cirrhosis 
in progressive stage [232]. 
Hepatic stellate cells (HSC) - also called vitamin A-storing cells, lipocytes, fat-storing cells, or 
Ito cells -, first described by Kupffer in 1876, have been identified as major cellular source of 
ECM and central mediators of hepatic fibrosis [9]. In normal liver, HSC account for 10-15% of 
the total cell number and are located in the persinusoidal space of Disse in contact to both 
hepatocytes and the abluminal surface of sinusoidal endothelial cells, in proximity to hepatic 
nerves [233]. Physiologically, HSC are the major storage site for retinoids, thus responsible 
for the vitamin A homoeostasis [234]. Retinoids are stored in form of their esters in 
cytoplasmic droplets. As a result of liver injury caused by e.g. viral infections, alcohol 
consumption, drug toxicity, autoimmune or metabolic disease, HSC undergo activation, 
transforming from resting vitamin A-rich cells into proliferative, fibrinogenic, and contractile 
myofibroblasts. This activation is considered as key step in the pathogenesis of hepatic 
fibrosis [10]. Initially, HSC activation is triggered by paracrine stimuli from injured 
hepatocytes, endothelial cells, Kupffer cells, and platelets, which release fibronectin, 
cytokines such as transforming growth factor β (TGF-β), platelet-derived growth factor 
(PDGF), and tumor necrosis factor α (TNF-α), reactive oxygen species (ROS), and others 
[235]. These factors mediate the phenotypic change of HSC, which yields in a quantitative 
and qualitative alteration of ECM. Due to an imbalance between ECM degradation and 
accumulation, total collagen content increases three to eight fold and the composition of 
ECM proteins shifts to predominantly fibrillar collagens (type I, III, and IV). ECM degradation 
is controlled by zinc-dependent matrix metalloproteinases (MMP) and their inhibitors, the 
tissue inhibitors of metalloproteinases (TIMP). In progressive fibrosis, TIMP-1 and TIMP-2 
are up-regulated leading to a decreased activity of MMP-1 (interstitial collagenase, 
collagenase I) and therefore accumulation of ECM proteins [236]. Activated HSC themselves 
show up-regulated levels of alpha smooth muscle actin (α-SMA) and mitogenic (e.g. PDGF, 
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endothelin-1 ET-1), and fibrogenic (e.g. TGF-β1) factors. Furthermore, released cytokines 
contribute to the perpetuation of HSC activation in an autocrine manner [235]. 
Longtime, therapeutic approaches have mainly focused on the suppression of hepatic 
inflammation and the removal of injurious stimuli [233]. In recent years, targeting of HSC as 
source of fibrinogenic mediators has awakened more and more interest [237]. The inhibition 
of HSC activation and proliferation is addressed by various strategies [238] including 
treatment with interferon, anti-oxidants, TGF-β antagonists, inhibitors of signal transduction 
or cell-matrix interaction, or herbal compounds [239] (e.g. Chinese herbs like extracts of Xiao 
Caihu Tang [240], glycyrrhizin [241], silymarin [242]). It is discussed whether reversion of 
activated HSC into the quiescent state, apoptotic clearance, or both mechanisms are 
involved in the resolution of the fibrotic process [243,244]. Hence, apoptosis-inducing agents 
constitute as well a therapeutic approach in treatment of hepatic fibrosis, however, specific 
effect on activated HSC remaining the bottleneck. 
4.1.2 Pharmacological characterization of the test compounds 
The compounds used in this study (Figure 4.1) comprise a set of natural and synthetic 
(dihydro)chalcones with different aryl substituents such as hydroxy-, methoxy-, and prenyl-
groups. Biosynthetically, chalcones (1,3-diaryl-2-propen-1-ones) belong to the huge flavonoid 
family, more precisely they constitute flavanone precursors with open C ring, which arise 
from a mixed biosynthesis including both the shikimate (B ring, C6-C3) and the acetate 
malonate (A ring) pathway. Chalcones possess a wide range of biological activities such as 
anti-oxidant [245], anti-inflammatory [246,247], anti-cancer [248,249], and anti-infective 
effects [250,251], to mention just the most important ones (for an overview of chalcone 
effects see [252]). Moreover, chalcones constitute an interesting basic structure in medicinal 
chemistry to create derivatives with enhanced pharmacological properties and to investigate 
structure-activity relationships [253,254]. 
 
Xanthohumol (XAN), the most abundant prenylated chalcone in hop cons, has already been 
isolated and synthesized by various working groups [96,255–258]. Xanthohumol H (XANH), 
4-acetlyxanthohumol (4AcXAN), and 4-methylxanthohumol (4MeXAN) were found as 
metabolites of XAN in rat feces [259]. These compounds were included in the study to 
estimate the activity of putative XAN metabolites as they may occur after administration of 
XAN in vivo. Both 3-hydroxyxanthohumol H (3OHXANH) and 3-methoxyxanthohumol H 
(3OMeXANH) are synthetic derivatives of the metabolite XANH. The non-natural chalcone 
4’-methylxanthohumol (4’MeXAN) was included as it is a prenyl structure analogue of 
flavokawain C (FKC). Xanthohumol C (XANC), 1'',2''-dihydroxanthohumol C (dhXANC), and 
FKC were found as minor constituents in Humulus lupulus L. [260,261]. FKC was also 
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identified in Piper methysticum FORST., as well as flavokawain A (FKA) and flavokawain B 
(FKB) (see chapter 3.1.2). The latter compound and alpinetin chalcone (A) were isolated 
from Alpinia rafflesiana WALL. EX BAKER [262]. FKA was also identified in aerial parts of 
Goniothalamus gardneri HOOK F. ET. THOMS [263]. Pinostrobin chalcone (P) was found 
amongst others in Alpinia mutica ROXB. rhizome [264]. Helichrysetin (Heli) is a natural 
chalcone derived from Helichrysum odoratissimum L. [265]. 3-Hydroxyhelichrysetin 
(3OHHeli) is a synthetic derivative possessing a catecholic substitution of the B ring. 
Furthermore, three synthetic dihydrochalcones, dihydroflavokawain C (dhFKC), 
dihydrohelichrysetin (dhHeli), and tetrahydroxanthohumol C (thXANC), were investigated to 
evaluate the impact of the α,β-unsaturated ketone structure element on the chalcone activity. 
 
The pharmacological properties of XAN are well studied and enclose a broad spectrum of 
effects and modes of action described in a large number of publications, which mainly 
address its anti-infective, anti-inflammatory, anti-oxidant, anti-obesity, anti-osteoporosis, anti-
invasive, anti-angiogenic, and pro-apoptotic activities (for an overview [261,266–268]). 
Decisively for this study, XAN has already demonstrated inhibitory effects on hepatic 
inflammation and fibrosis in in vitro and in vivo studies (see chapter 4.1.3). 
 
FKA caused strong anti-proliferative and apoptotic effects in human bladder cancer cell lines. 
Apoptosis was mediated by a Bax protein-dependent pathway involving loss of mitochondrial 
membrane potential and release of cytochrome c [269]. Furthermore, FKA reduced the 
overexpression of anti-apoptotic factors (X-linked inhibitor of apoptosis, survivin). Bladder 
tumor growth in mice was inhibited to 57%. The effect of FKA on the cell cycle was 
investigated in wild type (RT4) and different p53 mutant bladder cancer cell lines [270]. 
Differences in cell cycle arrest occurred: cyclin-dependent kinase-2 (CDK2) activity was 
decreased in RT4 cells, which led to G1 arrest; in contrast, G2/M arrest was observed in p53 
mutants attended by enhanced growth-inhibitory effects of FKA in these cell lines. The 
regulation of the cell cycle in bladder cancer cells seems to be associated with the p53 
status, favoring FKA for the treatment of p53 mutant-cancers. 
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Figure 4.1: Structures of the investigated prenylated and non-prenylated chalcones. 
 
H 
72 4 Inhibitory activity of structurally related chalcones on activated human hepatic stellate cells 
FKB exhibited apoptosis-inducing activities in several cancer cell lines by affecting different 
molecular targets. In a uterine leiomyosarcoma cell line (SK-LMS-1) growth inhibition was 
associated with a G2/M arrest [271]. Besides, FKB increased the expression of death 
receptor (DR5) and mitochondrial pro-apoptotic proteins (Bim, Puma) indicating that both 
apoptotic pathways may be involved. Similar effects were observed in a hormone-refractory 
prostate cancer cell line (HRPC) [272] and in synovial sarcoma cell lines (SYO-I, HS-SY-II) 
[273]. FKB was also effective against oral cancer cell lines. FKB inhibited the proliferation of 
oral adenoid cystic cancer cells by causing cell cycle G2/M arrest and apoptosis via up-
regulation of pro-apoptotic proteins (Bim, Bax, Bak) and down-regulation of Bcl-2 [274]. In 
oral carcinoma HSC-3 cells, FKB induced again G2/M cell cycle arrest through inhibition of 
cyclin-dependent kinases (Cdc2) [275]. Different pathways of apoptosis were addressed by 
FKB. Apoptotic cell death was induced through the intrinsic pathway evident by 
dysregulation of the Bax/Bcl-2 ratio, cytochrome c release, and caspase-9/-3 activation and 
the extrinsic pathway by induction of Fas/FasL expression and caspase-8 activation. 
Activation of Bax, caspase-4 and -12 suggest that ER stress pathway was involved as well. 
FKB increased intracellular ROS apparent by up-regulation of oxidative stress markers (HO-
1, Nrf2). Moreover, FKB inhibited Akt/p38 MAPK signaling pathways which both play a 
critical role in the regulation of cell proliferation and apoptosis. The same observations were 
made in a human squamous carcinoma (KB) [276]: FKB induced apoptosis involving both 
mitochondrial and death cell receptor mediated pathway. Again, G2/M arrest was caused by 
repression of cyclin A, cyclin B1, Cdc2, and Cdc25C. Interestingly, FKB had also an impact 
on MMP and TIMP, which play a role in tumor metastasis and - as mentioned above - in 
pathogenesis of liver fibrosis. FKB led to mitochondrial dependent apoptosis in colon cancer 
cells (HCT116) [277]. Again, ROS and ER-dependent mechanism are discussed. GADD153 
(growth arrest and DNA damage-inducible gene 153), a marker for ER stress, was up-
regulated by FKB treatment. Consistently, expression of Bcl-2 was reduced whereas pro-
apoptotic Bim was up-regulated causing mitochondrial apoptosis. Like in other cell lines, 
proliferation was inhibited via induction of G2/M arrest. Finally, autophagy signs were 
observed after FKB treatment. FKB targeted mitochondrial dependent pathways 
(dysregulation of Bcl/Bax, cytochrome c release, caspase activation) and mitogen-activated 
protein kinase (JNK) in lung cancer cells (H460) [278]. The anti-proliferative activity of FKB is 
once again in accordance with caused G2/M cell cycle arrest.  
Moreover, the anti-inflammatory potential of FKB was assessed: FKB showed potent COX-I 
inhibitory activity [118]. The LPS-induced generation of NO and PGE2 was significantly 
decreased by FKB in RAW 264.7 cells [279]. NF-κB translocation was inhibited by FKB, 
which was connected to prevention of IκB degradation. Furthermore, FKB (200 mg/kg) 
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decreased the NO concentration after LPS treatment in mouse serum and suppressed the 
expression of pro-inflammatory proteins (iNOS, COX-2, NF-κB) in mouse liver. 
However, FKB raised suspicion of being responsible for the hepatotoxic side effects 
observed after consumption of kava (see chapter 3.3.3). Zhou et al. demonstrated enhanced 
cytotoxicity in human hepatoma HepG2 cells (IC50 15.3 µM) and the human hepatocyte cell 
line L-02 (IC50 32 µM) using MTT assay [212]. The mechanism discussed for apoptosis-
inducing effects in several cancer cell lines may in the same way affect normal cells, in 
particular hepatocytes. FKB induced oxidative stress and depleted GSH levels leading to 
sustained activation of mitogen activated protein-kinases (mainly p38 and JNK) and 
subsequent cell death. Through inhibition of IκB kinase (IKK) followed by down-regulation of 
NF-κB transcriptional activity, hepatocellular survival is impaired. Interestingly, exogenous 
supply with GSH normalized NF-κB and MAPK signaling suggesting that GSH depletion is 
basically responsible for observed toxicity. In vivo, FKB (25 mg/kg/d, one week) inhibited 
hepatic NF-κB transcriptional activity and caused severe liver damage in mice. Li and 
coworkers evaluated the cytotoxicity of flavokawains (FKA, FKB, and FKC) and A on HepG2 
and L-02 using MTT assay [280]. Toxicity was found to be A (IC50 31 ± 4 µM) > FKB (IC50 35 
± 3 µM) > FKC (IC50 57 ± 2 µM) for L-02 and A (IC50 23 ± 3 µM) > FKB (IC50 59 ± 3 µM) > 
FKC (IC50 62 ± 5 µM) for HepG2. The findings suggest a certain hepatotoxic potential of 
these compounds, which has to be incorporated in the valuation of the results determined on 
activated HSC. For additional information, the hepatotoxic potential of flavokawains is 
extensively discussed in chapter 3. Toxicity studies of suspicious compounds, especially 
flavokawains and A, on primary human hepatocytes (PHH) are urgently required. Validation 
of assay results obtained with HSC will be not possible until impairment of “healthy” liver 
cells, especially hepatocytes, is excluded. For XAN, lacking hepatotoxicity has already been 
proven on PPH and in vivo [281,282]. 
 
The anti-inflammatory activity of A (also known as cardamonin) is addressed in several 
publications. Lee et al. first identified A as potent inhibitor of NF-κB activation in LPS-
stimulated RAW 264.7 cells [283]. TNFα and NO production as well as the expression of 
iNOS and COX-2 were decreased by A in a dose-dependent manner. Thereby, A inhibited 
the translocation of NF-κB through suppression of IκB degradation and phosphorylation and 
IKK activation. Another study on IFN-γ and LPS-induced RAW 264.7 cells largely confirmed 
these results [284]. Authors found that reduced NO and PGE2 production was attributed to 
down-regulation of both inducible enzymes, iNOS and COX-2, and not to direct enzyme 
inhibition. A showed similar inhibitory effects on these pro-inflammatory mediators in 
LPS/INF-γ-stimulated microglia cells (BV-2) [285], in LPS-stimulated ICR mice [286], and 
myeloma cells [287]. A exhibited also anti-inflammatory activity in whole blood systems by 
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decreasing both NO and PGE2 production after stimulation with LPS or INF-γ [288]. 
Moreover, thromboxane B2 (TxB2) secretion was suppressed with a certain selectivity of 
COX-2 pathway inhibition. Another study on human monocytes and murine macrophages 
(RAW) revealed again inhibition of NO production and iNOS expression, however, no effect 
on COX-2 expression was observed in this model [289]. In contrast to other studies, NF-κB 
signaling pathways were affected through inhibition of NF-κB-DNA binding and not through 
inhibition of IκB degradation or phosphorylation of NF-κB. Furthermore, no effect on MAPK 
phosphorylation was observed. 
A induced apoptosis by enhancement of TNF-related apoptosis inducing ligand (TRAIL)-
related pathways [290]. Apoptosis was mediated by up-regulation of death receptors (DR4 
and DR5), decrease of Bcl-xL levels, and activation of caspases-8, 9, and 3. A further study 
could show that up-regulation of death receptors was due to induction of CCAAT/enhancer 
binding protein homologous protein (CHOP) and increased production of ROS [291]. 
Furthermore, the impact of A on the migration and invasion of sarcoma cells was 
investigated. A targeted the expression of transglutaminase-2 and several matrix 
metalloproteinases [292].  
 
The cytotoxic effect of P was evaluated in several cancer cell lines, including HeLa and 
HepG2 [293], KB, MCF7, A549, Caski, HCT116, HT29, and non-human fibroblast cell line 
(MRC 5) [264]. Remarkable cytotoxic effects at low micromolar concentrations were 
observed on KB, MCF7, and Caski cells. 
 
The influence of the test compounds on LPS-induced NO production and iNOS expression 
were examined in RAW 264.7 [101]. Dihydrochalcones and 3OHHeli were the least active 
compounds. In the Griess assay, inducing NO production either with LPS or a combination of 
LPS and INF-γ, highest inhibitory activity was found for FKB, FKC, A, Heli, XANH, and 
pyrano-chalcones respectively. A, Heli, and XANC already reduced NO at low 
concentrations of 2 µM. The expression of iNOS was significantly inhibited by all test 
compounds except 4MeXAN, and 3OHHeli. At 5 µM, A was the most active compound, 
followed by XANC, FKB, XANH, and Heli. Summing up, chalcones in general possess a 
potential impact on LPS and INF-γ induced NO production and iNOS expression. The α,β-
unsaturated ketone seems to be a required structure element as dihydrochalcones lacked 
distinct activity. Furthermore, additional hydroxylation in position 3 in case of Heli (3OHHeli) 
lowers the activity perhaps due to higher hydrophilicity and resulting lower intracellular 
concentration. Prenylation in position 3’ does not enhance the biological activity. Non-
prenylated chalcones (A, FKB, Heli) were more active.  
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The cytotoxicity of prenylated and non-prenylated chalcones with different substitution 
pattern was assessed in HeLa cells. IC50 values ranged in low two digit micromolar 
concentrations, Heli (5.2 ± 0.8 µM) being the most cytotoxic of the test compounds [98,294]. 
Furthermore, anti-oxidant and anti-inflammatory properties were determined using oxygen 
radical absorbance capacity (ORAC)-fluorescein and ICAM-assay respectively [97]. Most 
compounds showed moderate to high anti-oxidant activities in a concentration range 
between 0.1 and 1.0 μM. The anti-oxidant capacity, expressed as Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) equivalents, was highest for XANH (4.8 ± 0.1), Heli 
(4.4 ± 0.6), and FKC (4.0 ± 0.5). The TNFα-induced expression of the adhesion molecule 
ICAM-1 was most strongly inhibited by 3OHHeli and 3OHXANH both possessing caffeoyl 
substructure [97]. 
4.1.3 Chalcones with anti-fibrotic effects 
To date, only a few chalcones have been analyzed regarding their inhibitory, anti-
proliferative, or apoptotic effects on activated hepatic stellate cells in vitro and in vivo. 
Zhang and coworkers discovered protective effects of hydroxysafflor yellow A (HSYA), a 
glucosylic chalcone derivative from safflower, against carbon tetrachloride-induced liver 
fibrosis in Sprague-Dawley rats [295]. Animals were subjected to CCl4 injections twice a 
week, with or without additional intraperitonial application of 5 mg/kg/d HSYA over a period of 
12 weeks. Control animals received isovolumetric olive oil i.p. injections alone or in 
combination with HSYA at same doses. Liver histology and determination of hydroxyproline 
content, a marker of collagen disposition in the liver, resulted in a significant reduction of 
CCl4-elevated fibrotic areas and hydroxyproline levels in HSYA treated rats. Moreover, gene 
expression of α-SMA, collagen α type 1, TIMP-1, MMP-9 was inhibited by HSYA suggesting 
a suppression of HSC activation. In accordance to these effects, an inhibition of TGF-β 
signaling pathways leading to reduced phopho-Smad4 levels was observed within the HSYA 
group. Taken together, the data imply an anti-fibrotic effect of HSYA by blocking TGF-β1-
regulated HSC activation. An additional hepatoprotective potential is postulated as serum 
transaminase levels were significantly reduced by HSYA as well. Another study using the 
same experimental design explained the observed anti-fibrotic effects of HYSA by decreased 
expression levels of myocyte enhancer factor (MEF-2C), inhibition of ERK5 phosphorylation, 
and attenuated TGF-β signaling [296]. Furthermore, HSYA induced apoptosis in culture-
activated stellate cells from rats by suppression of ERK1/2 activation, subsequent decrease 
of Bcl-2/Bax ratio, enhanced cytochrome c release, and caspase-9/-3 activation, suggesting 
the involvement of mitochondrial pathways [297]. 
Butein (2’,3,4,4’-tetrahydroxychalcone) showed an anti-proliferative effect on cytokine 
stimulated rat stellate cells [298]. In addition, mRNA expression levels of key factors in 
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hepatic fibrogenesis, namely collagen I, α-SMA, and TIMP-1 were significantly suppressed 
after butein treatment. Taken together, these finding indicate an inhibition of HSC 
transformation and exuberant collagen deposition. A recent in vitro study investigated the 
protective effects of butein, betulin, and betulinic acid on acetaldehyde-induced cytotoxicity 
and activation of rat liver stellate cells [299]. Preincubation with betulin (10 µM), but not with 
betulinic acid and butein, significantly decreased the toxicity of acetaldehyde on HSC. The 
intracellular levels of α-SMA and procollagen type 1, migration of HSC, TIMP-1/-2 and ROS 
production were significantly reduced by all three compounds. However, only butein (10 µM) 
decreased the acetaldehyde-induced production of TGF-β1 and TNF-α without having effects 
on MMP-2 concentrations. As described before, the chalcone butein is a potent inhibitor of 
lipid peroxidation and ROS generation. As ROS derived from Kupffer cells or damaged 
hepatocytes is known to mediate HSC activation, the anti-oxidant activity of butein may 
contribute to its inhibitory effects regarding HSC transformation. 
The synthetic chalcone derivative 2’,4’,6’-tris(methoxymethoxy)chalcone (TMMC) exhibited 
anti-proliferative effects on activated rat HSC in a dose dependent manner (5-20 µM) [300]. 
These findings were attributed to observed induction of heme oxygenase 1 (HO-1) by 
TMMC. HO-1 is expressed in HSC during chronic liver injury and its specific activation is 
discussed to trigger anti-proliferative effects and therefore may limit the progression of 
fibrosis. Furthermore, TMMC decreased intracellular GSH, which activates extracellular 
signal-regulated kinase (ERK) belonging to the family of MAPK. TMMC induced ERK 
activation and in turn led to transcriptional activation of activator protein 1 (AP-1), a major 
transcription factor involved in HO-1 gene transcription. Authors conclude that the described 
pathway is responsible for observed anti-proliferative effects of TMMC. Another study 
investigated the induction of apoptosis by TMMC on activated rat HSC [301]. As mentioned 
before, apoptosis of activated HSC is proposed as therapeutic strategy in the resolution of 
the fibrotic process. At concentrations of 30 to 50 µM, TMMC induced apoptosis in activated 
HSC by a caspase-dependent pathway. Authors attribute the effects of TMMC on apoptosis 
to histone deacetylase (HDAC) inhibition which is involved in the expression of apoptosis-
related genes. Indeed, TMMC enhanced the expression of Fas-ligand (FasL) which 
subsequently leads to caspase-3 activation and apoptosis. Moreover, TMMC exhibited 
protective effects in CCl4-injured rat livers and reduced the expression and mRNA levels of 
α-SMA. Increased poly(ADP-ribose) polymerase (PARP) cleavage products after TMMC 
treatment suggest the elimination of CCl4-activated HSC by apoptosis as PARP is a 
substrate of active caspase-3. 
Similar effects on the proliferation of serum or growth factor-induced rat HSC were 
demonstrated for isoliquiritigenin (2’,4,4’-trihydroxychalcone) [302]. Again, the induction of 
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HO-1 expression and the involvement of mitogen-activated protein kinase and 
phosphatidylinositol 3-kinase-Akt-p70S6K pathways could be shown in vitro.  
Six flavonoids, including chalcone and the dihydrochalcone phloretin, were tested on 
stimulated HSC-T6 [303]. All compounds inhibited the proliferation of activated HSC in low 
micromolar concentration ranges. Ring-closed flavonoids and chalcones showed similar 
activities. The hydroxylation in position 4’ enhanced the anti-proliferative activity. 
XAN, which was also investigated in the present study, demonstrated inhibitory effects on 
liver inflammation and fibrosis both in vitro and in vivo [281]. In vitro, the mRNA expression of 
two markers of HSC activation, α-SMA and collagen type I, were significantly reduced after 
treatment with 5 µM and 10 µM XAN for 3 days. Apoptosis was induced in activated HSC 
already at low concentrations of 5 µM. Noteworthy, cytotoxic effects of XAN were absent in 
PHH up to concentrations of 50 µM. The expression of pro-inflammatory cytokines, MCP-1 
and IL-8, was reduced in HSC and PPH respectively. Both basal and TNF induced NF-κB 
activity was significantly decreased by XAN (5 µM). NF-κB is a central factor responsible for 
HSC activation and resistance to apoptosis and regulates as well the expression of pro-
inflammatory chemokines. In vivo, the effect of XAN was assessed in a murine model of 
NASH which is characterized by fatty infiltration (cholesterol) of the liver, leading to 
inflammation, hepatocellular damage, and fibrosis. Although XAN (1% w/w in the chow) 
showed no effects on hepatic steatosis, hepatic inflammation was inhibited by XAN treatment 
displayed in the suppression of TNF, IL-1, MCP-1, and ALT and AST serum levels. 
Furthermore, the expression of the pro-fibrogenic genes TGF-β and TIMP-1 was reduced by 
XAN nearly to control state. The elevated collagen type I mRNA levels were as well 
decreased in mice receiving XAN. In addition to the NASH model, protective effects of XAN 
feeding (1 mg/g body weight) were studied in carbon tetrachloride-induced liver fibrosis in 
mice [304]. Liver weight and serum transaminase levels were significantly elevated 72 h after 
CCl4-injection in both the control and XAN group. Nevertheless, XAN exhibited a distinct 
inhibitory activity on pro-inflammatory (TNF, IL-1, MCP-1, ICAM-1, NF-κB) and pro-fibrogenic 
(TGF-β, collagen I, TIMP-1, α-SMA) gene expression. These results indicate a suppressive 
effect of XAN on both hepatic inflammation and HSC activation, which protects against the 
progression of CCl4-induced hepatic fibrosis. A previous study has shown that XAN feeding 
alone did not impair organ functions or homoeostasis in mice [282]. 
Summing up, the chalcone structure comprises promising pharmacological properties for the 
prevention and treatment of hepatic fibrosis due to modulatory activity on ECM proteins, anti-
inflammatory activity, and anti-proliferative and apoptosis-inducing effects. These 
encouraging results were picked up in the present study for further investigation of 
structurally related prenylated and non-prenylated chalcones and dihydrochalcones on 
activated human HSC. 
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4.2 Aim of the study 
The study was aimed to evaluate the inhibitory activity of chalcones on activated human 
hepatic stellate cells. Therefore, the effect of the test compounds on cell viability and 
proliferation was assessed using MTT assay, CV assay, and fluorescence microscopy. 
Moreover, to investigate the impact on cell organelles, a high content analysis (HCA) assay 
was established on HSC applying fluorescent staining of nuclei, mitochondria, and F-actin. 
This allows a comparative and contemporaneous evaluation of chalcone-induced alterations 
on the organelle level. Furthermore, cytochrome c release as an early apoptosis marker was 
determined. By analyzing the fluorescence intensity of Hoechst-stained cell nuclei, the DNA 
content and herein the influence of the test compounds on the cell cycle phase distribution 
can be studied. 
Finally, the objective of the study was to identify structure elements, which enhance or 
attenuate the activity on HSC. XAN has already shown protective effects against hepatic 
inflammation and fibrosis in vitro and in vivo [281,304]. This study provides additional 
information on XAN metabolites and other prenylated and non-prenylated derivatives that 
have not been tested on HSC yet. Based on the findings of this study, potent chalcones may 
be identified and elected for further pharmacological testing and elucidation of molecular 
mechanisms. 
4.3 Results and discussion 
4.3.1 Analytical characterization of test compounds 
Prior to in vitro testing, the 21 structurally related test compounds were analytically 
characterized to ensure adequate purity degrees and to gain a first insight in lipophilicity of 
the test chalcones, which might have influence on cellular absorption, distribution, and finally 
biological activity. Therefore, also log P values as a measure of lipophilicity are indicated in 
Table 4.1. Among the test compounds, there were seven chalcones with variable 
methoxylation pattern of the A ring and different B ring moieties, four prenylated chalcones, 
three 3’-(3’’-hydroxy-3’’-methylbutyl)-derivatives, two pyrano-, and three dihydrochalcones 
(Figure 4.1). 
XAN was provided by the Nookandeh Institute with a purity degree of 98%. P was purchased 
from PhytoLab with a purity degree of 91%. The other test chalcones were obtained by 
synthesis (see chapter 2.4). 
Identity of synthesized chalcones was confirmed by 1H NMR spectroscopy (see chapter 
2.1.3.2). Purity of test compounds was determined by HPLC (10 µM; 20 µL) using method P2 
(see chapter 2.1.3.3). Additionally, for estimation of purity and lipophilicity, HPTLC analysis 
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(500 µM; 7.5 µL) was performed using solvent system T1+FA and derivatization reagent D2 
(see chapter 2.1.3.1). 
Table 4.1: Analytical features of the test compounds. Rf values for estimation of lipophilicity 
determined by HPTLC. Purity (p [%]) analysis was performed by HPLC (P2). Log P 
values are derived from SciFinder. (*) not tested, (-) not determined. 
 Compound systematic name Rf p  log P 
1 FKA 2’-Hydroxy-4,4’,6’-trimethoxychalcone 0.49 99 4.24 ± 0.42 
2 FKB 2’-Hydroxy-,4’,6’-dimethoxychalcone 0.56 94 4.21 ± 0.37 
3 FKC 2’,4-Dihydroxy-,4’,6’-dimethoxy-chalcone 0.25 99 4.00 ± 0.41 
4 A 2’,4’-Dihydroxy-6’-methoxychalcone 0.31 99 3.61 ± 0.34 
5 P 2’,6’-Dihydroxy-4’-methoxychalcone 0.34 91 4.22 ± 0.35 
6 4AcXAN 4-Acetoxy-2’,4’-dihydroxy-6’-methoxy-3’-
prenylchalcone 
0.25 96 4.49 ± 0.41 
7 dhXANC 2’’,2’’-Dimethyl-3’’,4’’-dihydro-(2H)-
pyrano[2’’,3’’:3’,4’]-2’,4-dihydroxy-6’-
methoxychalcone 
0.35 98 4.47 ± 0.42 
8 XANC 2’’,2’’-Dimethylpyrano[2’’,3’’:3’,4’]-2’,4-
dihydroxy-6’-methoxychalcone 
0.33 97 4.84 ± 0.40 
9 XANH 2’,4’,4-Trihydroxy-3’(3’’-hydroxy-3’’-
methylbutyl)-6’-methoxychalcone 
0.08 97 3.24 ± 0.41 
10 4MeXAN 2’,4’-Dihydroxy-4,6’-dimethoxy-3’-prenyl-
chalcone 
0.29 96 5.08 ± 0.41 
11 Heli 2’,4,4’-Trihydroxy-6’-methoxychalcone 0.14 99 3.41 ± 0.37 
12 3OHHeli 2’,3,4,4’-Tetrahydroxy-6’-methoxy-
chalcone 
0.07 98 2.63 
13 XAN 2’,4’-Dihydroxy-6’-methoxy-3’-prenyl-
chalcone 
0.15 98 4.82 ± 0.42 
14 SV 171
 (*) 2’,4,4’,6’-Tetrahydroxy-3’-prenyl-
chalcone 
0.09 86 - 
15 4’MeXAN 2’,4-Dihydroxy-4’,6’-dimethoxy-3’-prenyl-
chalcone 
0.21 - 5.52 ± 0.43 
16 SV 249 
(
*
) 4,6’-Dihydroxy-2’,4’-dimethoxy-3’-prenyl-
chalcone 
0.34 - - 
17 3OHXANH 2’,3,4,4’-Tetra(hydroxy)-3’(3’’-hydroxy-3’’-
methylbutyl)-6’-methoxychalcone 
0.04 - 2.90 ± 0.42 
18 3OMeXANH 2’,4’,4-Tri(hydroxy)-3’(3’’-hydroxy-3’’-
methylbutyl)-3,6’-dimethoxychalcone 
0.06 - 3.20 ± 0.42 
19 dhHeli 2’,4,4’-Trihydroxy-6’-methoxy-dihydro-
chalcone 
0.10 88 3.36 
20 dhFKC 2’,4-Dihydroxy-,4’,6’-dimethoxy-dihydro-
chalcone 
0.23 94 3.98 ± 0.38 
21 thXANC 2’’,2’’-Dimethyl-3’’,4’’-dihydro-(2H)-
pyrano[2’’,3’’:3’,4’]-2’,4-dihydroxy-6’-
methoxy-dihydrochalcone 
0.34 87 - 
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Figure 4.2: HPTLC of test chalcones. Numbers correspond to the compounds listed in 
Table 4.1. Images were recorded after derivatization with natural product reagent 
and macrogol (D2) under UV 365 nm.   
The purity of the test compounds ranged from 87 to 99%, most chalcones exhibiting a purity 
degree greater than 95% (Table 4.1). Compound 14 and 16 were excluded from testing due 
to insufficient purity (< 87%). 
Figure 4.2 shows the results of the HPTLC analysis on silica coated glass plates. Rf values 
of the chalcones in descending order were found to be 2 > 1 > 7 > 5 = 21 > 8 > 4 > 10 > 3 = 
6 > 20 > 15 > 13 > 11 > 19 > 9 > 7 > 18 > 17. Log P values approximately ranged between 3 
and 5. XANH and derivatives, Heli and 3OHHeli are the most hydrophilic test compounds. 
Chalcones with unsubstituted B ring exhibit a higher lipophilicity (FKB, A, P). Added prenyl- 
and methoxy-groups render the molecule even more lipophilic (FKA, XAN derivatives) 
whereas hydroxyl groups increase the hydrophilicity. The impact of lipophilicity and structural 
alterations on the biological effects is discussed in the following chapter. 
4.3.2 Effects on cell viability and proliferation 
Initially, the influence of selected test compounds on cell viability and proliferation of HSC 
was assessed in the MTT and CV assay respectively (see chapters 2.2.5.1 and 2.2.5.2). 
Therefore, the cells were treated with 10, 20, 30, 40, 50, 60, 80, and 100 µM of the test 
chalcones for 24 h (see chapter 2.2.4.3). Sigmoidal response curves were used for nonlinear 
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regression and calculation of IC50 values. Furthermore, the effect of the compounds on the 
remaining cell number was analyzed by fluorescence microscopy in the context of HCA (see 
chapter 2.2.6.1). Test concentrations ranged from 1 to 50 µM. After staining and cell fixation, 
the fluorescent cell nuclei were automatically counted and the number of nuclei was equated 
with the number of cells. The number of untreated control cells was set as 100% value and 
the amount of remaining cells after treatment was referred to this control value. This 
convenient assay approach directly provides information about the influence on cell 
proliferation and cytotoxicity comparable to the CV assay. 
A summary of assay results is given in Table 4.2. Whenever possible, IC50 values were 
calculated. 
Table 4.2: IC50 values of chalcones in the different assays determined by nonlinear regression 
using GraphPadPrism 4 software. Values are expressed as mean ± SE [µM]. (*) 
values determined by Dr. Magdalena Motyl [101], (NA) not analyzed, (#) non-
sigmoidal behavior of dose response, (no effect) no significant influence up to the 
highest test concentration (100 and 50 µM respectively). 
 IC50 [µM] 
Compound MTT CV HCA 
A # > 100 > 50 
P no effect no effect no effect 
FKA 90 ± 12 > 100 > 50 
FKB 39 ± 3 68 ± 8 43 ± 10 
FKC 76 ± 8 > 100 > 50 
dhFKC NA NA no effect 
Heli 97 ± 2* > 100* > 50 
dhHeli NA NA no effect 
3OHHeli no effect* no effect* no effect 
XAN 65 ± 4* 78 ± 3* > 50 
4AcXAN 75 ± 7* 87 ± 17* > 50 
4MeXAN #* #* no effect 
4’MeXAN NA NA 30 ± 5 
XANH 49 ± 6* > 100* no effect 
3OHXANH NA NA > 50 
3OMeXANH NA NA > 50 
XANC 69 ± 3* 74 ± 9* > 50 
dhXANC 55 ± 4* 55 ± 7* > 50 
thXANC NA NA no effect 
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Figure 4.3 compares the compounds’ effects on the cell number determined by fluorescence 
microscopy (HCA). Significant deviances to control cells are indicated above the bar 
diagrams.  
Figure 4.3: Cell number determined by fluorescence microscopy in the context of HCA for test 
concentrations of 25 µM (left) and 50 µM (right). Values are presented as mean ± SD 
(n = 3) and refer to untreated control cells (ctl, 100%). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs. ctl cells. 
None of the test compounds had significant effects on the cell number at concentrations of 1 
and 10 µM (data not shown). Neither P nor 3OHHeli affected cell viability or proliferation up 
to the highest test concentration of 100 µM (Table 4.2). The dihydrochalcones (dhFKC, 
dhHeli, thXANC) as well did not show significant influence on the cell number although for 
thXANC a slight decrease could be observed at 50 µM (Figure 4.3). 
The mono-, di-, and trimethoxylated compounds Heli, FKC, and FKA exhibited similar effects 
on cell viability, proliferation, and cell number. IC50 values of 97 ± 2, 76 ± 8, and 90 ± 12 µM 
were determined in the MTT assay, whereas for the CV assay, IC50 values ranged above 
100 µM (Table 4.2). The compounds showed significant cytotoxicity at a concentration of 
50 µM (Figure 4.3). In comparison, the B ring unsubstituted chalcones A and FKB decreased 
viability and cell number to a higher extent. Albeit no IC50 could be determined for A due to 
non-sigmoidal behavior of dose response curves, the substance significantly affected 
metabolic functions and cell number at low concentrations of 10 and 25 µM respectively. For 
FKB, IC50 values of 39 ± 3 µM (MTT assay), 68 ± 8 µM (CV assay), and 43 ± 10 µM (HCA) 
were found (Table 4.2). Thereby, this chalcone constitutes one of the most potent of all test 
compounds.  
The prenylated chalcone XAN and its acetylated metabolite 4AcXAN had comparable IC50 
values in the MTT (65 ± 4 and 75 ± 7 µM) and the CV assay (78 ± 3 and 87 ± 17 µM, Table 
4.2), and both reduced the cell number to around 60% at 50 µM determined by fluorescence 
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microscopy (Figure 4.3). However, 4MeXAN behaved differently. This compound significantly 
decreased cell viability already at low concentrations (20 µM) in a dose-independent manner 
without having significant impact on the cell number. In contrast, 4’MeXAN exhibited strong 
inhibitory effects regarding the cell number. In the fluorescence microscopic assay, an IC50 
value of 30 ± 5 µM was calculated for 4’MeXAN (Table 4.2), thus being the most cytotoxic 
compound in this set-up. 
XANH decreased the cell viability of HSC with an IC50 of 49 ± 6 µM whereas the cell number 
was not significantly affected up to 50 µM. The very polar 3-OH and 3-OCH3 derivatives of 
XANH significantly reduced the cell number at 25 and 50 µM respectively.  
The pyrano-chalcones XANC and dhXANC diminished the cell viability and proliferation to 
same extents (IC50 for MTT 69 ± 3 and 74 ± 9 µM, for CV 55 ± 4 and 55 ± 7 µM). At 50 µM, a 
significant reduction of the cell number was detected for both compounds. 
 
The investigated chalcones show structural similarity regarding the 2’ hydroxyl moiety. Jin et 
al. demonstrated that this structure element has a strong impact on the anti-inflammatory 
activity of chalcones [305]. Pharmacological properties of chalcones (such as NF-κB 
inhibition) are often attributed to nucleophilic reactions with the α,β unsaturated ketone. The 
authors suggest that the electrophilicity of the α,β unsaturated ketone is increased by the 2’ 
hydroxyl group due to formation of a hydrogen bond with the electron pair of the ketone. 
Furthermore, electron-donating groups in the A ring (e.g. methoxy groups) stabilize the 
Michael adduct by lowering the acidity of the α-hydrogen. Indeed, this effect could be 
observed for the test compounds regarding their ability to inhibit NO production and iNOS 
expression [101]. Inhibitory effects on HSC activation have already been demonstrated for 
chalcones such as butein [298], isoliquiritigenin [302], and XAN [281], all of which exhibiting 
anti-inflammatory properties. Hence, these properties constitute a beneficial pharmacological 
feature in the treatment of fibrosis, which is connected to chronic inflammation and 
inflammatory signals playing also a crucial role in activation of HSC. Moreover, the 2’ 
hydroxyl group increased the anti-proliferative activity of chalcones on HepG2 [306]. 
From assay results, further structure elements can be identified that enhance or reduce the 
effect of chalcones on activated HSC. First, the B ring moieties influence both the lipophilicity 
and the activity. In comparison, the B ring unsubstituted chalcones A and FKB show a high 
anti-proliferative potential. A and especially FKB exhibited a distinct anti-proliferative activity 
in several cancer cell lines (see chapter 4.1.2). Li et al. found as well that cytotoxic potential 
of chalcones lacking B ring substitution was enhanced [307]. Hydroxylated or methoxylated 
derivatives (FKA, FKC, Heli) affected also viability and cell proliferation, however, they were 
less active. Similar effects were observed on HepG2. The absence of methoxy moieties in 
the B ring increased the activity [308]. The 4-acetylated XAN derivative (4AcXAN) behaved 
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similarly to XAN itself. This might be due to rapid deacetylation by cellular esterases. The 
same observations were made with human hepatoma cell lines (HuH-7, HepG2). Both 
compounds inhibited cell viability and proliferation to nearly same extents [101]. In contrast, 
methylation of the hydroxyl group lowered the activity as 4MeXAN lacked significant effects 
on the cell proliferation but showed a decline of cell viability already at low concentrations.  
The catechol group in ring B constitutes an important structure element favoring the anti-
oxidant activity of chalcones [97,309]. However, the ortho-dihydroxy group led to loss of 
activity in case of 3OHHeli whereas for 3OHXANH cytotoxicity was increased compared to 
XANH. Nevertheless, the enhanced radical scavenger activity of 3,4-dihydroxylated 
chalcones such as butein [310] may contribute to the anti-fibrotic effects due to inhibition of 
ROS, a mediator of HSC activation. Additional methoxylation in position 3 of XANH 
(3OMeXANH) slightly augmented the compound’s impact on the cell number at higher 
concentrations.  
The substitution pattern of the A ring triggered as well the pharmacological properties of the 
chalcones. Contrarily to the B ring substitution, additional methoxy groups in the A ring seem 
to enhance the activity of the chalcones. A structure activity relationship study found 
enhanced anti-cancer and NF-κB inhibitory activity of A ring methoxylated compounds [311]. 
The 4’-methoxylated FKC (IC50 76 ± 8) showed a stronger effect on cell viability of HSC than 
Heli (IC50 97 ± 2). However, these slight effects were absent concerning cell proliferation. 
The activity of XAN was significantly increased with an additional methoxy group (4’MeXAN) 
which led to a noteworthy increase of cytotoxicity. The 3’-prenyl side chain contributes to the 
chalcones’ effects on HSC. Prenyl side chains are associated with different pharmacological 
effects. For example, the prenyl group contributes to the anti-oxidant [98,312] and cytotoxic 
[313–315] activity of flavonoids. Compared to Heli, the 3’-prenylated XAN exhibits stronger 
effects on cell viability and proliferation. Even more pronounced, this effect can be observed 
for 4’MeXAN, which is the 3’-prenylated derivative of FKC and shows, as mentioned before, 
a very strong anti-proliferative activity.  
Oxidation of the prenyl side chain results in the formation of phase I metabolite XANH. 
Compared to the parent structure of XAN, XANH had unexpectedly a distinct impact on cell 
viability of HSC but only a week effect on cell proliferation was observed. After formation of 
an epoxide and subsequent ring closure, the pyrano-chalcone XANC and its hydrated analog 
dhXANC arise from XAN metabolism. XAN has shown to affect viability and induce 
apoptosis in activated human HSC before [281]. This in vitro study now included the 
investigation of putative XAN metabolites, which might occur in vivo. Despite the structural 
variation, the biological activity was quite similar to the parent chalcone concerning their 
influence on viability and proliferation of HSC, dhXANC being slightly more potent. Thus, 
these XAN metabolites may contribute to XAN’s anti-fibrotic activity in vivo [304].  
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The Michael system (acceptor of nucleophilic species like GSH or cysteine residues on 
proteins) has been identified as crucial structure element for biological activity of chalcones 
before. Hydrogenation of the α,β double bond often led to loss or attenuation of biological 
activity [305,316,317]. However, the dihydrochalcone phloretin exhibited anti-proliferative 
activity on stimulated HSC-T6 [303]. In this study, the hydrated derivatives dhFKC and 
dhHeli lacked any effects on the cell number of HSC. thXANC showed a week inhibition of 
cell proliferation which was not significant in the test concentration range. This compound 
might cause different effects due to the pyrano structure element. Nevertheless, once more 
the α,β-unsaturated ketone seems to presuppose the chalcone reactivity.  
A possible explanation of inactivity of P could be the unprotected OH-group in position 6’. 
This may lead to formation of the corresponding flavanone pinostrobin and account for the 
loss of activity compared to structurally related chalcones. 
No direct correlation between log P and anti-proliferative activity can be observed. The 
cytotoxic activity of the chalcones rather seems to be influenced by the substitution pattern 
than by lipophilicity. However, the quite lipophilic A (log P 3.61), FKB (log P 4.21), and 
4’MeXAN (log P 5.52) were the most active compounds regarding the anti-proliferative 
activity on activated HSC. 
4.3.3 Effects on cell organelles 
The influence of the test compounds on different cellular compartments was investigated by 
HCA (see chapter 2.2.6.1) to identify possible targets or mechanism of toxicity and draw 
connections between structure elements and biological activity. In general, HCA assays 
combine a multi-parameter setup usually together with automatic data acquisition and 
analysis for a fast and information-rich screening of test compounds. In this study, 
fluorescence microscopy was applied to investigate the influence of the test chalcones on 
cell organelles of HSC. For this, cell nuclei were stained with Hoechst 33342 and the mean 
nucleus area was analyzed. Fluorescently labeled actin filaments were used to detect 
cytoskeleton reorganization and morphological changes. Finally, the mean fluorescence 
intensity of stained mitochondria served as an indicator for mitochondrial impairment 
attended by loss of mitochondrial membrane potential. 
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The alteration of the nucleus area came along with the observed cytotoxic effects of the test 
compounds (Figure 4.4). The changes of the nucleus area were absent for compounds which 
neither have shown effects on the cell number before (P, dhFKC, dhHeli, 3OHHeli, 
4MeXAN, thXANC). A increased the nucleus area to 1.13 ± 0.06 at 25 µM where it reduced 
the cell number to 60%. For FKB and 4’MeXAN, a slight decrease of the nucleus area was 
observed at 50 µM. These compounds are highly toxic and only cell fragments were detected 
at this concentration. For the other chalcones, a significant increase of the nuclear area was 
found at 50 µM. 
Figure 4.4: Influence of the test compounds on mean nucleus area at 25 µM (left) and 50 µM 
(right). The mean nucleus area of untreated cells was used as reference and a 
value of 1.0 was defined for these control cells. The values are presented as the 
mean ± SD. Statistical analysis (one-way ANOVA following Dunnett’s multi-
comparison post-hoc test) was performed using GraphPad Prism 4 software. 
Levels of significance *p < 0.05, **p < 0.01 vs. ctl cells. 
Alteration of the nuclear area is a frequently used marker of cytotoxicity in high content 
screening [318]. In summary, the influence on the nucleus area can serve as a sensitive 
marker for cytotoxicity but in the present study it did not reveal pre-lethal effects as 
alterations only occurred when cell number was already significantly affected. 
 
The dying cell undergoes several morphological and biochemical changes. Necrosis leads to 
loss of membrane integrity, swelling, and disruption of the cells whereas apoptosis is 
characterized by membrane blebbing, cell shrinkage, chromatin condensation, and DNA 
fragmentation. During apoptosis, the reorganization of the cytoskeleton is a crucial process 
[319]. First, the formation of stress fibers (short, bundled actin filaments) and lamellipodia 
can be observed leading to cell rounding and detachment from ECM. Cell rounding is 
accompanied by actin-reorganization into a peripheral ring. Myosin light chain 
phosphorylation leads to contraction of the actin ring and formation of membrane protrusions 
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(blebs). These blebs play a major role for chemotaxis and recognition by phagocytes. Finally, 
actin is depolymerized and the cell is dismantled into apoptotic bodies [319]. 
 
Interestingly, the area of detected actin filaments was more selectively affected by the test 
chalcones (Figure 4.5). Significant effects were only present for A, FKA, FKB, and 
4’MeXAN. The latter two compounds exhibit strong cytotoxic effects at 50 µM and the results 
have to be assessed carefully. Although the prenylated chalcones, the XANC, and the XANH 
derivatives significantly reduced the cell number, no alterations of the actin area were 
observed. Heli and FKC neither affected the actin area, contrarily to the structurally related A 
and FKA which might be due to a different mechanism of action. 
Figure 4.5: Influence of the test compounds on mean area of detected actin filaments at 25 µM 
(left) and 50 µM (right). The mean actin area of untreated cells was used as 
reference and a value of 1.0 was defined for these control cells. The values are 
presented as the mean ± SD. Statistical analysis (one-way ANOVA following 
Dunnett’s multi-comparison post-hoc test) was performed using GraphPad Prism 4 
software. Levels of significance *p < 0.05, **p < 0.01 vs. ctl cells. 
Overall, within the used image analysis protocol, the observed effects on actin were only 
weak. For a more sensitive and precise analysis of the effects on actin, protocols should 
further be refined and adapted. Moreover, by choosing suitable positive controls the 
influence on actin polymerization and depolymerization could be studied. 
 
Mitochondria fulfill numerous tasks. They are responsible for the energy supply and the Ca2+ 
homoeostasis in cells, and occupy as well a regulatory role in apoptosis [320]. In early stages 
of programmed cell death, mitochondrial transition pore opening leads to dissipation of 
mitochondrial transmembrane potential, and permeabilization of the mitochondrial outer 
membrane [321,322]. The fluorescence intensity of mitochondria was analyzed to detected 
impairment of these organelles by the test compounds. Mitochondria constitute sensitive and 
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early indicators of cellular dysfunction that are affected long before cell number decreases. 
Either an increase or a decrease in mitochondrial fluorescence intensity indicates a 
disturbance of the mitochondrial health of the cell. An increase of fluorescence intensity 
shows an accumulation of the fluorescent dye often attended by swelling of mitochondria and 
loss of function. A decrease of fluorescence intensity indicates a loss of mitochondrial 
membrane potential, which can precede both necrotic and apoptotic cell death. 
Figure 4.6: Influence of the test compounds on the fluorescence intensity of mitochondria at 
10 µM (left) and 25 µM (right). The mean total fluorescence intensity of 
mitochondria of untreated cells was set as 100% value. Values are presented as 
mean ± SD. Statistical analysis (one-way ANOVA following Dunnett’s multi-
comparison post-hoc test) was performed using GraphPad Prism 4 software. 
Levels of significance *p < 0.05, **p < 0.01 vs. ctl cells. 
Effects on the mitochondrial fluorescence intensity could be observed already at low 
concentrations starting at 10 µM (Figure 4.6). Remarkably, only the 3’-prenylated compounds 
and the dihydrochalcone thXANC showed a significant decrease of the fluorescence 
intensity at this concentration. At 25 µM, besides the prenylated chalcones, also the pyrano-
chalcones reduced the mitochondrial fluorescence intensity. Neither the 3’-unsubstituted 
chalcones nor the XANH derivatives exhibited significant effects at this concentration. This 
constitutes a quite interesting finding since on the one hand the potent decrease of 
fluorescence intensity is limited to the prenyl- and pyrano-chalcones and one the other hand 
this effect can be observed at pre-lethal concentrations where the cell number is not yet 
affected.  
For A (232 ± 80%), FKA (163 ± 39%), and FKB (463 ± 180%) a strong increase of 
fluorescence intensity was measured at 50 µM. This might be due to the observed 
cytotoxicity of these test compounds, which is attended by mitochondrial damage. Despite 
the structural relation, Heli showed no influence on the fluorescence intensity although being 
cytotoxic at this concentration. For FKC (62 ± 29%) and 3OHXANH (37 ± 5%) a significant 
fluorescence intensity reduction was detected at 50 µM. P, dhFKC, dhHeli, 3OHHeli, XANH, 
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and 3OMeXANH lacked any effects on the fluorescence intensity of mitochondria even at 
50 µM. 
The impact of hydroxychalcones on the mitochondrial membrane potential has been 
examined before in cancer cell lines [323] and rat hepatocytes [324]. GSH depletion and the 
generation of ROS were observed. Both trigger the formation and opening of mitochondrial 
transition pores, leading to loss of mitochondrial transmembrane potential and the release of 
pro-apoptotic factors [322]. 
4.3.4 Cytochrome c release 
Apoptosis (programmed cell death) is essential for embryogenesis, tissue homoeostasis, and 
the removal of unwanted cells. Dysregulation of this crucial event can lead to 
immunodeficiency, autoimmune disorders, and cancer in the last resort. Aberrant apoptosis 
is also linked to the progression of chronic liver diseases such as liver fibrosis [243]. Hence, 
the apoptotic clearance of activated hepatic stellate cells, the key mediators in the 
fibrinogenic process, constitutes an interesting therapeutic tool in the resolution of hepatic 
fibrosis [244]. 
Two major pathways of apoptosis are known: the extrinsic (death receptor pathway) and the 
intrinsic pathway (mitochondrial pathway) [325]. Besides, alternative signaling pathways exist 
(e.g. autophagy, ER stress pathway). Furthermore, considerable cross talk between the 
different pathways can be observed. Based on the observed effects on the fluorescent 
intensity of mitochondria in the HCA assay, further studies concerning mitochondria-related 
apoptosis were conducted. Therefore, cytochrome c release as an early apoptosis marker 
was investigated. The intrinsic apoptosis is mainly controlled by the family of B-cell 
lymphoma 2 (Bcl-2) proteins [326]. Activation of pro-apoptotic proteins Bax and Bak initiate 
the permeabilization of the outer mitochondrial membrane, which leads to the release of 
cytochrome c and other pro-apoptotic factors from the mitochondrial inter-membrane space 
to the cytosol. Here, cytochrome c interacts with apoptotic protease-activating factor-1 (Apaf-
1), which leads to ATP-dependent conformational changes, self-aggregation and 
oligomerization (formation of apoptosome), recruitment of procaspase 9 and its subsequent 
proteolytic activation. Caspase 9 directly activates effector caspases 3 and 7, which 
consequently leads to cell death due to controlled proteolytic cleavage of multiple 
downstream targets [327]. 
 
To investigate the cytochrome c release, HSC were seeded in 96-well plates and treated with 
10, 25, 50 µM of test compounds for 24 h (see chapters 2.2.4.2 and 2.2.4.3). The assay was 
performed according to the described methodology (see chapter 2.2.6.2). Cytochrome c was 
detected by immunofluorescence. Apoptotic signals lead to a release of cytochrome c from 
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mitochondria, which then diffuses into the cytosol and nucleus (Figure 4.7, staurosporine-
treated cells). This translocation of cytochrome c was used for analysis. Staurosporine, 
known to trigger cytochrome c release from apoptotic mitochondria, was used as a positive 
control (p.ctl) for assay protocol development and served also as reference system (100% 
value). 
 
Figure 4.7: Immunofluorescent staining of cytochrome c in untreated (n.ctl, left) and 
staurosporine (4h, 1 µM)-treated (p.ctl, right) HSC. 
Cytochrome c release was detected first in cells treated with 10 µM of A, FKB, XAN, 
4AcXAN, 4MeXAN, XANH, XANC, or dhXANC, and 25 µM of FKA, Heli, 4’MeXAN, and 
XANH derivatives (Figure 4.8). 
Figure 4.8: Cytochrome c release [%] from HSC after treatment with 10 and 25 µM of test 
compounds for 24h. Staurosporine (1 µM, 4h) was used as positive control (p.ctl) 
and reference system (staurosporine effect = 100%) for chalcone effects. Untreated 
cells (n.ctl) were set as zero value. Values are presented as the mean ± SD. 
Statistical analysis (one-way ANOVA following Dunnett’s multi-comparison post-
hoc test) was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs. n.ctl cells. 
These results are partly consistent with the results obtained by the analysis of mitochondrial 
fluorescence intensity (see chapter 4.3.3). Whereas the prenyl- and pyrano-chalcones have 
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shown effects on the mitochondria in the HCA before, cytochrome c release was also 
observed for XANH and its derivatives, A, FKA, FKB, and Heli, obviously independent from 
mitochondrial transmembrane depolarization. There is evidence that cytochrome c release 
can occur prior to the loss of mitochondrial membrane potential [328]. However, thXANC 
exhibited a strong effect on the mitochondrial fluorescence intensity without inducing 
cytochrome c release at these concentrations. At 50 µM, the effects were very unspecific. 
Nearly all compounds (except P, dhFKC, dhHeli) caused a significant increase. These 
results have to be rated carefully as the release of cytochrome c constitutes an early step of 
apoptosis and should be observed in pre-lethal states where cell number is not affected yet. 
Perhaps, also a shorter incubation period would have as well enhanced the specificity of 
observed effects. At a concentration of 50 µM test compound, also cell morphology was 
partly altered what limited interpretation of data. 
The mitochondrial dependent pathway is an important target of chalcones triggering 
apoptosis. FKA induced apoptosis in bladder cancer cells causing loss of mitochondrial 
membrane potential and release of cytochrome c via Bax-mediated pathway [269]. As more 
precisely described in chapter 4.1.2, FKB induced apoptosis in several cancer cell lines via 
the mitochondrial-dependent pathway [274–277]. Enhanced ROS production observed in 
HCT-116 and HSC-3 seems to serve as a catalyst. XAN is known to induce apoptosis in a 
broad panel of cell lines [101]. Thereby, dependent on the cell type and expression levels, 
different cell death mechanisms are addressed. Regarding mitochondrial dependent 
apoptosis, a connection to ROS production was drawn by Strathmann et al. [329]. XAN 
increased the production of superoxide radical anion in isolated mouse liver mitochondria, 
affected the ATP concentration and mitochondrial membrane potential and led to release of 
cytochrome c in cancer cells. The same effects were observed in mouse embryo fibroblasts 
by Yang et al. [330]. XAN increased the ROS production which was directly associated with 
its apoptosis-inducing effects displayed in loss of mitochondrial membrane potential, 
cytochrome c release, and PARP cleavage. Moreover, XAN induced apoptosis in human 
glioblastoma cells [331]. Increased intracellular ROS was again made responsible for the 
activation of the intrinsic pathway. Indeed, cytochrome c release, caspase 9 and 3 activation, 
and down-regulation of Bcl-2 indicated that apoptosis is mediated by mitochondria. 
Furthermore, XAN induced mitochondria-dependent apoptosis in human colon [332] and 
prostate cancer cells [333]. Taken together, a clear correlation between the enhanced 
production of ROS, GSH depletion, and the activation of the mitochondrial pathway is likely 
for the investigated chalcones and has been already demonstrated for FKB, XAN, and 
several hydroxychalcones.  
Summing up, the prenyl- and pyrano-chalcones provoke a loss of mitochondrial fluorescence 
intensity followed by a significant release of cytochrome c. The latter is also caused by 
92 4 Inhibitory activity of structurally related chalcones on activated human hepatic stellate cells 
XANH and its derivatives but to a lesser extent. XANH has shown to evoke a considerable 
effect on cell viability of HSC, but it did not cause any impairment of the mitochondrial 
transmembrane potential. Cytochrome c release is also observed after A, FKB, and FKA 
treatment. None of these compounds induced a loss of mitochondrial fluorescence intensity. 
However, a distinct increase of fluorescence intensity at 50 µM suggests a remarkable 
mitochondrial damage. Compared to their 3’-prenylated analogs, Heli and FKC only 
exhibited a weak effect, which even was not significant in case of FKC. The two compounds 
neither affected the fluorescence intensity of mitochondria at same concentrations. As 
expected from previous results, the dihydrochalcones, P, and 3OHHeli constituted again the 
least active compounds. 
4.3.5 DNA content and cell cycle analysis 
Furthermore, the DNA content of treated and untreated HSC was analyzed in the context of 
HCA. For that purpose, the fluorescence intensity of Hoechst 33342 stained cell nuclei was 
determined (see chapter 2.2.6.3). As the fluorescence intensity is proportional to the DNA 
content, the corresponding cell cycle state can be determined and potential influences of the 
test compounds can be assessed. 
DNA replication and cell division are the two primary events in cell proliferation. The cell 
cycle is divided in sequential phases (Figure 4.9 left): 
 the first gap phase (G1), in which the cell prepares for DNA replication, 
 the period of DNA synthesis (S), during which a second copy of the genetic material 
is generated, 
 the second gap phase (G2), in which the cell prepares for division, 
 the mitosis phase (M), during which the two copies of DNA are segregated into two 
daughter cells. 
Cell cycle progression is regulated by an ordered activation of different cyclin-dependent 
kinases (Cdk). Activation of the Cdk requires the presence of different cyclins, which show 
altered protein levels during cell cycle. Several checkpoints ensure the proper order and 
timing of events. Loss of cell integrity or DNA damage leads to arrest of the cell cycle at 
these checkpoints. Deprivation of growth factors, modulation of Cdk-cyclin activity and other 
signaling proteins, DNA damage, inhibition of DNA synthesis, interference with 
topoisomerase II and microtubules, and various apoptotic stimuli may cause cell cycle arrest 
at different stages. As is known, modulation and arrest of the cell cycle is an important target 
of anti-proliferative and apoptosis-inducing chalcones [334]. 
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To get an insight into the distribution of cell cycle phases in a normal cell population, the 
DNA content of untreated control cells was analyzed first (Figure 4.9 right). 
Figure 4.9: Left: Correlation of cell cycle phases and DNA content of the cells. The DNA 
content of cells can be determined by measurement of fluorescence intensity of 
Hoechst33342 stained cell nuclei. Right: DNA content of untreated HSC (ctl) ; DNA 
content (cell cycle phase): 2N (G0/G1), 2N_4N (S), 4N (G2/M), <2N and >4N 
(abnormal). 
In a normal cell population, the major number of the cells should be in the G1/G0 phase (2N), 
a smaller in the G2/M phase (4N), and a small number in the S phase (2N_4N). This was 
confirmed by our results. Approximately 56% of the cells had a DNA content of 2N, 11% of 
2N_4N, 17% of 4N, 5% of less than 2N, and 11% more than 4N. Hence, round about half of 
the cell population was in the G0/G1 phase and one third in the S/G2/M phase.  
 
For studying the chalcones’ effect on the DNA content of HSC, the ratio of cells with 2N and 
4N DNA content was calculated and compared to untreated control cells with a ratio of 3.3 
(Figure 4.10). The ratio of 2N/4N is a commonly used value in cell cycle analysis to describe 
influences of test compounds on cell cycle phase distribution. An increase of the quotient 
compared to control value indicates an arrest in G1/G0 whereas a G2/M arrest is reflected by 
a decrease of this ratio. 
<2N 2N 2N_4N 4N >4N
0
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Figure 4.10: Ratio of cells [%] with DNA content of 2N (G1) and 4N (G2) (2N/4N) at 25 µM (left) 
and 50 µM (right). (#) not determined. Values are presented as the mean ± SD. 
Statistical analysis (one-way ANOVA following Dunnett’s multi-comparison post-
hoc test) was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs. ctl cells. 
At 50 µM, all compounds which significantly inhibited cell proliferation showed a reduced 
ratio of 2N to 4N. For the highly cytotoxic chalcones A and 4’MeXAN this effect already 
occurred at 25 µM. For FKB and 4’MeXAN, the ratio could not be determined at 50 µM due 
to low amount of viable cells, however, FKB lacked significant effects at lower concentrations 
either. Again, significant effects were absent for the dihydrochalcones, P, and 3OHHeli which 
is attended by the low toxicity of these compounds on HSC. 4MeXAN that affected both cell 
viability and mitochondrial membrane potential did not have any influence on the DNA 
content of cells. This finding correlates well with its missing anti-proliferative activity. 
The antimitotic activity of chalcones has been recognized quite early [335]. Colchicine, a 
reversible inhibitor of microtubule assembly, referred as a model substrate for the synthesis 
of 3’,4’,5’-trimethoxylated chalcones. Previous SAR studies on colchicine have revealed the 
importance of the methoxy substituents and the carbonyl group for binding to tubulin. These 
structure elements were incorporated into the synthesized chalcones. Indeed, these 
compounds revealed anti-mitotic effects in HeLa comparable to colchicine. The effect of 2’-
oxygenated chalcones on cell cycle phase distribution has been studied before in human 
cancer cell lines (Jurkat, U937) [336]. A distinct anti-proliferative activity and altered 
distribution of cell cycle phases was observed for the hydroxylated and methoxylated 
chalcones, 2’-hydoxy-2,3,4’,6’-tetramethoxychalcone being the most active and causing G2/M 
arrest. A recent study investigated the antimitotic effect of chalcones against leukemia cells 
K562 [337]. Propidium iodide staining was used for determination of cell cycle state. Several 
compounds induced G2/M arrest comparable to vincristine. The methoxylation pattern of the 
A ring influenced the antimitotic activity clearly favoring di- and trimethoxylation at 2’,4’,6’-
carbons. Substitution of the B ring was found to be less important, however, dimethoxylation 
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in position 2 and 6 seems to be relevant. In fact, for the 4’,6’-dimethoxylated compounds 
FKA [270] and FKB [271,274–278], G2/M arrest was made responsible for their anti-
proliferative effect in several cancer cell lines. Also FKA led to G2/M arrest in HSC. XAN 
caused S arrest in breast cancer cells (MDA-MB-435) [338] and S/G2/M arrest in ovarian 
cancer cell lines (SKOV3, OVCAR3) [339]. The compounds’ influence on the cell cycle is 
dependent on the cell type, test concentration, and other factors. On activated HSC, XAN 
and its structure analogs induced G2/M arrest: the number of cells in G1 was decreased 
whereas the number of cells in G2/M increased (Figure 4.10). 
The analysis of the DNA content can help to understand and interpret the anti-proliferative 
activity of the chalcones. The amount of cells with a DNA content of 2N is decreased in favor 
of cells with a content of 4N. Thus, cells still proceed through the G1 and S phase but remain 
in the G2/M phase whereby normally following cell division is blocked. This is reflected in a 
decreased cell number after chalcone treatment. Thereby, A and 4’MeXAN showed the 
strongest impact on the cell cycle phase distribution already at 25 µM. 
4.4 Conclusion 
The chalcones possess a favorable pharmacological profile for the treatment of diseases, 
which are attended by inflammatory processes. Moreover, their anti-proliferative and pro-
apoptotic activities are broadly investigated in numerous cellular and animal models. Some 
chalcones have already been tested with regard to their activity against activated hepatic 
stellate cells, which are considered as the most important cellular target in the treatment of 
hepatic fibrosis. 
A high content analysis (HCA) assay was established to determine effects on the organelle 
level. This multi-parameter approach enables the detection of pre-lethal effects and can also 
be combined with other established viability and toxicity assays. HCA therefore constitutes 
an interesting tool for the quick and simultaneous investigation of several cellular parameters 
and qualifies this method for structure activity relationship studies. 
Table 4.3 summarizes the assay results and effects of the investigated chalcones. For more 
detailed information about assay results, see the supplementary data in chapter 10.1 (Figure 
10.1 – Figure 10.19). 
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Table 4.3: Overview of assay results. Viability (MTT), prolif (cell proliferation by CV and HCA 
cell number), nucleus (HCA nucleus area), actin (HCA actin area), mito (HCA 
mitochondrial fluorescence intensity), cyto c (cytochrome c release), DNA (HCA 
DNA content). (+ +) strong increase, (+) increase, (- -) strong decrease, (-) decrease, 
(~) weak effect, (NA) not analyzed.  
 viability prolif nucleus actin mito cyto c DNA 
A - - - + ++ + + + + + + 
P no effect no effect no effect no effect no effect no effect no effect 
FKA - - +  + + + + 
FKB - - - -  + + + + + ~ 
FKC  - - + no effect ~ no effect + 
dhFKC NA no effect no effect no effect no effect no effect no effect 
Heli - - + no effect no effect + ~ 
dhHeli NA no effect no effect no effect no effect no effect no effect 
3OHHeli no effect no effect no effect no effect no effect no effect no effect 
XAN - - + no effect - - + + + 
4AcXAN - - + no effect - - + + + 
4MeXAN - ~ - no effect - - + no effect 
4’MeXAN NA - - - - - - + + 
XANH - - ~ + no effect no effect + + 
3OHXANH NA - - + no effect ~ + + 
3OMeXANH NA - + no effect no effect + + 
XANC - - + no effect - + + 
dhXANC - - + no effect - + + 
thXANC NA ~ no effect no effect - - no effect ~ 
 
XAN was identified as effective inhibitor of hepatic inflammation and fibrosis in vitro and in 
vivo. The present in vitro study first provides information concerning the activity of XAN 
metabolites and other structurally related 2’-hydroxy chalcones on activated HSC. XAN 
treatment led to apoptosis in HSC through activation of caspase 3 [281]. This study proposes 
a mitochondrial mediated pathway, attended by loss of mitochondrial membrane potential 
and subsequent cytochrome c release already at low concentrations of 10 µM. Interestingly, 
this was also observed for the XAN metabolites 4’AcXAN, 4MeXAN, XANC, and dhXANC. 
Thereby, the effect on cell viability and proliferation compared to XAN was slightly enhanced 
for the pyrano-chalcones and decreased for 4MeXAN which did not affect cell number or cell 
cycle distribution up to a concentration of 50 µM. XANH decreased cell viability but had a 
weaker impact on cell proliferation. However, XANH induced G2/M arrest and release of 
cytochrome c without affecting mitochondrial membrane potential. The different behavior 
might be due to higher hydrophilicity (log P), lower cellular absorption, and altered cellular 
distribution. Nevertheless, data suggest that tested XAN metabolites contribute to XAN’s 
effects in vivo affecting same cellular targets and pathways. Data of conjugated XAN 
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metabolites (glucuronides, sulfates) are still missing and should be addressed in future 
studies because of high in vivo relevance (see chapter 5.1.2 for XAN metabolism). 
In addition, the study was aimed to identify structure elements, which influence the activity of 
chalcones on HSC (Figure 4.11). 
 
R1 R2 R3 R4 R5 α,β 
OH OH H H H sat 
OCH3 OCH3 prenyl OH OH unsat 
 pyrano OCH3 OCH3  
 2H-pyrano OAc   
Figure 4.11: General structure and substitution pattern of investigated 2’-hydroxy chalcones. 
Structure elements, which enhance the activity on activated HSC, are indicated in 
bold letters. 
Like described before, the double bond in α,β position to the carbonyl group is required for 
the activity of the chalcones. Hydrogenation led to complete loss of activity in case of dhFKC 
and dhHeli whereas for thXANC still mitochondrial fluorescence intensity was affected. 
Thus, the Michael system constitutes a crucial structure element, however, substitution of the 
A ring as well triggers the chalcone activity. P with an unprotected hydroxyl group in position 
6’ lacked any influence on HSC. Perhaps, the cyclisation to the corresponding flavanone is 
attended by loss of activity. Further investigations of 2’,6’-dihydroxy chalcones and 
corresponding flavanones could verify this assumption. The substitution pattern of the A ring 
clearly influence the chalcone effects. By comparison, B ring substituents had a weaker 
impact, even favoring unsubstituted compounds such as A and FKB. The 3’-prenyl group 
enhanced the activity of chalcones: in comparison to FKC and Heli the prenylated analogs 
4’MeXAN and XAN were more effective. Furthermore, a prenyl group or a pyrano 
substitution seems to be a structural requirement for interaction with the mitochondrial 
membrane. Distinct decrease of mitochondrial fluorescence intensity was selectively 
observed for these chalcones. In contrast to the B ring, further methoxy groups in the A ring 
increased particularly the anti-proliferative activity: the 4’-methoxy derivatives FKB and 
4’MeXAN were more cytotoxic than A and XAN. As mentioned above, no explicit connection 
of log P and activity of the chalcones was found. In general, log P values between 1 and 4 
are considered as beneficial for absorption [340]. For quite lipophilic chalcones like XAN, 
rapid cellular uptake, accumulation, and intracellular formation of protein complexes (thiol 
adducts) were observed in hepatic stellate cells [341]. Chalcones with similar log P might 
show analog kinetics. 
The structural alterations uncovered several chalcones with enhanced in vitro activity against 
activated HSC. Among the test compounds, A, FKB, and 4’MeXAN were the most potent. 
They exhibit strong anti-proliferative activity, induce a release of cytochrome c, and cause 
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G2/M arrest. The distinct anti-inflammatory activity of chalcones could turn out to be 
advantageous for treatment of hepatic fibrosis. A, FKB, XAN, and other chalcones have 
shown to inhibit NF-κB pathways. Enhanced NF-κB activity plays a central role in HSC 
activation and perpetuation of hepatic inflammation. Further pharmacological testing of the 
chalcones should be conducted to illuminate the mechanism of HSC inhibition on the 
molecular level. The study provides information about structure elements, which contribute to 
biological effects. Hence, further structures could be synthesized and evaluated concerning 
their inhibitory activity on activated HSC. In addition, toxicity studies of the compounds are 
strongly needed. FKB is suspicious causing hepatotoxic effects, which would exclude this 
compound from therapeutic application. In vitro evaluation of toxicity on primary human 
hepatocytes therefore is an indispensable issue. 
 
 5 In vitro metabolism of chalcones: identification and 
structure elucidation of microsomal metabolites 
5.1 Introduction 
5.1.1 In vitro metabolism systems and their applications 
In vitro metabolism studies constitute an important tool in fundamental research and 
preclinical screening of drug-like properties [342]. As is known, metabolism is carried out in 
two general phases: in phase I polar groups are either introduced by oxidation, reduction, 
and hydrolysis, or uncovered by dealkylation. In phase II polar groups are conjugated with 
glucuronic acid, sulfate, glycine, glutamine, glutathione, acetate, or methyl groups in order to 
render the molecule more polar and facilitate the excretion [343]. Metabolites are often less 
active than the parent drug or even inactive. Sometimes however, biotransformation products 
show enhanced bioactivity or toxicity. In case of prodrugs, biotransformation is even 
necessary to convert the drug in its active form as the parent drug is inactive. Metabolism 
may consequently be involved in both “activation or toxification” and “inactivation or 
detoxification” [344]. The liver is the major site for metabolism although other tissues as well 
as the bacterial flora of the gastrointestinal tract contribute to overall biotransformation 
reactions. 
Most important enzymes in drug metabolism are the cytochrome P450 monooxygenases 
(CYP450) followed by uridine diphosphoglucuronosyl transferases (UGT) and esterases 
[345]. The cytochrome P450 system consists of a superfamily of isoenzymes with different 
tissue distribution, regulation, and of course substrate affinity. Two protein components, a 
hemeprotein (substrate and oxygen binding site) and a flavoprotein (electron carrier), 
compose the enzyme system [344]. Cytochrome P450 enzymes are present in the 
endoplasmic reticulum, thus can be found in microsomal preparations. To date, about 36 
human isoforms are known [346]. However, only nine isoforms are mainly involved in drug 
metabolism, CYP3A4 being the most important isoenzyme responsible for the metabolism of 
around 50% of approved drugs, followed by CYP2C9, CYP2C19, and CYP2D6 [345,347]. 
Table 5.1 compiles the main human CYP isoforms, their tissue distribution, model substrates, 
(selective) chemical inhibitors and inducers.  
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Table 5.1: Compilation of major human CYP isoforms involved in drug metabolism, their 
occurrence, model substrates used for quantification of enzyme activity, selective 
inhibitors, and known inducers of enzyme activity. 
[1]
 Recommendation of FDA, 
American Association of Pharmaceutical Sciences (AAPS), and the European 
Federation of Pharmaceutical Sciences; 
[2]
 according to Khojasteh et al. [348]; 
[3]
 
according to Brandon et al. [349]. 
Isoform Occurrence Model substrate 
[1] 
Inhibitor 
[2] 
Inducer 
[3] 
CYP1A1 Mainly 
extrahepatic 
7-Ethoxyresofurin  
O-deethylation 
(α-Naphtho-
flavone) 
Polycyclic  
hydrocarbons 
CYP1A2 Liver Phenacetin  
O-deethylation 
Furafylline Smoking 
3-Methylchol-
anthrene 
Char-grilled meat 
CYP2A6 Liver Coumarin C7- 
hydroxylation 
Tranylcypromine Pyrazoles 
Barbiturates 
CYP2B6 Liver (S)-Mephenytoin 
N-desmethylation 
2-Phenyl-2-(1-
piperdinyl)propane 
(Sertraline) 
 
CYP2C9 Liver, 
intestine 
(S)-Warfarin C6-,  
C7 hydroxylation 
Sulfaphenazol Rifampicine 
Phenobarbital 
CYP2C19 Liver (S)-Mephenytion  
C4’-hydroxylation 
(-)-N-3-Benzyl-
phenobarbital 
(Ticlopidine) 
Rifampicine 
Carbamazepine 
CYP2D6 Liver, 
intestine, 
kidney 
Bufuralol C1’-
hydroxylation 
Dextromorphan  
O-demethylation 
Quinidine  
CYP2E1 Liver, 
intestine, 
leucocytes 
Chlorzoxazone  
C6-hydroxylation 
4-Methylpyrazole Ethanol 
CYP3A4 Liver, GIT Midazolam C1’-
hydroxylation 
Testosterone C6- 
β-hydroxylation 
Ketoconazol Rifampicine 
Barbiturates 
 
Flavin monooxygenases (FMO) are involved in oxidation of heteroatoms such as nitrogen 
and sulfur. These membrane-bound enzymes can be found in microsomes as well. 
Monoamine oxidases are responsible for oxidation of endogenous and exogenous amines 
[350]. 
Further important for phase I metabolism are the previously mentioned esterases (as well as 
serum esterases present in blood), and the cytosolic enzymes carbonyl reductases and 
alcohol and aldehyde dehydrogenases. Moreover, also the microsomal and soluble epoxide 
hydrolases may play a role in drug metabolism. 
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The membrane-bound UGTs catalyze the conjugation of glucuronic acid at hydroxyl, amine, 
and carboxylic acid groups of endo- and exogenous molecules. UGTs are grouped in two 
subfamilies, UGT1A and UGT2B, which each contain again several isoforms. UGT1A1, 
UGT1A6, and UGT2B7 are the most important ones for drug metabolism. UGTs can be 
found in liver, gastrointestinal tract, kidney, brain, mammary, and prostate [351]. 
The cytosolic sulfotransferases (SULT) are responsible for the transfer of sulfate to their 
substrates. Again, several isoforms are known with different sites of expression (liver, GIT, 
skin, prostate, placenta, platelets, adrenal, endometrium, brain, fetal kidney and lung). 
Sulfation is known to be involved in the metabolism of e.g. acetaminophen, minoxidil, and 
salbutamol [352]. 
Other important phase II enzymes are the glutathione-S-transferases (GST), the N-
acetyltransferases (NAT), and the methyltransferases (such as catechol-O-
methyltransferase). 
Except the membrane-bound UGTs, microsomal preparations lack these conjugation 
enzymes, thus they are limited in their ability of phase II metabolite formation.  
 
For in vitro metabolism studies, a number of different systems has been established. 
However, the suitable application should be chosen carefully because each system is 
associated with advantages, disadvantages, and limitations (see Table 5.2).  
In vitro metabolism techniques are a valuable tool in preclinical testing to screen and 
characterize drug metabolites, elucidate the metabolic pathways, and assess metabolic 
stability as a first approach to pharmacokinetic parameters. Additionally, they constitute an 
important tool for prediction of drug-drug interactions, enzyme inhibition, or induction [342]. 
Supersomes are microsomes, which consist of vesicles of the hepatocyte ER of human CYP- 
or UGT-transfected insect cells. They are suitable for the determination of metabolite 
formation with regard to individual isoforms. Moreover, they are used for drug-interaction 
studies and examination of the impact of enzyme polymorphismus on drug biotransformation. 
Another application is the specific formation of metabolites for isolation purpose. As the 
perhaps most “non-physiological” model, in vivo correlation is a doubtful issue. 
The use of subcellular fractions (S9, cytosol, microsomes) is very common, well established 
and characterized. Fractions are obtained from (liver) tissue by differential centrifugation 
steps. The S9 fraction contains both phase I and II enzymes, thus can be used for metabolite 
profiling choosing individual, species-, or gender-specific probes. However, enzyme activities 
are lower than in microsomal or cytosolic preparations so that some metabolites may not be 
detected. 
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Table 5.2: Overview of in vitro metabolism systems and their advantages and disadvantages. 
From top to bottom increasing resemblance of true in vivo situation. The table was 
compiled and adapted according to Brandon et al. [349], Jia et al. [347], Asha et al. 
[353] and FDA Guidance for Industry (Drug metabolism/Drug interaction; Studies in 
vitro). 
In vitro system Advantages Disadvantages 
Supersomes easy to use 
studies of individual enzyme 
isoforms and different genotypes 
high enzyme activity  
only CYP, FMO, UGT, GST, SULT 
available 
difficult correlation to in vivo 
no induction models 
Microsomes easy to use, cheap 
individual, gender- and species-
specific studies 
incomplete metabolic profile 
addition of cofactors 
no induction models 
Cytosol phase II metabolism of different 
enzymes can be studied 
separately 
high enzyme activities 
easy to use, cheap 
individual, gender- and species-
specific studies 
incomplete metabolic profile, only 
NAT, SULT, GST 
addition of cofactors 
no induction models 
S9 fraction phase I and II metabolism 
easy to use, cheap 
individual, gender- and species-
specific studies 
low enzyme activities than in 
microsomes 
addition of cofactors 
no induction models 
Liver cell lines easy to culture 
quite stable enzyme activities 
CYPs inducible 
low expression levels 
 
Hepatocytes whole metabolic profile 
self-sufficient cofactors 
well established and characterized 
induction models 
pools for cryopreserved cells 
presence of drug transporters 
good in vivo correlation 
quite expensive 
complex isolation 
batch variability 
instability of enzyme activity and 
down regulation of transporters 
loss of cell viability 
damage of cells during isolation  
Liver slices whole metabolic profile 
intact cellular association 
morphological studies  
interindividual studies 
good in vivo correlation 
expensive 
ex vivo animal trial 
complex methodology and high 
technical effort 
penetration problems 
limited viable period 
damaged cells on the edges 
batch variability 
Perfused liver whole metabolic profile 
bile formation 
three dimensional architecture 
best in vivo correlation 
very costly 
ex vivo animal trial 
complex methodology and high 
technical effort 
limited viable period 
poor reproducibility 
no human livers 
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Microsomes constitute a popular and affordable model for metabolic screening. Individual, 
gender-specific, and pooled probes from different species are commercially available. They 
are used for assessing the metabolic stability (kinetics, estimation and extrapolation of 
hepatic clearance) as well as for interspecies comparisons of metabolic profile. The latter can 
give valuable hints for choosing the appropriate animal model for subsequent in vivo 
investigations.  Nevertheless, it has to be noted that only membrane-bound enzymes (CYPs, 
UGTs) are enclosed. Due to the lack of many conjugation enzymes, microsomes are mainly 
applied for phase I studies, and for identification of metabolic pathways by selective inhibition 
of CYP isoforms with either chemical inhibitors or antibodies. Glucuronidation can be 
examined by addition of uridine diphosphoglucuronic acid. 
The cytosol fraction contains the soluble phase II enzymes (SULT, NAT, GST etc.). 
Metabolism of individual enzymes can be studied by addition of enzyme specific cofactors. 
However, due to the lack of phase I enzymes the metabolic profile remains incomplete. 
On the cellular level, both cell lines and primary cultured hepatocytes are applied. The most 
common liver cell line is the human hepatocellular carcinoma cell line HepG2. As basal 
enzymes activity is very low, CYP enzymes have to be induced by supplementation of 
inducers to the culture medium. Cell lines are generally easier in handling as primary 
hepatocytes and show relatively stable enzyme concentrations. However, they are rarely 
used because of low expression levels of most metabolizing enzymes, which may lead to 
detection problems of formed metabolites. 
Primary hepatocytes are a popular and physiological in vitro system for any studies of drug 
metabolism. The whole range of metabolizing enzymes is present as well as drug specific 
transporters. The isolation of primary hepatocytes is a quite complex procedure and in 
conventional cultures there is a rapid loss in transporter and enzyme activity. However, 
nowadays with establishment of cryopreservation techniques, hepatocytes from different 
species as well as pooled probes are commercially available and enzyme activity can be 
maintained by special culture methods (e.g. sandwich-culture in collagen matrix). 
Tissue cultures and studies on isolated perfused livers are the high-end models in in vitro 
biotransformation studies with best in vivo correlation due to presence of three-dimensional 
structures and cell-cell interactions. Both techniques are very complex and make a high 
demand on technical equipment. Due to practical inconveniences, poor reproducibility, high 
costs, and short viable period, perfused organs are seldomly used for biotransformation 
studies only when bile excretion is necessary. Liver slices and hepatocyte culture constitute 
the more feasible methodology with good in vivo correlation. 
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5.1.2 Absorption, bioavailability, and metabolism of flavonoids and 
chalcones 
Chalcones (derivatives of trans-1,3-diphenyl-2-propen-on) belong to the large group of 
polyphenolic compounds, more precise they are flavonoid derivatives (C6-C3-C6) lacking the 
heterocyclic C ring [354]. For chalcones many interesting pharmacological activities have 
been discovered, such as anti-infective, anti-oxidative, anti-inflammatory, chemopreventive, 
and anti-cancer effects [250] (see chapter 4). Sometimes, chalcones may also contribute to 
toxicity observed for drugs (e.g. kava-chalcones, see chapter 3.3.3). In any case, chalcones 
as small molecules seem to possess a very high and widespread ability for pharmacological 
interactions. Chalcones may be ingested (as minor constituents) via dietary sources (e.g. 
phloretin/phloridizin in apple, naringenin chalcone in tomato, xanthohumol in beer) or herbal 
drugs (e.g. isosalipurposide in willow bark, flavokawains in kava kava root, 
isoliquiritigenin/isoliquiritin and licochalcone A in licorice, cardamonin in TCM drugs like 
Alpinia katsumadai). Although pharmacological properties of chalcones are extensively 
investigated, little is known about their absorption, bioavailability, and metabolism in general 
[355]. 
In contrast, pharmacokinetics of C ring-closed flavonoids (flavones, flavonols, flavanones, 
catechins, anthocyanidines, and isoflavones) are far better investigated as they are abundant 
in plant foods and connected to constitutional and protective effects [356–359]. Mainly, 
dietary flavonoids, except catechins, are present in plants as β-glycosides. Longtime, very 
poor absorption was predicted for glycosylated flavonoids. However, hydrolyzation by 
bacterial enzymes might take place in lower parts of the intestine and liberated aglycones 
might be partly absorbed or further metabolized [356] (Figure 5.1). On the contrary, Hollmann 
et al. could show that quercetin glucosides are obviously absorbed intact in the small 
intestine via the sodium-dependent glucose transporter 1 (SGLT1) [360]. In further 
investigations, however, no intact quercetin-glucosides were detected in plasma [361]. 
Alternative mechanisms of absorption were proposed such as the pre-involvement of 
hydrolyzing enzymes of the small intestine (broad-specific β-glucosidase enzyme (BSβG) 
and lactase phlorizidin hydrolase (LPH)). Substrate specificity of these enzymes highly 
depends on the sugar moiety and only rarely on the aglycone part [362]. Efficacy of 
absorption of certain flavonoid glycosides might also be decreased by efflux transporters as 
the multidrug resistance-associated protein 2 (MRP2) [363]. 
Glycosides which are not substrates of SGLT1 or LPH (e.g. quercetin-3-β-rutinose) will be 
transported toward the colon where they are hydrolyzed by bacterial enzymes. Liberated 
aglycones either can be absorbed in colon as well (but in a lesser extent than in the small 
intestine), or further metabolism and degradation by microorganisms to a variety of 
hydroxylated phenyl carboxylic acids and CO2 takes place. A rash of these “colon-
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metabolites” namely benzoic acids, phenylacetic acids, and phenylpropionic acids were 
detected in urine and plasma [364]. 
Figure 5.1: Absorption, transport pathways, and metabolism of flavonoid glycosides (FG) and 
aglycones (F) in enterocytes. SGLT1 sodium dependent glucose transporter 1, 
MPR2 multidrug resistance-associated protein 2, BSβG broad-specific β-
glucosidase, LPH lactase phloridizin hydrolase, β gluc β-glucosidase, UGT uridine 
diphosphoglucuronosyl transferase, SULT sulfonyltransferase, COMT catechol-O-
methyltransferase, Bact bacterial enzymes, Fg flavonoid glucuronide, Fs flavonoid 
sulfate, Fm methylated flavonoid. Adapted from [359,356]. 
Also bioavailability of flavonoid aglycones and glycosides has been examined. The best-
studied aglycone is querectin. In a study using [14C]quercetin, absoption of 36-53% was 
found, however, nearly no free quercetin could be detected in plasma. This is due to 
extensive metabolism to conjugated metabolites, mainly glucuronides [365]. 
The quite lipophilic flavone chrysin showed very poor oral biovailability of 0.003-0.02% albeit 
high membrane permeability. However, it was extensively metabolized by intestinal cells to 
glucuronic acid and sulfate metabolites, which were almost quantitatively eliminated via efflux 
proteins [366].  
Bioavailability of flavonoid glycosides is strongly determined by the sugar moiety as could be 
shown for different quercetin glycosides [362]. Original quercetin glycosides are not 
detectable in plasma. Instead, deconjugation (hydrolysis) and reconjugation to phase II 
metabolites occurs in the intestinal cells. Meanwhile, bioavailability studies have been 
conducted for different flavonoid subclasses, such as catechins, anthocyanines, and 
isoflavones [357]. 
For metabolism of flavonoids, mainly two compartments are important: on the one hand 
tissues like the small intestine and the liver, on the other hand the microorganisms of the 
colon (as previously mentioned). Conjugation of hydroxyl groups with glucuronic acid (by 
UGTs), sulfate (by SULTs), or glycine has been reported for different flavonoids. For 
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catechol-like structure elements (e.g. B ring of quercetin) also O-methylation by cytosolic 
catechol-O-methyltransferase (COMT) plays a role. Isorhamnetin was found as quercetin 
metabolite in human [367]. 
As oxidative metabolism of drugs and other xenobiotics often has a key role in 
biotransformation, the influence of cytochrome P450 enzymes on flavonoid metabolism has 
been focused as well. Exemplarily, in vitro studies with human liver microsomes identified 
kaempferol as primary metabolite of both galangin, by ring hydroxylation (CYP2C9), and 
kaempferide, by O-demethylation (CYP1A2) [368]. In contrast, metabolism studies of 
galangin in primary hepatocyte culture and with S9 fraction have rather revealed the 
importance of conjugated metabolites (glucuronides and sulfates) while kaempferol was only 
found as minor metabolite [369]. Hence, in vivo relevance of CYP mediated metabolism of 
flavonoids is ambiguous in many cases and generally, conjugated metabolites seem to 
dominate the biotransformation of most abundant flavonoids. 
 
However, the absorption and metabolism of chalcones may differ from “normal” flavonoids 
due to their different molecule structure and chemical properties. Thus, as chalcones 
constitute the molecules of interest in this study, their metabolism is treated separately and 
more detailed in the following. 
In comparison to other chalcones, metabolism of xanthohumol (XAN), a prenylated chalcone 
from hop cones, is quite extensively examined. So far, both in vitro and in vivo studies have 
been conducted. First, the in vitro inhibition of cytochrome P450 enzymes by prenylated 
flavonoids from hops was investigated using cDNA-expressed human CYP1A1, CYP1B1, 
CYP1A2, CYP3A4, and CYP2E1 [370]. At 10 µM, XAN almost inhibited completely the 
activity of CYP1A1 and CYP1B1, and partly the activity of CYP1A2 (~35%). Most potent 
CYP1A2 inhibitors (> 90%) at 10 µM were the prenylated flavanones 8-prenylnaringenin and 
isoxanthohumol. The isoenzymes CYP3A4 and CYPE1 were only marginally affected by 
prenylated flavonoids. Yilmazer et al. studied the metabolism of XAN using rat liver 
microsomes [371] and also XAN glucuronidation by rat and human microsomes [372]. Three 
major phase I metabolites were identified in the microsomal incubation assay. Structure 
elucidation of formed metabolites was performed by LC–MS and 1H NMR. Major metabolites 
were formed via oxidation of the prenyl side chain (epoxidation) and subsequent ring closure, 
which yielded isopropyldihydrofurano metabolites (Km 20 ± 9 and 119 ± 39 µM) of XAN. The 
third metabolite constitutes a derivative with an additional hydroxyl group at the B ring (Km 
246 ± 116 µM). Besides, pretreatment with isosafrole and β-naphthoflavone (inducers of 
CYP1A) led to formation of a nonpolar metabolite, which was found to be 
dehydrocycloxanthohumol. The formation of multiple phase I metabolites suggests the 
involvement of different CYP isoforms. Indeed, incubation with CYP inhibitors of CYP1A and 
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CYP3A did not lead to complete inhibition of metabolite formation [371]. In vitro 
glucuronidation of XAN by liver microsomes yielded two major glurcuronides, the C-4’ and C-
4 monoglucuronide of XAN [372]. Biotransformation of XAN was also performed using 
human liver microsomes [373]. For major and two minor metabolites of XAN were found and 
identified by liquid chromatography / tandem mass spectrometry. The major metabolites 
were mono-oxidation products of XAN among hydroxylation of the terminal methyl group of 
the prenyl moiety being the most abundant. The latter metabolite has not been identified with 
rat liver microsomes. Hydroxylation of the prenyl group also took place at the 2’’-carbon 
changing the double bond to the terminal position. However, epoxidation of the prenyl moiety 
and subsequent ring closure to isopropyldihydrofurano and dimethylpyrano derivatives was 
observed as well with human microsomes. Ruefer and coworkers examined the involvement 
of phase II isoenzymes on XAN metabolism using nine recombinant human UGT and five 
SULT [374]. Mainly, UGT 1A8, 1A9, and 1A10 are predominantly responsible for the 
glucuronidation. In addition, sulfatation was observed but to lesser extent. Mainly, SULT 
1A1*2, 1A2, and 1E1 were involved. The isoenzymes can be found in the liver as well as in 
the gastrointestinal tract. All three possible hydroxyl groups were conjugated; however, 
position for conjugation could not be identified with the used analytical methods. 
Bioavailability and metabolism of XAN was also studied in vivo. Nookandeh et al. analyzed 
XAN metabolism after a single oral dose of 1 g/kg and identified 22 metabolites in the feces 
of rats using LC–MS and LC–NMR techniques [259]. Three metabolites with hydroxylated 
prenyl side chain (position 2’’, 3’’, 5’’), four metabolites with substituted (C4’ O-glucuronide, 
C4 methoxy and acetoxy derivatives) or altered (α,β-epoxide) chalcone moiety, two 
flavanones (isoxanthohumol and 3”-OH isoxanthohumol), eight benzodihydro-/benzofurane 
derivatives, and five benzoisochromane/-chromene derivatives were identified. Bioavailability 
and metabolism of XAN was studied with focus on the impact of gut flora in germ-free (GF) 
and human microbiota-associated (HMA) rats [375]. After application of 17 mg/kg XAN, XAN 
itself, XAN conjugates, and isoxanthohumol conjugates were detected in blood of rats 
(concentration range 0.11-4.87 µM). Isoxanthohumol only occurred in the blood of HMA rats 
(1.04 µM). Total excretion of XAN and its metabolites was only 4.2% in HMA rats and 4.6% 
in GR rats, feces being the major route of excretion. Low urinary excretion was found for 
XAN and its metabolites (< 0.1% of dose). Interestingly, 8-prenylnaringenin was detected 
only in feces of HMA rats, indicating that O-demethylation is catalyzed by intestinal bacteria. 
Thus, impact of the gut flora in XAN metabolism has to be considered. 
Jirásko et al. detected further phase II metabolites in rats after administration of hop extract 
[376]. Metabolites were extracted from feces. Mainly, sulfatation, oxidation, and 
hydrogenation of initial hop compounds were observed. 
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Legette and coworkers dealt with pharmacokinetics of XAN after oral and intravenous 
administration in rats [377]. Rats received either 1.86 mg/kg i.v. or low (1.86 mg/kg), medium 
(5.64 mg/kg), or high (16.9 mg/kg) oral doses of XAN. Resulting bioavailability of total XAN 
(free and conjugated) was found to be 33%, 13%, and 11% for low-, medium-, and high 
dose-group, showing dose-dependency of oral bioavailability.  
Motyl et al. recently investigated the absorption, the distribution in different compartments, 
and the phase II metabolism of XAN in mice, particularly with regard to matrix effects of other 
hop polyphenolics present in the extract [101]. Dose-dependency of XAN bioavailability was 
observed as well; mainly, however, an increased absorption of XAN in presence of other hop 
polyphenolics could be shown. Relevant concentrations of XAN conjugates were found in all 
analyzed compartments whereas the concentration of free XAN was significantly lower. This 
once more highlights the importance of investigations concerning the biological effects of 
phase II metabolites as they may contribute to pharmacological actions in vivo or even 
constitute the active principle. Besides, XAN and XAN metabolites accumulated in liver 
tissue and, above all, the bile where the highest concentrations were detected.  
 
The metabolism of isoliquiritigenin (2’,4’,4-trihydroxychalcone), a chalcone in licorice, was 
assessed using human liver microsomes [378]. Seven metabolites were found and identified 
by liquid chromatography-tandem mass spectrometry. In addition to hydroxylated metabolites 
(2’, 4, 4’, 5’-tetrahydroxychalcone and butein), also hydrogenation of the double bond 
(dihydroisoliquiritigenin) and cyclization to liquiritigenin and (E/Z)-6,4’-dihydroxyaurone was 
observed. Finally, by incubation with monoclonal antibody inhibitors of CYP isoforms, 
CYP2C19 could be identified as significant enzyme for isoliquititigenin hydroxylation to 
butein. Furthermore, the involvement of reactive oxygen species and peroxidases, 
responsible for the formation of aurones, was discussed. Guo et al. further examined the 
phase II metabolism of isoliquiritigenin using human hepatocytes and liver microsomes [379]. 
Five monoglucuronides of both isoliquiritigenin and liquiritigenin were detected whereas 
conjugation to sulfate was not observed. UGT1A1 and UGT1A9 were responsible for the 
formation of the major glucuronide, isoliquiritigenin-4’-O-glucuronide, and UGT1A1 and 
UGT1A10 for the 2’-O-glucuronide. Unexpectedly, the 4-O-glucuronide was the least 
abundant isoliquiritigenin glucuronide. The half-life of isoliquiritigenin in the incubation assay 
was determined at 25 min. The estimated intrinsic clearance was calculated to be 
36 mL/min/kg. 
 
The metabolism of other chalcones is rarely investigated, as they usually constitute minor 
compounds in drugs or extracts. However, data are available for chalcones that have 
showed pronounced pharmacological actions or can be found in food.  
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Cardamonin (alpinetin chalcone), a mono-methoxylated chalcone with anti-inflammatory, 
iNOS-inhibitory, and vasorelaxant effects was metabolized using human and animal liver 
microsomes [380]. Two hydroxylated metabolites (B ring, double bond of α,β-unsaturated 
ketone) could be identified by MS fragmentation. Furthermore, kinetic parameters of 
cardamonin hydroxylation were calculated (Km 32 µM, Vmax 35 pmol/min/mg) and responsible 
CYP isoenzymes were identified by incubation with selective chemical CYP inhibitors. 
Furafylline and clomethiazole significantly inhibited the hydroxylation of cardamonin. Thus, 
CYP1A2 and CYP2E1 seem to be responsible for biotransformation of cardamonin. 
However, no IC50 values were determined. Interestingly, they compared the hydroxylation 
capacities of different species to metabolism by human microsomes and found the metabolic 
activity of guinea pigs being closest to human in this case. Hence, they suggest using guinea 
pigs for in vivo pharmacokinetic studies. 
Kohono et al. assessed the metabolism of chalcone and trans-4-phenyl-3-buten-2-one (PBO) 
in rat liver microsomes [381]. Oxidative metabolism led to formation of the major metabolites 
4-OH chalcone (CYP1A1/2) and 4-OH PBO (CYP2C6, 1A2) which possess estrogenic 
activity. Minor metabolites observed for the chalcone were the 4’-OH (CYP1A1, 2C6) and 2-
OH (CYP3A1, 1A1) derivative. PBO is also converted by liver cytosolic double bond 
reductase to 4-phenyl-2-butanone, which is further oxidized to 4-hydroxyphenyl-2-butanone. 
Both show no estrogenic activity. 
Two glycosylic dihydrochalcones of rooibos (Aspalathus linearis (N.L.BURM.) R.DAHLGR.), 
aspalathin and nothofagin, were investigated with regard to phase II metabolism using rat 
liver microsomes and cytosolic fractions [382]. Following LC–MS analysis revealed the 
presence of two glucuronides for aspalathin (3-OH, 4-OH) and nothofagin (4-OH, 6’-OH), 
respectively, whereas only for aspalathin also sulfation was observed. 
Moreover, the biotransformation of synthesized chalcone analogues with anti-plasmodial 
properties has been studied in vitro using human liver microsomes [383,384]. 
A further study deals with the in vivo metabolism of naringenin chalcone, present in tomato 
skin, after oral administration (20 mg/kg) in rats [385]. Urine and plasma samples were 
analyzed. Naringenin chalcone-2’-O-β-D-glucuronide was the major metabolite found both in 
urine and plasma samples. Besides, naringenin-7-O-β-D-glucuronide and naringenin-4’-O-β-
D-glucuronide were found in urine but not in plasma. The peak plasma level (5.0 ± 1.0 µM) of 
naringenin chalcone-2’-O-β-D-glucuronide was reached within 1 h and its half-life was 5.5 ± 
1.7 h. Total recovery of the metabolites in urine was only 21% of the dosage which may be 
due to the high ingested dose. 
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5.2 Aim of the study 
Chalcones possess a broad spectrum of biological activities and a high potential for 
therapeutic application (see chapter 4). In contrast to the large number of publications 
dealing with the pharmacological effects, only few studies have focused on the bioavailability 
and metabolism of chalcones. Nevertheless, besides the pharmacodynamic interactions, 
pharmacokinetic parameters are indispensable for a complete pharmacological profile.  
Hence, this study examines the microsomal metabolism of flavokawains (FKA, FKB, and 
FKC) and alpinetin chalcone (A) which have already been introduced as test compounds in 
the previous chapters 3 and 4. Different microsomal incubation systems are used (including 
suitable negative and positive controls) to study both phase I and phase II metabolism. For 
identification and structure elucidation of microsomal metabolites, LC–HRESIMS and HPLC–
NMR techniques are applied to propose a metabolic profile of these chalcones. To date, only 
phase I metabolism of alpinetin chalcone (cardamonin) has been studied. Phase II 
metabolism and the biotransformation of flavokawains have not been examined yet.  
5.3 Results and discussion 
5.3.1 Preliminary experiments 
For the establishment of the microsomal incubation systems, 7-ethoxycoumarin (7-EC) was 
chosen as a cheap and commonly used probe for the investigation of both phase I 
metabolism and glucuronidation reaction. Samples were prepared and processed as 
described in chapter 2.3.3.1. HPLC analysis was performed using method C1 (see chapter 
2.3.3.2). Furthermore, for identification of metabolite masses, samples were subjected to 
liquid chromatography–high resolution electrospray ionization mass spectrometry (LC–
HRESIMS, see chapter 2.3.3.3). 
As metabolism of 7-EC is well described, 7-EC served as positive control for qualification of 
the different incubation systems comparing the formation of metabolites to literature data. 
Oxidative deethylation of 7-EC by CYP1A2 and CYP2E1 to 7-hydroxycoumarin (7-HC, 
umbelliferone, M3) is used as a model reaction for specific P450 enzyme activity [387]. 7-HC 
is further transformed by yet uncharacterized UGT isoforms to the corresponding 7-HC 
glucuronide (M4). Fisher et al. identified two novel metabolites of 7-EC resulting from 3-
hydroxylation (M1) and subsequent glucuronidation (M2) [386]. Figure 5.2 illustrates the 
proposed metabolism scheme for 7-EC in alamethicin-treated human liver microsomes 
supplemented with NADPH and UDPGA. 
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Figure 5.2: Suggested metabolism scheme of 7-EC according to Fisher et al. [386]. Metabolites 
were identified by LC–NMR and LC–MS. 
Table 5.3: Results of high resolution LC–MS using positive electrospray ionization. 
 detected metabolites of 7-EC 
 Rt             
[min] 
m/z [M+H]+ 
found 
m/z [M+H]+ 
calculated 
M 
formula  
metabolite 
7-EC 3.78 191.0706 191.0703 C11H10O3 parent 
Ph I 2.00 
3.48 
163.0391 
207.0675 
163.0390 
207.0652 
C9H6O3 
C11H10O4 
M3 
M1 
Ph II - - - - - 
Ph I+II 1.32 
2.00 
2.56 
339.0711 
163.0389 
383.0976 
339.0711 
163.0390 
383.0973 
C15H14O9 
C9H6O3 
C17H18O10 
M4 
M3 
M2 
 
As can be seen from results of LC–MS analysis (Table 5.3), all described metabolites were 
also detected within the used incubation systems. Phase I metabolism generated both 7-HC 
(M3) and the 3-hydroxy metabolite of 7-EC (M1). As expected, no metabolites are formed in 
incubation systems with only UDPGA supplementation, as no reactive groups are available 
for glucuronidation. For combined phase I and II metabolism, the masses of 7-HC (M3) and 
its glucuronide (M4) were detected whereas the 3-hydroxy metabolite (M1) was completely 
converted into its corresponding glucuronide (M2). Moreover, using negative electrospray 
ionization, a fifth compound (Mx) could be identified in phase I metabolism (m/z [M-H]- found 
177.0197, calculated 177.0193, C9H6O4) which corresponds to 3,7-dihydroxycoumarin. The 
latter compound has been identified as metabolite of coumarin using liver microsomes [388], 
but has not been described for 7-EC metabolism yet. 
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Taken together, the formerly known microsomal metabolites of 7-EC were confirmed in the 
different incubation systems. In addition, a further phase I metabolite was detected. Hence, 
the suitability of applied incubation systems studying phase I, phase II, and combined 
metabolism is approved regarding the use for metabolite profiling. 
5.3.2 Identification of microsomal chalcone phase I and II metabolites 
The microsomal metabolism of four chalcones (10 µM) FKA, FKB, FKC, and A, was studied 
within an incubation period of 60 min. Meanwhile, the compounds’ stability in the phosphate 
incubation buffer (stabi) was controlled by HPLC. Furthermore, no unspecific metabolism or 
degradation of the compounds was observed in incubation systems without microsomes (w/o 
micr) or cofactors (w/o cof). 
For metabolite profiling, the chalcones were incubated in the established microsomal 
systems for investigation of phase I (Ph I), phase II (Ph II), and combined metabolism (Ph 
I+II) as described in chapter 2.3.3.1. Additionally, the compounds’ stability was controlled in 
incubation systems without microsomes (w/o micr) or cofactors (w/o cof). Obtained samples 
were subjected to HPLC analysis using method C2 (see chapter 2.3.3.2). Exact metabolite 
masses were determined by LC–HRESIMS using positive and negative electrospray 
ionization (see chapter 2.3.3.3). 
 
For FKA, two phase I metabolites (demethyl and bisdemethyl FKA) were found (Table 5.4). 
According to the retention times of 4.02 and 5.07 min, the metabolites were identified as FKC 
and helichrysetin (Heli), FKC being the major phase I metabolite of FKA. Despite only one 
available OH group (C-2’), two FKA glucuronides (Rt 3.38 min and 3.50 min) were detected. 
Most likely, cis-trans isomerization of FKA might be an explanation (see chapter 5.3.3). For 
combined phase I and II metabolism, besides the FKA glucuronide (Rt 3.50 min), also two 
masses corresponding to FKC glucuronides (Rt 2.81 min and 3.87 min) were found. 
Additionally, two metabolite masses corresponding to OH-FKA glucuronides (Rt 3.71 and 
3.81 min) were identified as minor phase II metabolites of FKA. According to MS data, Figure 
5.3 proposes a metabolism scheme for FKA. 
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Table 5.4: High resolution LC–MS of FKA samples using positive and negative electrospray 
ionization. (Corresponding mass spectra see Figure 10.20). 
 detected metabolites of FKA 
 Rt  
[min] 
m/z [M+H]+ 
found 
m/z [M+H]+ 
calculated 
m/z [M-H]- 
found 
m/z [M-H]- 
calculated 
M  
formula 
FKA 6.18 315.1234 315.1227 - - C18H18O5 
Ph I 4.02 
5.07 
- 
301.1073 
- 
301.1071 
285.0766 
299.0925 
285.0768 
299.0925 
C16H14O5 
C17H16O5 
Ph II 3.38 
3.50 
491.1150 
491.1151 
491.1548 
491.1548 
489.1402 
489.1405 
489.1402 
489.1402 
C24H26O11 
C24H26O11 
Ph I+II 2.81 
3.50 
3.71 
3.81 
3.87 
5.07 
477.1389 
491.1549 
- 
- 
477.1391 
301.1072 
477.1391 
491.1548 
- 
- 
477.1391 
301.1071 
475.1238 
489.1399 
505.1345 
505.1345 
475.1239 
299.0920 
475.1246 
489.1402 
505.1351 
505.1351 
475.1246 
299.0925 
C23H24O11 
C24H26O11 
C24H26O12 
C24H26O12 
C23H24O11 
C17H16O5 
 
 
Figure 5.3: Suggested metabolism scheme of FKA using human liver microsomes. Metabolites 
were identified by LC–ESI-MS in different incubation systems. 
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For FKB, also FKC (Rt 5.07 min) was detected as major phase I metabolite after 
hydroxylation in position C-4 (Table 5.5). Demethylation in position C-4’ and C-6’, leads to 
formation of A (Rt 5.17 min) and 2’,4’,6’-trihydroxychalcone (Rt 4.48 min), respectively. The 
2’-O-glucuronide of FKB (Rt 3.46 min) was found as phase II metabolite. Combined 
metabolism resulted in the formation of 2’-O-Glu-FKB and four glucuronides with 
corresponding masses of 476.1319 g/mol. Two of them (Rt 2.81 min and 3.87 min) were 
identified as the 2’- and 4-O-glucuronide of FKC. Furthermore, the phase I metabolite A was 
conjugated to glucuronic acid (Rt 3.95 min) either at positions C-2’ or C-4’. The suggested 
metabolism of FKB is pictured in Figure 5.4. 
Table 5.5: High resolution LC–MS of FKB samples using positive and negative electrospray 
ionization. (Corresponding mass spectra see Figure 10.21). 
 detected metabolites of FKB 
 Rt  
[min] 
m/z [M+H]+ 
found 
m/z [M+H]+ 
calculated 
m/z [M-H]- 
found 
m/z [M-H]- 
calculated 
M 
formula 
FKB 6.26 285.1125 285.1121 - - C17H16O4 
Ph I 4.48 
5.07 
5.17 
- 
301.1070 
- 
- 
301.1071 
- 
255.0659 
299.0927 
269.0819 
255.0663 
299.0925 
269.0819 
C15H12O4 
C17H16O5 
C16H14O4 
Ph II 3.46 461.1445 461.1442 459.1297 459.1297 C23H24O10 
Ph I+II 2.81 
3.15 
3.46 
3.75 
3.87 
3.95 
5.07 
- 
- 
461.1441 
477.1388 
- 
- 
- 
- 
- 
461.1442 
477.1391 
- 
- 
- 
475.1239 
475.1239 
459.1293 
475.1241 
475.1241 
445.1123 
299.0920 
475.1246 
475.1246 
459.1297 
475.1246 
475.1246 
445.1140 
299.0925 
C23H24O11 
C23H24O11 
C23H24O10 
C23H24O11 
C23H24O11 
C22H22O10 
C17H16O5 
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Figure 5.4: Suggested metabolism scheme of FKB using human liver microsomes. Metabolites
 were identified by LC–ESI-MS in different incubation systems.  
 
In phase I metabolism of FKC, demethylation to Heli (Rt 4.03 min) and hydroxylation at 
unknown position (Rt 4.00 min and 4.52 min) occurred (Table 5.6). Three FKC-glucuronides 
were detected in phase II metabolism. Two major glucuronides (Rt 2.81 min and 3.86 min) 
might correspond to 2’-O- and 4’-O-Glu-FKC respectively. The third minor glucuronide (Rt 
2.71 min) could possibly arise from flavanone- or cis-trans-isomerization (see chapter 5.3.3). 
In combined phase I and II metabolism, additionally a glucuronide of Heli (Rt 3.03 min) and 
three different glucuronides of OH-FKC (Rt 2.83 min, 3.18 min, and 3.72 min) were found. 
Figure 5.5 proposes a possible metabolism scheme for FKC. 
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Table 5.6: High resolution LC–MS of FKC samples using positive and negative electrospray 
ionization. (Corresponding mass spectra see Figure 10.22). 
 detected metabolites of FKC 
 Rt  
[min] 
m/z [M+H]+ 
found 
m/z [M+H]+ 
calculated 
m/z [M-H]- 
found 
m/z [M-H]- 
calculated 
M 
formula 
FKC 5.07 301.1071 310.1070 299.0926 299.0925 C17H16O5 
Ph I 4.00 
4.03 
4.52 
- 
287.0911 
317.1019 
- 
287.0914 
317.1019 
315.0872 
285.0767 
315.0871 
315.0874 
285.0768 
315.0874 
C17H16O6 
C16H14O5 
C17H16O6 
Ph II 2.71 
2.81 
3.86 
477.1389 
477.1392 
477.1395 
477.1391 
477.1391 
477.1391 
475.1244 
475.1245 
475.1248 
475.1246 
475.1246 
475.1246 
C23H24O11 
C23H24O11 
C23H24O11 
Ph I+II 2.71 
2.81 
2.83 
3.03 
3.18 
3.72 
3.86 
- 
477.1391 
- 
463.1234 
- 
- 
477.1390 
- 
477.1391 
- 
463.1235 
- 
- 
477.1390 
475.1241 
475.1241 
491.1183 
461.1085 
491.1188 
491.1187 
475.1241 
475.1241 
475.1241 
491.1195 
461.1089 
491.1195 
491.1195 
475.1241 
C23H24O11 
C23H24O11 
C23H24O12 
C22H22O11 
C23H24O12 
C23H24O12 
C23H24O11 
 
 
Figure 5.5: Suggested metabolism scheme of FKC using human liver microsomes. Metabolites 
were identified by LC–ESI-MS in different incubation systems. 
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Three hydroxylated metabolites of A were identified in phase I metabolism. One phase I 
metabolite could be identified as Heli (Rt 4.03 min) which is the 4-OH derivative of A (Table 
5.7). Hydroxylation might also occur at different positions of the molecule including A and B 
ring and the α,β double bond. For the two other metabolites (Rt 4.43 min and 4.52 min), the 
exact position of the OH group could not be elucidated. He and coworkers have investigated 
the CYP450 dependent metabolism of A before [380]. Two monohydroxylated metabolites 
were identified by MS fragmentation. For the major metabolite (M1), the exact position of 
hydroxylation in the B ring could not be determined, however, the authors suggest C-4 being 
the most likely position. C-4 has also been identified before as preferential for hydroxylation 
of chalcone [381]. Accordingly, 4-OH-A would correspond to Heli that has been as well 
detected in this study. In addition, fragment ions suggest the hydroxylation in β-position of 
the unsaturated ketone (M2), which might correspond to another hydroxyl-derivative in this 
study (Rt 4.43 min or 4.52 min). In contrast to our findings, a third hydroxylated metabolite of 
A was not described by He et al. Three glucuronides of A were detected in phase II 
metabolism (Rt 2.67 min, 3.01 min, and 3.95 min). Again, despite only two free OH groups, a 
third corresponding mass suggests the presence or formation of A isomers. Besides the A-
glucuronides, one glucuronide of OH-A (Rt 3.58 min) was found in combined metabolism. 
Figure 5.6 suggests a metabolism scheme for A.  
Table 5.7: High resolution LC–MS of A samples using positive and negative electrospray 
ionization. (Corresponding mass spectra see Figure 10.23). 
 detected metabolites of A 
 Rt  
[min] 
m/z [M+H]+ 
found 
m/z [M+H]+ 
calculated 
m/z [M-H]- 
found 
m/z [M-H]- 
calculated 
M 
formula 
A 5.17 271.0970 271.0965 269.0820 269.0819 C16H14O4 
Ph I 4.03 
4.43 
4.52 
287.0915 
287.0917 
287.0917 
287.0914 
287.0914 
287.0914 
285.0763 
285.0763 
285.0762 
285.0768 
285.0768 
285.0768 
C16H14O5 
C16H14O5 
C16H14O5 
Ph II 2.67 
3.01 
3.95 
447.1286 
447.1282 
447.1287 
447.1286 
447.1286 
447.1286 
445.1141 
445.1138 
445.1140 
445.1140 
445.1140 
445.1140 
C22H22O10 
C22H22O10 
C22H22O10 
Ph I+II 2.67 
3.00 
3.58 
3.95 
447.1284 
447.1283 
463.1232 
447.1287 
447.1284 
447.1283 
463.1235 
447.1286 
445.1135 
445.1136 
461.1081 
445.1135 
445.1140 
445.1140 
461.1089 
445.1140 
C22H22O10 
C22H22O10 
C22H22O11 
C22H22O10 
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Figure 5.6: Suggested metabolism scheme of A using human liver microsomes. Metabolites 
were identified by LC–ESI-MS in different incubation systems. 
5.3.3 Structure elucidation of major flavokawain metabolites 
For structure elucidation of flavokawain A, B, and C metabolites, samples of combined phase 
I and II metabolism (Ph I+II) were prepared and subjected to HPLC–NMR analysis as 
described in chapter 2.3.3.4 using one- (1H) and two-dimensional (1H,1H-COSY, 1H,13C-
HSQC, 1H,13C-HMBC) NMR techniques. Due to the higher detection limit of NMR compared 
to MS, only the structures of major metabolites could be elucidated. 
 
Trans-flavokawain A-2’-O-glucuronide (Figure 5.7) was identified as major metabolite of 
FKA. The metabolite was manually isolated via HPLC fraction collection and subjected to 1H 
NMR and COSY analysis (see chapter 2.3.3.4). In HSQC and HMBC experiments, the 
signals appeared too weak for a full 13C assignment. Similarity of the 1H NMR spectra of the 
major FKA metabolite with parent compound clearly shows slightly changed chemical shifts 
for the protons in ring B while a clear change in the chemical shift position occurs for H-3' 
and H-5' and for the two olefinic protons / (Table 5.8). The same was observed for FKB 
and FKC (Table 5.9 and 5.10) and constitutes evidence of the glucuronide moiety being 
attached to the OH in position 2'. The resonances from the glucuronide moiety could not be 
assigned due to the presence of the cis isoform and 3 methoxy groups that create an overlap 
of signals also in the COSY spectrum. The two detected metabolite masses of FKA-
monoglucuronides in Table 5.4 can now be assigned to the major trans and the minor cis 
isoform (Table 5.8). The latter might constitute an artifact that is formed during incubation, 
sample processing, or isolation procedure. 
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Figure 5.7:   Major metabolite of FKA. 
Table 5.8: 
1
H-NMR data of FKA, trans- and cis-FKA-2’-O-glucuronide. Recording conditions 
see chapter 2.3.3.4. 
 Flavokawain A FKA-2’-O-glucuronide 
  Trans form (major) Cis form (minor, artifact) 
# δ (ppm), m, J (|Hz|) δ (ppm), m, J (|Hz|) δ (ppm), m, J (|Hz|) 
3' 6.11 (d, 1H, J = 2.3) 6.57 (d, 1H, J = 2.3) 6.48 (d, 1H, J = 2.3) 
5' 6.09 (d, 1H, J = 2.3) 6.36 (d, 1H,  J = 2.3) 6.15 (d, 1H, J = 2.3) 
 7.71 (d, 1H, J = 15.9) 6.96 (d, 1H, J = 15.9) 6.39 (d, 1H, J = 12.8) 
 7.81 (d, 1H, J = 15.9) 7.39 (d, 1H, J = 15.9) 6.88 (d, 1H, J = 12.8) 
2/6 7.60 (AA', 2H, d, J = 8.7) 7.58 (2H, m) 7.56 (2H, m) 
3/5 6.98 (AA', 2H, d, J = 8.7) 6.95 (3H, m) 6.81 (3H, m) 
4'-OCH3 3.95 (3H, s) 3.83 (3H, s) 3.79 (3H, s) 
6'-OCH3 3.84 (3H, s) 3.78 (3H, s) 3.73 (3H, s) 
4-OCH3 3.85 (3H, s) 3.85 (3H, s) 3.80 (3H, s) 
1'' 
 Overlap with HDO 
signal 
Overlap with HDO  
signal 
2''  
3.5 – 3.6 (m) 3.5 – 3.6 (m) 3''  
4''  
5'' 
 Overlap with OCH3 
signals 
Overlap with OCH3 
signals 
 
Trans-flavokawain B-2’-O-glucuronide (Figure 5.8) constitutes the major metabolite of FKB 
identified by 1H NMR, COSY, HSQC, and HMBC (see chapter 2.3.3.4). Similarity of the 1H 
NMR spectrum of the major FKB metabolite with that of the parent compound clearly shows 
slightly changed chemical shifts for the protons in ring B while a clear change in the chemical 
shift position occurs for H-3' and H-5' and for the two olefinic protons / (Table 5.9). Signals 
from the glucuronide moiety are recognized and COSY spectrum enabled their assignment 
even if some signals overlapped. The proton at the anomeric C-1'' is partially suppressed 
and H-5'' is overlapped by the methoxy signal. 13C resonances were deduced from HMBC 
and in some cases it was not possible to discriminate close resonances as they were found 
in the ring B (Table 5.9). 13C NMR chemical shifts of C-2' and the COOH carbon atom were 
not detected (n.d.) because of low signal-to-noise ratio of the HMBC spectrum.  
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Figure 5.8:  Major metabolite of FKB. 
Table 5.9: 
1
H- and 
13
C-NMR data of FKA and trans-FKB-2’-O-glucuronide. Recording 
conditions see chapter 2.3.3.4. 
 Flavokawain B trans-FKB-2’-O-glucuronide 
  
1H 13C 
# δ (ppm), m, J (|Hz|) δ (ppm), m, J (|Hz|) δ (ppm) 
1'   113.5 
2'   n.d. 
3' 6.12 (d, 1H, J = 2.3) 6.55 (d, 1H, J = 2.0) 95.3 
4'   164.1 
5' 6.10 (d, 1H, J = 2.3) 6.37 (d, 1H, J = 2.0) 93.8 
6'   160.1 
C=O   196.0 
 7.72 (d, 1H, J = 15.9) 7.09 (d, 1H, J = 15.9) 129.5 
 7.92 (d, 1H, J = 15.9) 7.42 (d, 1H, J = 15.9) 145.7 
1   136.2 
2-6 7.65 (2H, m) 7.62 (2H, m) 129.5 
3-5 7.42 (3H, m) 
7.39 (3H, m) 
129.9 
4  131.6 
4'-OCH3 3.95 (3H, s) 3.85 (3H, s) 55.8 
6'-OCH3 3.84 (3H, s) 3.79 (3H, s) 56.1 
1''  5.02 (d, 1H, J = 7.8) 102.5 
2''  3.38 (m, 1H) 74.6 
3''  
3.49 (m, 2H) 
77.3 
4''  73.3 
5''  3.85 (overlap with 
OCH3) 
76.3 
COOH   n.d. 
 
Two monoglucuronides of FKC (4-O- and 2’-O-glucuronide named as FKC-1 and FKC-2; 
Figure 5.9) were found as major and 5,7-dimethoxy-flavanone-4’-O-glucuronide (named as 
FKC-3; Figure 5.10) as minor FKC metabolite by the means of HPLC–NMR (see chapter 
2.3.3.4). Similarity of the 1H NMR spectrum of FKC-1 with that of the parent compound 
clearly shows slightly changed chemical shifts for H-3' and H-5' and the olefinic protons / 
while a clear change in chemical shift is detected for the protons in ring B indicating a 
substitution (Table 5.10). Signals from the glucuronide moiety are recognized also based on 
the data from the other metabolites. The anomeric proton is partially suppressed due to the 
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proximity of the water signal, but it is visible. The other protons of the glucuronide moiety 
seem to collapse in two distinct signals present in the region 3.5 – 3.7 ppm. Integrals are not 
helpful but resonances have been assigned, considering also the other metabolites, as 
reported. 
Similarity of the 1H NMR spectrum of FKC-2 with that of the parent compound clearly shows 
slightly changed chemical shifts for the protons in ring B while a clear change in the chemical 
shift position occurs for H-3' and H-5' and for the two olefinic protons / (Table 5.10). 
Signals from the glucuronide moiety were clearly recognized and COSY spectrum enabled 
assignment of the single protons. An HMBC correlation between H-5'' and a 13C at 171.9, 
typical chemical shift for carboxylic carbons, proves the presence of the glucuronide. HMBC 
enabled assignment of those 1H resonances that would be otherwise interchangeable like the 
methoxy groups or protons H-3' and H-5'. 
For FKC-3 (Figure 5.10), the disappearance of the olefinic protons / together with the 
appearance of new resonances enables the recognition of the aglycone skeleton as a 
flavanone (Table 5.11). The molecule was fully assigned by means of 1D and 2D NMR 
spectra. There is some overlap among the glucuronide H-2'', H-3'', and H-4'' in the 1H NMR 
spectrum but the glucuronide moiety is clearly recognized. The signals of the H-3 proton 
appear as a “double pseudotriplet”. The reason might be that the compound is a racemate, 
consisting of two diastereomers with opposite configuration at C-2. The signals of H-2 of the 
2R- and the 2S-form as well as the signals of the H-3a at 3.04 ppm are isochronic. Only the 
dd signals of H-3b appear at slightly different chemical shifts (Δδ ~0.01 ppm). If this 
hypothesis is correct, it can be assumed that the FKC-3 is formed by a non-enzymatic 
chemical reaction and is possibly an artifact (similar to the cis isoforms of FKA and FKB 
metabolites). The HRESIMS spectrum (positive ionization) confirmed the structure (found 
477.1374 [M+H]+, calculated for C23H25O11
+: 477.1391, see chapter 2.3.3.4). 
 
Figure 5.9: Metabolites of FKC. 
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Table 5.10: 
1
H- and 
13
C-NMR data of FKC, FKC-4-O-glucuronide (FKC-1), and FKC-2’-O-
glucuronide (FKC-2). Recording conditions see chapter 2.3.3.4. 
 Flavokawain C FKC metabolite 
  FKC-1 FKC-2 
# δ (ppm), m, J (|Hz|) δ (ppm), m, J (|Hz|) δ (ppm), m, J (|Hz|) δ (ppm) 
1'    113.7 
2'    157.8 
3' 6.10 (d, 1H, J = 2.0) 6.12 (d, 1H, J = 2.3) 6.49 (d, 1H, J = 2.0) 95.1 
4'    163.8 
5' 6.09 (d, 1H, J = 2.0) 6.10 (d, 1H, J = 2.3) 6.38 (d, 1H, J = 2.0) 93.8 
6'    160.0 
C=O    196.4 
 7.71 (d, 1H, J = 
15.6) 
7.71 (d, 1H, J = 
15.5) 
6.89 (d, 1H, J = 
16.0) 
126.4 
 7.77 (d, 1H, J = 
15.6) 
7.84 (d, 1H, J = 
15.5) 
7.34 (d, 1H, J = 
16.0) 
147.4 
1    127.2 
2/6 7.51 (AA', 2H, d, J = 
8.7) 
7.62 (AA', 2H, d, J = 
8.7) 
7.48 (AA', 2H, d, J = 
8.9) 
131.6 
3/5 6.82 (AA', 2H, d, J = 
8.7) 
7.15 (AA', 2H, d, J = 
8.7) 
6.80 (AA', 2H, d, J = 
8.9) 
116.6 
4    161.5 
4'-OCH3 3.94 (3H, s) 3.95 (3H, s) 3.85 (3H, s) 55.7 
6'-OCH3 3.84 (3H, s) 3.85 (3H, s) 3.78 (3H, s) 56.1 
1''  5.05 (d, 1H, J = 7.7) 5.05 (d, 1H, J = 7.7) 102.4 
2''  3.52 (2H, m) 
 
3.37 (dd, 1H, J = 
7.7, 9.1) 
74.2 
3''  3.46 (dd, 1H, J = 
9.1, 9.1) 
76.9 
4''  3.65 (m) 3.56 (dd, 1H, J =9.6, 
9.1) 
72.5 
5''  3.93 (m) 3.97 (d, 1H J = 9.6) 76.3 
COOH    171.9 
 
 
Figure 5.10: Metabolite of FKC. 
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Table 5.11: 
1
H- and 
13
C-NMR data of 5,7-dimethoxyflavanone-4‘-O-glucuronide (FKC-3). 
Recording conditions see chapter 2.3.3.4. 
 FKC metabolite 
 FKC-3  
 1H 13C 
# δ (ppm), m, J (|Hz|) δ (ppm) 
2 5. 43 (dd, 1H, J = 12.8, 3.0) 79.9 
3 3. 04 (dd, 1H, J = 16.4, 12.8)  46.2 
2. 72 (dt, 1H, J = 16.4, 3.0) 
4  192.4 
5  163.6 
6 6.20 (d, 1H, J = 2.0) 93.7 
7  168.3 
8 6.22 (d, 1H, J = 2.0) 94.9 
9  167.5 
10  106.3 
1'  134.2 
2'/6' 7.44 (AA', 2H, d, J = 8.7) 128.7 
3'/5' 7.14 (AA', 2H, d, J = 8.7) 117.8 
4'  158.9 
5- and 7-
OCH3 
3.84 (6H, s) 56.2 
1'' 4.98 (d, 1H, J = 7.5) 102.3 
2'' 
3. 51 (m, 2H) 
74.6 
3'' 77.3 
4'' 3.59 (m, 1H) 73.1 
5'' 3.92 (d, 1H, J = 9.6) 76.3 
COOH  173.5 
 
5.4 Conclusion 
The in vitro metabolism of FKA, FKB, FKC, and A was studied using pooled human liver 
microsomes. For a metabolic profile, different microsomal incubation systems were 
established including phase I, phase II (glucuronidation), and combined reactions.  
Metabolites were identified by LC–HRESIMS. Moreover, the structure of major flavokawain 
metabolites was elucidated by the means of LC–NMR. 
In phase I metabolism, demethylation in position C-4 or C-4’ and hydroxylation predominantly 
in position C-4 occurs. This leads to the formation of FKC as major phase I metabolite of 
FKA and FKB and Heli as major phase I metabolite of FKC and A. Metabolites were 
assigned to found molecular masses (HRESIMS) and exact accordance to the retention 
times of the references (FKC and Heli) in the chromatographic system. Moreover, other 
monohydroxylated products were found as minor metabolites of FKC and A, but the position 
of hydroxylation could not be determined by mass spectrometric methods. The compounds 
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were even more extensively metabolized in presence of UDPGA by microsomal UGTs. For 
all test chalcones, the corresponding monoglucuronides were detected as the major 
metabolites in phase II and combined metabolism. The structures of the major flavokawain-
glucuronides were elucidated by LC–NMR techniques. The detection of two metabolite 
masses of 490.1475 g/mol corresponding to FKA-glucuronides can be explained by the 
coexistence of the major trans and the minor cis isomer. For both, 1H NMR signals were 
detected. Besides the 2’-O- and 4-O-chalcone-monoglucuronides of FKC, also the 
corresponding flavanone-glucuronide was identified by LC–NMR. This result is in accordance 
with MS data showing three metabolite masses of 476.1319 g/mol. The predominance of 
glucuronides over phase I metabolites generally emphasizes the important role of conjugated 
chalcones metabolites as possible in vivo active principles. This has also been shown for 
different flavonoids and chalcones such as XAN [101,376]. It has to be noticed that the 
extent of conjugated metabolites may even be underestimated by the use of microsomes, as 
phase II reactions are limited to glucuronidation reactions. Therefore, the concentration of 
conjugated metabolites in vivo may even be higher. Nevertheless, regarding the in vitro 
biological activity or toxicity of the chalcones, conjugated metabolites are to date not included 
in testing although they may rapidly be formed in vivo and therefore may constitute the actual 
active principles. Hence, the direct testing of phase II metabolites in in vitro assays would be 
an interesting issue. Toxicity studies - like performed for flavokawains in chapter 3 - should 
also be conducted in absence or presence of metabolizing enzymes to clarify if the 
compounds might be (de-)toxified. In comparison to e.g. FKB, which showed distinct toxicity 
against hepatoma cell lines, its major metabolite the 2’-O-glucuronide might show altered 
behavior. 
Summing up, a metabolic profile of investigated chalcones is proposed. Furthermore, major 
phase I and II metabolites were identified based on MS and NMR data. Like for other 
flavonoids, conjugation to glucuronic acid seems to be a major route in chalcone metabolism. 
In future studies, microsomal incubation systems can be used to identify involved 
cytochrome P450 enzymes by selective inhibition of isoenzymes. Moreover, kinetic studies 
could be performed. The synthesis, characterization, and testing of chalcones glucuronides 
and other phase II metabolites remains a challenging issue as it is likely that those 
metabolites predominate in vivo. 
 
*) Part of the data presented in this chapter are published in Chen et al., Tacrine-silibinin 
codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive effects in vivo, J 
Med Chem 55 (2012) 5231-5242 and in Zenger et al., In-vitro stability and metabolism of a 
tacrine-silibinin codrug, JPP (2013) accepted. 
6 In vitro stability, metabolism, and hepatotoxicity of a 
tacrine-silibinin codrug *) 
6.1 Introduction 
In recent years, much effort has been put into discovering new drugs for therapy of 
Alzheimer’s disease (AD), the most prominent form of dementia [389]. To date there are only 
few approved drugs available. In 1993, tacrine (1, Figure 6.1) was approved as a potent 
acetylcholinesterase (AChE) inhibitor for treatment of AD. It was withdrawn from the market 
because of its hepatotoxic effects in vivo [390–393]. 
 
Figure 6.1: Structures of the AChE inhibitor tacrine (1), hepatoprotective flavonolignan 
silibinin (2), succinic acid-bridged tacrine-silibinin codrug (3), and its metabolite 
tacrine hemi succinamide (4).  
In order to face this problem there have been several approaches in medicinal chemistry to 
create hybrid [394,395] or multitarget [396,397] compounds by addressing more than one 
relevant pharmacological target with additive beneficial effects. A novel approach was 
realized by combining tacrine with the natural product silibinin (2, Figure 6.1), a flavonolignan 
known for its hepatoprotective and potentially anti-oxidant activities, in the form of a “codrug”. 
Like hybrid molecules this codrug molecule combines two pharmacologically active 
molecules within one molecule. In a hybrid such a connection is stable, whereas in the 
codrug approach at least one connecting chemical bond should be cleavable in vivo. 
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Therefore, Chen et al. synthesized a codrug (3, Figure 6.1) consisting of a tacrine-based 
AChE inhibiting part and silibinin, respectively, linked by an ester bond. Since the structure of 
the codrug does not release tacrine but a related compound after cleavage, it is not a 
classical prodrug. Furthermore, a codrug releases two, not one biologically active compound 
after activation. The pharmacological properties of this tacrine-silibinin codrug were 
evaluated in comparison to tacrine and an equimolar mixture of tacrine and silibinin. The 
codrug showed quite promising pharmacological effects like AChE and butyrylcholinesterase 
(BChE) inhibitory activity, being slightly less potent than tacrine. Moreover, the codrug 
exhibited a neuroprotective effect against glutamate-induced toxicity using a neuronal cell 
line (HT-22). Finally, in a behavioral study, the codrug reversed scopolamine-induced 
cognitive impairment to the same extent as tacrine [100]. 
Beyond the pharmacological investigations, the objective of this study was to evaluate 
possible hepatotoxic or hepatoprotective effects of the codrug compared to tacrine and an 
equimolar mixture of tacrine and silibinin. In addition, it should be clarified if the chemical 
connection supplies any advantages over a physical mixture of components. 
Furthermore, open questions remained regarding the stability and metabolism of the codrug 
in the in vitro incubation assays and in vivo testings, respectively. Accordingly, it had to be 
elucidated if it is the codrug, any cleaved product, or metabolite that is responsible for the 
pharmacological actions. 
In our study, in vitro incubation conditions were mimicked in order to evaluate stability of the 
codrug during the incubation period of 24 h like in the in vitro assays [100]. In addition, the 
microsomal metabolism was examined to determine the stability in presence of metabolizing 
enzymes (metabolic stability). Moreover, this work was aimed to identify possible metabolites 
of the codrug, which may also occur in vivo and constitute the active principle of the 
compound. It can be assumed from the molecule structure that the ester bond of the codrug 
is easily cleaved and the tacrine-part of the molecule, a tacrine hemi succinamide (4, Figure 
6.1), is generated. 
 
Microsomal metabolism of both tacrine and silibinin has been well described in literature 
[398,399]. For tacrine, hydroxylated metabolites are most important. Cytochrome P4501A2 
(CYP1A2) was identified as major enzyme involved in tacrine metabolism and is responsible 
for the formation of both stable (1,2,4-OH tacrine) and protein-reactive metabolites (7-OH 
tacrine) [400,401]. Both in vitro [402] and in vivo [403] fluvoxamine (CYP1A2 inhibitor) was 
identified as potent inhibitor of tacrine metabolism. For silibinin, glucuronidated metabolites 
play the major role. The major sites for glucuronidation are the phenolic OH groups at C-20 
and C-7 [404]. 
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Investigating the microsomal metabolism of the codrug creates valuable data concerning 
possible metabolites, which can putatively be found also in vivo and reveals interesting 
aspects of identifying the active principle of the codrug. 
Tacrine’s liver toxicity is extensively described in literature [405]. Among other aspects it is 
controversially discussed whether toxicity of tacrine is mediated by CYP1A2 or not [406,407]. 
With respect to unknown metabolism of the codrug, the study also deals with the evaluation 
of putative toxicity of metabolites. 
6.2 Aim of the study 
As the tacrine-silibinin codrug offers promising pharmacological properties, this study should 
assess its in vitro hepatotoxicity in comparison to tacrine and an equimolar of tacrine and 
silibinin in order to reveal any beneficial effect of the codrug design. For valuation of the in 
vitro and in vivo testings, particularly with regard to the identification of the active principle, 
the degradation and metabolic stability of the codrug should be investigated in different in 
vitro incubation systems. These data would supply useful information about the stability, 
possible degradation products, and metabolites of the codrug. Furthermore, the toxicity of the 
codrug cleavage products should be studied, as they constitute the primary metabolites in 
vitro and likely occur in vivo. 
Taken together, this study was aimed to supplement preclinical data of the codrug in terms of 
drug toxicity and metabolism by choosing appropriate in vitro assays. 
6.3 Results and discussion 
6.3.1 Analytical characterization of the test compounds 
Structure confirmation of ((2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-6-((2R,3R)-3,5,7-
trihydroxy-4-oxochroman-2-yl)-2,3-dihydrobenzo[b][1.4]dioxin-2-yl)-methyl 4-oxo-4-(6-
(1,2,3,4-tetrahydroacridin-9-ylamino)-hexylamino)butanoate hydrochloride (3) and 4-oxo-4-
(6-(1,2,3,4- tetrahydroacridin-9-ylamino)butanoic acid (4) was carried out by Dr. Xinyu Chen 
applying NMR spectroscopy (see chapter 2.1.3.2) [100]. 
Purity of synthesized compounds was determined by HPLC using method P3 for the codrug 
and method P4 for the tacrine hemi succinamide (see chapter 2.1.3.3). For both compounds, 
a purity of 96% was found. 
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For evaluation of chromatographic behavior and rough estimation of purity and lipophilicity, 
HPTLC analysis was performed on silica coated glass plates with the solvent system T2 (see 
chapter 2.1.3.1). 
 
Figure 6.2: HPTLC of test compounds. Tacrine (1), silibinin (2), tacrine-silibinin codrug (3), 
tacrine hemi succinamide (4). Plates were analyzed under UV light: 254 nm (left) 
and 365 nm (right). Rf values (1) 0.70, (2) 0.13, (3) 0.22, (4) 0.12. Basic solvent 
system T2. 
Under alkaline solvent conditions, 1 likely exists as a free base clarifying its high Rf value. 
Both 3 and 4 are negatively charged leading to high affinity on silica gel and relatively low Rf 
values. However, for 3 and 4 some impurities are detectable (Figure 6.2). 
Table 6.1: Calculated pKa and logP values. (*) SciFinder, (
#
) 
 1 3 4 
pKa* most acidic group 
 most basic group 
- 
9.94 
7.39 ± 0.6 
9.10 ± 0.2 
4.75 ± 0.1 
9.10 ± 0.2 
logP# 3.3 6.7 3.1 
 
Based on calculated pKa values (Table 6.1) the state of charge at physiological pH value can 
be estimated. For the most part, 1 and 3 are positively charged at pH 7.4. For 4, zwitterion 
structure can be assumed at a physiological pH value. This “amino-acid” like property might 
be an explanation for its different solubility, distribution, and metabolism. However, in 
consideration of logP values (Table 6.1), 3 is supposed to be the most lipophilic of the 
compounds followed by 1 and 4. 
Previous studies have not addressed oral bioavailability. Nevertheless, drug-like properties of 
the codrug can be assessed by its physical and chemical characteristics applying Lipinski’s 
Rule of Five [340,342]. This rule predicts absorption or permeation problems for chemicals 
that possess the following characteristics: 
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 H-bond donors > 5 
 A molecular weight > 500 
 A ClogP > 5 
 A sum of Ns and Os > 10. 
As the codrug fulfills Lipinski’s Rule of Five in all regards, poor oral bioavailability is 
expected. For an encompassing evaluation, however, screening assays for intestinal 
permeability have to be conducted in future studies. For highly lipophilic compounds like the 
codrug, transcellular absorption through the lipid bilayer might be possible anyway. The 
intestinal permeability can be examined e.g. in in vitro cell culture assays using Caco-2 cells. 
Differentiated Caco-2 cells develop tight junctions as well as uptake/efflux transporters 
mimicking intestinal mucosa epithelium. 
From a biopharmaceutical point of view, assays concerning drug absorption, disposition, and 
excretion should be addressed in further preclinical studies to enlarge the already existing 
data of in vitro metabolism and toxicity. 
6.3.2 Degradation stability under in vitro assay conditions 
For pharmacological evaluation, the codrug has been tested in several in vitro assays to 
investigate its neuro- and hepatoprotective activities [100]. So far, it could not be excluded 
that during the incubation period of 24 h the compound is cleaved or decomposed into other 
(active) products. For this reason, the stability of the codrug under in vitro assay conditions 
was investigated (see chapter 2.3.4.2). The concentration of the codrug was determined by 
HPLC using method C3 (see chapter 2.3.4.1). 
 
Figure 6.3: Degradation stability of the codrug in culture medium under in vitro assay 
conditions (37 °C, 5% CO2). Concentrations were determined by HPLC calibration 
(method C3). Data are shown as mean ± SD; n = 3. Statistical analysis was 
performed by one-way ANOVA followed by Dunnett’s multiple comparison post-
hoc test. **p < 0.01 vs. 0 h. 
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As illustrated in Figure 6.3, the concentration of the compound in the incubation medium was 
not markedly reduced during incubation time. Even after 24 h, around 80% of the initial 
concentration was detectable. Thus, these results suggest that the codrug and not cleaved 
products contribute to in vitro activities. Nevertheless, it has to be kept in mind that the 
stability assay was conducted in a cell-free system so that influence of cells on the stability 
cannot be excluded. In further studies, cellular uptake and intracellular codrug concentration 
should be investigated as the codrug is also supposed to be cleaved by cellular esterases. 
6.3.3 Microsomal metabolism and metabolic stability in microsomal 
incubation systems 
Furthermore, stability of the codrug was examined in several microsomal incubation systems 
(see chapter 2.3.4.3). Samples were taken at different time points and subjected to HPLC 
analysis (method C4 chapter 2.3.4.1) for quantification of codrug amount (Figure 6.4). In 
addition, samples (6 h) were analyzed using LC–MS (see chapter 2.3.4.1) in order to 
determine metabolite masses and identify possible metabolites (Figure 6.5). 
 
Figure 6.4: Metabolic stability of the codrug in microsomal incubation systems for phase I 
(Ph I), phase II (Ph II), and combined (Ph I+II) metabolism within 6 h including 
stability controls without microsomes (w/o micr) or without cofactors (w/o cof). 
Initial concentration of the codrug: 25 µM. Concentrations were determined by 
HPLC (method C4). 
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Figure 6.5: HPLC chromatogram of the microsomal incubation assay (6 h samples). a) without 
microsomes, b) without cofactors, c) phase I metabolism, d) phase II metabolism, 
e) combined phase I and II metabolism; λ = 287 nm. Structures were identified via 
LC–ESI-MS. Codrug (C), codrug glucuronides (CG), silibinin (S), silibinin 
glucuronides (SG), tacrine hemi succinamide (THSA). 
As expected from the data acquired under in vitro conditions, the codrug showed good 
stability in the incubation system without microsomes. In the incubation system without 
NADPH and UDPGA no metabolism should take place as CYP reactions and glucuronidation 
cannot be performed without these cofactors/substrates. However, as can be seen from 
Figure 6.4, only half of the initial amount of codrug was detected after 6 h indicating that the 
compound is “metabolized” independently of CYP enzymes and UGTs. The structures 
formed were identified by LC–MS data as silibinin and tacrine hemi succinamide (Figure 
6.5b). This indicates a cleavage of the ester bond by microsomal esterases – as expected 
from the design of the codrug. This ester bond is not cleaved at pH 7.4 in the buffer solution 
in absence of microsomes (Figure 6.4 and Figure 6.5a). In the set-up for phase I reaction the 
same products were detected as described for ester bond hydrolysis. The codrug is cleaved 
into two parts as indicated by the HPLC chromatogram (Figure 6.5c). No other metabolites 
were found by LC–MS. In contrast to known tacrine metabolism, the tacrine part of the 
codrug (the tacrine hemi succinamide) seems not to get hydroxylated anymore. Therefore, 
the compound is glucuronidated extensively. In phase II reactions two MS peaks 
corresponding to glucuronidated codrug molecules, the diglucuronide of the codrug, and 
silibinin glucuronides were identified besides the cleavage products (Figure 6.5d). The same 
compounds were detected in combined phase I and II metabolism (Figure 6.5e), but in higher 
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amounts. After 6 h (Figure 6.4) the codrug was converted completely to its glucuronides, 
silibinin glucuronides and the tacrine hemi succinamide. This reveals the importance of 
having a closer look on the tacrine hemi succinamide (and the codrug-glucuronides) as 
possible active principle of the codrug as it is possibly also formed quickly in vivo. 
According to LC–MS data, a metabolism scheme of the codrug is proposed in Figure 6.6. 
Detailed information about calculated and found substance and metabolite masses can be 
found in chapter 10.3. Table 10.1 supplements the HPLC chromatogram in Figure 6.5. 
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Figure 6.6:  Suggested metabolism scheme of the codrug using human liver microsomes. 
Metabolites were identified in different incubation systems via LC–ESI-MS. 
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6.3.4 Comparative evaluation of the in vitro hepatotoxicity of tacrine, an 
equimolar mixture of tacrine/silibinin, and the codrug 
To evaluate a possible hepatoprotective effect of the codrug and the tacrine/silibinin mixture 
compared to tacrine, the compounds’ effect on human hepatic cell lines was investigated. 
For a first estimation of tacrine’s hepatotoxicity, the influence of tacrine on the viability of 
three liver cell lines (see chapter 2.2.2.3) was determined by MTT assay (see chapter 
2.2.5.1) choosing different incubation times (Table 6.2). 
Table 6.2: Incubation time dependent IC50 values [µM] of tacrine for three different cell lines 
determined from sigmoidal viability curves (MTT assay). MEAN ± SE (n = 3). 
Chosen cell line and incubation period for further testing is highlighted in grey. 
 3 h 6 h 24 h 48 h 72 h 
HuH-7 749 ± 91 264 ± 65 94 ± 2 45 ± 6 37 ± 16 
HepG2 814 ± 126 395 ± 104 64 ± 9 30 ± 3 23 ± 2 
HSC 471 ± 295 179 ± 81 128 ± 29 59 ± 12 25 ± 9 
 
Tacrine showed a time and dose dependent toxicity on HuH-7, HepG2, and HSC. 
Determined IC50 values ranged in comparable concentrations for the three cell lines. At short 
incubation times (3 h and 6 h) HSC prove to be the most sensitive and HepG2 the least 
sensitive; at longer incubation times (24 - 72 h) it was the other way round. The determined 
IC50 values were compared to data from literature (HepG2) [408–411] which were found to 
be in the same concentration ranges. 
All further assays were carried out on HSC as a representative model choosing an incubation 
time of 24 h because of already quite pronounced toxicity of tacrine and best applicable 
experimental setup. 
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Table 6.3: Influence of tacrine (T), an equimolar mixture of tacrine and silibinin (T + S), and 
the codrug (C) on viabilitiy and proliferation of HSC after 24 h incubation. Test 
concentration range 1-200 µM. Concentrations are indicated for significant effects 
(mean ± SD; p < 0.01). 
 MTT CV 
compound concentration 
in µM 
remaining 
viability in % 
concentration 
in µM 
remaining cell 
number in % 
T 10 
25 
50 
75 
100 
200 
77 ± 4 
82 ± 10 
90 ± 5 
81 ± 5 
64 ± 10 
16 ± 15 
- 
- 
- 
75 
100 
200 
- 
- 
- 
81 ± 2 
79 ± 8 
51 ± 3 
T + S 75 
100 
200 
84 ± 6 
64 ± 3 
70 ± 3 
75 
100 
200 
82 ± 3 
74 ± 8 
74 ± 9 
C 200 79 ± 14 no influence 
 
First, the influence of test compounds on cell viability was determined by MTT assay (see 
chapter 2.2.5.1, Table 6.3). For tacrine, significant effects were detected already starting 
from 10 µM. From a concentration of 100 µM, cell viability was strongly affected by tacrine 
(see IC50 128 µM). For the equimolar mixture, significant impact on cell viability was detected 
starting at 75 µM. At 100 µM, cell viability decreased in the same way as for tacrine to 64%. 
At high concentrations (200 µM), silibinin seems to exhibit a protective effect since viability 
was still 70% compared to only 16% for tacrine. The influence of the codrug on cell viability 
remained small and was significant only for the highest concentration tested. 
Following, the compounds’ effect on cell number was investigated by CV staining (see 
chapter 2.2.5.2, Table 6.3). Whereas both tacrine and the equimolar mixture had a significant 
impact on the cell number starting at a concentration of 75 µM, the codrug showed no 
significant toxicity up to 200 µM. 
For a more precise analysis, we applied fluorescence microscopy and examined the 
influence on cell number and mitochondria (see chapter 2.2.6.1, Figure 6.7). Data confirmed 
the results of the crystal violet assay, being even more sensitive. As can be seen in Figure 
6.7A, tacrine decreased the amount of cells already starting at a concentration of 50 µM with 
higher concentrations being more toxic. 
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Figure 6.7: A Comparison of cell numbers determined by fluorescence microscopy after 
treatment of HSC with different concentrations of tacrine, an equimolar mixture of 
tacrine and silibinin, and codrug. B Fluorescence intensity of mitochondria after 
treatment of HSC with different concentrations of tacrine, an equimolar mixture of 
tacrine and silibinin, and codrug. Data were subjected to one-way ANOVA followed 
by Tukey’s multiple comparison post-hoc test using GraphPad Prism 4 Software 
(Levels of significance * p < 0.05; ** p < 0.01; *** p < 0.001). 
An interesting observation can be made when the influence of the codrug is compared with 
the tacrine/silibinin mixture (Figure 6.7A): Statistically significant differences were observed 
from a concentration of only 25 µM. The mixture shows lower cell viability and therefore 
higher cytotoxicity than the codrug. At concentrations where tacrine is toxic, also the mixture 
exhibits toxicity. Therefore, the codrug is greatly superior to the equimolar mixture in being 
non-toxic even at the highest concentration tested. 
Additionally, we investigated the impact of the compounds on the mitochondria of HSC, as 
mitochondrial dysfunction is an important mechanism of hepatotoxicity [412] and is discussed 
to be involved in tacrine-induced liver toxicity [413]. One possible mechanism is the onset of 
mitochondrial permeability transition caused by opening of permeability transition pores in 
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the inner mitochondrial membrane. This pore opening causes mitochondrial depolarization, 
uncoupling, and large amplitude swelling and can lead to both necrotic and apoptotic cell 
death [321,414]. For mitochondrial analysis, mitochondria were stained after the treatment of 
cells with different concentrations of tacrine, tacrine/silibinin, and codrug, respectively, with a 
mitochondria specific dye that followed the determination of mitochondrial fluorescence 
intensity (figure 6.7B). 
Mitochondrial fluorescence intensity dramatically increases after the treatment of cells with 
50 µM tacrine to a value of 220% of the control. This increase in fluorescence intensity 
indicates a swelling of mitochondria and therefore mitochondrial dysfunction which can lead 
to necrotic or apoptotic cell death. This effect is significantly lower for the tacrine/silibinin 
mixture at 50 and 75 µM. The codrug shows the same effect as the mixture at these 
concentrations. In terms of hepatotoxicity indicated by increased mitochondrial fluorescence 
intensity in HSC, both the physical mixture and the codrug show greatly decreased toxicity 
compared to tacrine. Regarding the effect of the codrug at 25 µM, both tacrine and the 
tacrine/silibinin mixture show significantly higher fluorescence intensity, again indicating a 
superior effect of the codrug over the physical mixture of compounds. 
Hepatotoxicity of tacrine and hepatoprotective activity of silibinin has been demonstrated 
before on HepG2 cells [415]. Our studies revealed also pronounced cyto- and mitotoxicity of 
tacrine on HSC. The mitotoxic effect is significantly lower for both the physical mixture of 
tacrine/silibinin and the codrug. Already at lower concentrations, the codrug’s cytoprotective 
effect is more pronounced than that one of the mixture. Here the mixture was only 
moderately superior to tacrine’s toxicity, whereas the codrug did not show any toxicity even 
at the highest concentration tested. 
6.3.5 In vitro hepatotoxicity of the codrug’s primary metabolites 
In the previous chapter 6.3.4, the in vitro hepatotoxicity of tacrine was compared to an 
equimolar mixture of tacrine and silibinin and the codrug respectively. 
The pronounced hepatotoxicity of tacrine has been shown before on several cell lines 
[407,416,417] and correlates well with our findings. In contrast, for the codrug, hepatotoxic 
effects were completely absent both in vitro and in vivo [100].  
The codrug showed to be stable under in vitro assay conditions but is likely cleaved and 
metabolized quickly in vivo. Consequently, the effect of the codrug metabolites tacrine hemi 
succinamide and silibinin on viability, cell number, and mitochondria of HSC was examined in 
the same way. 
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Table 6.4: Influence of tacrine hemi succinamide (THSA), silibinin (S), and an equimolar 
mixture of tacrine hemi succinamide and silibinin (THSA + S) on viability and 
proliferation of HSC. Test concentration range 10-200 µM. Concentrations are 
indicated for significant effects (mean ± SD). 
 MTT CV 
compound concentration 
in µM 
remaining 
viability in % 
concentration 
in µM 
remaining cell 
number in % 
THSA no influence no influence 
S no influence no influence 
THSA + S 200 77 ± 7 no influence 
 
Viability of the cells was investigated by MTT assay (see chapter 2.2.5.1, Table 6.4). For the 
tacrine hemi succinamide and silibinin no influence on viability of HSC was detected. For the 
mixture of tacrine hemi succinamide and silibinin viability slightly decreased at 200 µM. In 
comparison, tacrine affected cell viability already at 10 µM and caused a decrease down to 
16% at 200 µM.  
The influence of the compounds on the cell number was determined by CV staining (see 
chapter 2.2.5.2, Table 6.4). Comparable to the results of the codrug, there was no significant 
impact on the cell number within the highest concentration tested (200 µM). In contrast, 
tacrine exhibited a concentration dependent toxicity starting at 75 µM (Table 6.3). 
 
Additionally, the effect of the codrug metabolites on cell number was analyzed by 
fluorescence microscopy applying Hoechst staining and counting cell nuclei (see chapter 
2.2.6.1, Figure 6.8A). The number of cells remained unaffected by the compounds up to 
75 µM whereas tacrine decreased the cell number already starting at a concentration of 
50 µM (Figure 6.7A). 
The influence of the compounds on mitochondria was investigated as mitochondrial 
impairment such as alterations in mitochondrial membrane potential can cause lethal cell 
death [414]. The mechanism of tacrine’s toxicity is not yet fully investigated. However, a 
possible role of mitochondrial dysfunction and uncoupling is discussed in literature 
[413,416,418,419]. With respect to these findings, tacrine showed a significant increase in 
fluorescence intensity of mitochondria already at low concentrations (25 µM) where it did not 
affect cell number yet (Figure 6.7B). While the influence on mitochondria already was 
significantly less pronounced for the codrug (Figure 6.7B), mitotoxicity was completely 
absent for tacrine hemi succinamide and silibinin in the tested concentration range (Figure 
6.8B). Only the mixture of tacrine hemi succinamide and silibinin slightly decreased 
mitochondrial fluorescence intensity at a concentration of 75 µM (Figure 6.8B). 
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Figure 6.8: In vitro hepatotoxicity of the codrug’s cleavage product tacrine hemi succinamide 
(THSA), silibinin (S), and equimolar mixture of THSA and silibinin (THSA + S) on 
HSC. A Cell number determined by fluorescence microscopy. B Fluorescence 
intensity of mitochondria. Untreated cells (ctl) were set as 100% values. Data are 
shown as mean ± SD. Statistical analysis was performed by one-way ANOVA 
followed by Dunnett’s multiple comparison post-hoc test. **p < 0.01 vs. ctl. 
In summary, there was no detectable in vitro hepatotoxicity of tacrine hemi succinamide and 
silibinin, which might both be the primary metabolites of the codrug in vivo. The results also 
support and complete the already published findings of codrug’s lacking hepatotoxicity in 
vivo. There probably would have been detectable hepatotoxic effects in vivo if the 
metabolites of the codrug exerted any toxicity. 
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6.4 Conclusion 
In this study, the in vitro stability, hepatotoxicity, and metabolism of a tacrine-silibinin codrug 
with pro-cognitive effects was investigated. The results of the degradation assay implicate a 
good stability of the codrug in the incubation medium. However, in a microsomal incubation 
assay using HLM the codrug was rapidly cleaved and extensively metabolized into tacrine 
hemi succinamide and codrug- and silibininglucuronides. These findings have to be 
considered for evaluation of the in vivo results respectively the in vivo hepatotoxicity and 
behavioural studies. The data point out the role of the cleavage products especially the 
tacrine hemi succinamide as possible active principle in vivo. Indeed, the tacrine hemi 
succinamide showed also inhibition of AChE (IC50 = 101.9 nM) [100]. In further studies, the 
knowledge of microsomal metabolites can provide valuable hints for identification of 
metabolites in serum or tissue samples (e.g. liver, brain). 
In a comparative evaluation of hepatotoxic effects on HSC, the physical mixture of tacrine 
and silibinin did not exhibit a significant improvement over tacrine regarding cell number 
whereas the codrug lacked cytotoxicity even at high concentrations. Both the codrug and the 
mixture, however, decreased mitochondrial fluorescence intensity compared to tacrine 
indicating a less pronounced mitotoxicity. Noteworthy, the in vivo hepatotoxicity testing in rats 
confirmed the in vitro hepatotoxicity findings showing a good predictability of the in vitro 
assay system in this case. Additionally, the in vitro hepatotoxicity testing revealed also the 
absence of any toxic effects of the codrug’s cleavage products. This is again an advantage 
over tacrine whose protein-reactive metabolites, as it is known to date, exhibit harmful 
effects. 
Taken together, the tacrine-silibinin codrug as well as its cleavage products lacked tacrine’s 
therapy-limiting hepatotoxic effects. The stability studies help to understand and interpret the 
previous results and supply important information for further studies to finally identify the 
active principle of the codrug also in vivo. Whether the low in vitro hepatotoxicity of the 
metabolite tacrine hemi succinamide can explain the codrug’s absence of hepatotoxicity in 
vivo or to which extent the silibinin part of the codrug actually contributes to the overall in vivo 
effects cannot be answered yet. 
 
 7 Summary 
(1) Kava kava, traditionally used by the Pacific Islanders as a socio-ceremonial beverage and 
remedy, was approved as an anxiolytic drug in Western countries. However, the reports of 
severe hepatotoxic side effects led to the withdrawal of kava-containing products in most of 
these countries. Since then, responsible constituents and possible mechanisms of 
hepatotoxicity are controversially discussed. 
To evaluate the hepatotoxic potential of single compounds, six kavalactones were isolated 
from an acetonic kava root extract and the three kava-chalcones (flavokawains) were 
obtained by synthesis. Subsequently, these major and minor constituents were tested 
towards their effects on cell viability and proliferation of human hepatoma cell lines. Whereas 
the toxicity of five tested kavalactones was found to be very low (K, M, DMY) or completely 
absent (DHK, DHM), distinct effects on both cell viability and proliferation were observed for 
the kavalactone Y and the kava-chalcones, FKB being the most toxic (IC50 ~ 30 µM on 
HepG2 and IC50 ~ 40 µM on HuH-7) of the test compounds.  
The results of this study suggest that the flavokawains might contribute to the hepatotoxic 
potential of kava. Based on obtained in vitro toxicity data, further testing of long-term toxicity 
of Y and flavokawains is recommended preferably on primary human hepatocytes or in vivo 
in a suitable animal model. 
 
(2) Therapy options for the treatment of Alzheimer’s disease are still constricted to a few 
approved drugs. Facing the therapy limiting hepatotoxic side effects of tacrine in a new 
approach, a tacrine-silibinin codrug was synthesized that showed promising pharmacological 
properties such as AChE and BChE inhibitory activity in vitro and pro-cognitive effects in vivo 
in rats. 
Driven by these promising results, the in vitro hepatotoxic potential of the codrug was 
assessed and compared to tacrine and an equimolar mixture of tacrine and silibinin. 
Therefore, the compounds’ effects on cell number and fluorescence intensity of mitochondria 
of hepatic stellate cells were investigated. For both, the codrug and the physical mixture, 
reduced mitotoxicity compared to tacrine was observed. Additionally, the codrug did not 
show any influence on the cell number up to concentrations of 200 µM. The results 
correlated well with the findings of the in vivo hepatotoxicity studies in rats. Furthermore, to 
find first hints of the active principle of the codrug, in vitro stability and microsomal 
metabolism studies were performed. In the presence of microsomes, the codrug was rapidly 
cleaved by esterases into tacrine hemi succinamide and silibinin. In phase II metabolism, 
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codrug- and silibininglucuronides were detected. As these metabolites are likely also formed 
in vivo, they may constitute the active principles of the codrug. Indeed the tacrine hemi 
succinamide showed pronounced AChE inhibition. Noteworthy, for the codrug cleavage 
products tacrine hemi succinamide and silibinin, toxicity in the in vitro HSC model was 
completely absent. 
 
(3) Chalcones possess an interesting pharmacological profile for the treatment of hepatic 
fibrosis, as they comprise several favorable biological activities such as anti-inflammatory, 
anti-oxidant, antiviral, and apoptosis-inducing effects. The activation and the perpetuation of 
this activiation of hepatic stellate cells are considered as the key steps in the pathogenesis of 
liver fibrosis. Hence, the inhibitory activity of structurally related prenylated and non-
prenylated chalcones on activated human hepatic stellate cells was investigated.  
With exception of the dihydrochalcones, P, and 3OHHeli, the investigated chalcones had a 
significant impact on cell viability, proliferation, cell organelles, and cytochrome c release. For 
the metabolites 4’AcXAN, XANC, and dhXANC, similar activities were found as for the 
parent compound XAN whereas 4MeXAN and XANH behaved differently. The induction of 
apoptosis via mitochondrial pathways is suggested as the test chalcones provoked a release 
of cytochrome c together with altered fluorescence intensity of mitochondria at low 
concentrations of 10 µM. Several structure elements were identified which enhance or 
attenuate the activity of chalcones. The double bond in α,β position was essential for the 
activity. The unprotected hydroxyl group in position C-6’ led to a complete loss of activity in 
case of P. Prenylation of C-3’ and methoxy-groups in the A ring enhanced the activity 
whereas substituents in the B ring mostly attenuated the chalcones’ effects. 4’MeXAN, A, 
and FKB showed the strongest inhibitory effects on HSC. Based on the findings of this study, 
the most effective chalcones may be chosen to investigate the mechanisms on the molecular 
level. In addition, toxicity studies on primary human hepatocytes are needed. 
 
(4) For studying the in vitro metabolism of flavokawains and alpinetin chalcone, different 
microsomal incubation systems were established. LC–HRESIMS was applied to identify 
phase I and II metabolites and to compile a metabolic profile for these compounds. Obtained 
data can be used to predict the in vivo metabolism and provide first information about main 
biotransformation pathways.  
Demethylation (C-4, C-4’) and hydroxylation (mainly C-4) constitute the major phase I 
reactions in flavokawain and A metabolism. FKC is generated as major metabolite of both 
FKA by demethylation and FKB by hydroxylation in position C-4. Heli is formed as major 
metabolite of FKC and A after demethylation in position C-4’ and hydroxylation of C-4 
respectively. In phase II metabolism, extensive conjugation to glucuronic acid was observed. 
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In combined metabolism, the conjugated metabolites clearly predominated also. 
Glucuronidation of the parent chalcones is consequently considered as major reaction in the 
microsomal metabolism of investigated chalcones. The structures of major flavokawain-
glucuronides were additionally elucidated using HPLC–NMR techniques. According to the 
results of this study, the chalcone monoglucuronides may constitute the major metabolites in 
vivo. It is not known if these metabolites contribute to pharmacological activities of 
chalcones. Regarding the observed in vitro hepatotoxicity of flavokawains, the 
biotransformation may also constitute a detoxifying reaction. 
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 9 Abbreviations 
3OHHeli  3-hydroxyhelichrysetin 
3OHXANH 3-hydroxyxanthohumol H 
3OMeXANH 3-methoxyxanthohumol H 
4’MeXAN 4‘-methylxanthohumol 
4AcXAN  4-acetylxanthohumol 
4MeXAN 4-methylxanthohumol 
5-HT  5-hydroxytryptamine (serotonin) 
7-EC  7-ethoxycoumarin 
7-HC  7-hydroxycoumarin 
A  alpinetin chalcone 
AA  anisaldehyde 
AChE  acetylcholinesterase 
AD  Alzheimer’s disease 
Ala  alamethicin 
ALP  alkaline phosphatase 
ALT  alanine amino transferase 
AP-1  activator protein 1 
Apaf-1  apoptotic protease-activating factor 1 
ASI  Anxiety Status Inventory 
AST  aspartate amino transferase 
ATCC  American Type Culture Collection 
ATP adenosine triphosphate 
BChE  butyrylcholinesterase 
Bcl-2  B-cell lymphoma 2 protein family 
BfArM  Bundesinstitut für Arzneimittel und Medizinprodukte 
BSβG  broad-specific β-glucosidase 
C  tacrine-silibinin codrug 
CB  cannabinoid 
CDK/Cdk  cyclin-dependent kinase 
Ch  channel 
CHOP  CCAAT/enhancer binding protein homologous protein 
CM  culture medium 
Cmax  maximum (peak) concentration 
CNS  central nervous system 
178 9 Abbreviations 
cof  cofactors 
COMT  catechol-O-methyltransferase 
conc.  concentrated 
COSY  correlation spectroscopy 
COX  cyclooxygenase 
ctl  control 
CV  crystal violet 
CYP(450)  cytochrome P450 enzyme 
DAC  Deutscher Arzneimittel Codex 
DAD  diode array detector 
dhFKC  dihydroflavokawain C 
dhHeli  dihydrohelichrysetin 
DHK  dihydrokawain 
DHM  dihydromethysticin 
dhXANC  dihydroxanthohumol C 
DILI  drug induced liver injury 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  dimethyl sulfoxide 
DMY  desmethoxyyangonin 
DNA  deoxyribonucleic acid 
DPPH  2,2-diphenyl-1-picrylhydrazyl 
DR  death receptor 
EC50  half maximal effective concentration 
ECM  extracellular matrix 
EDTA  ethylenediaminetetraacetic acid 
ER  endoplasmic reticulum 
ERK  extracellular signal-regulated kinase 
ESI  electrospray ionization 
ET-1  endothelin-1 
EtOAc  ethyl acetate 
EtOH  ethanol 
ex/em  excitation/emission 
FA  formic acid 
FasL  Fas-ligand 
FCS  fetal calf serum 
FDA  Food and Drug Administration 
FKA  flavokawain A 
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FKB  flavokawain B 
FKC  flavokawain C 
FMO  flavin monooxygenase 
G-6-P  glucose-6-phosphate 
G-6-P-DH  glucose-6-phosphate dehydrogenase 
GABA  γ-aminobutyric acid 
GADD  growth arrest and DNA-damage-inducible proteins 
GF  germ-free 
GGT  glutamyl transpeptidase 
GIT  gastrointestinal tract 
Glu  glucuronic acid 
GSH  glutathione 
GST  glutathione-S-transferase 
HAM-A  Hamilton Anxiety Scale 
HAV  hepatitis A virus 
HBsAg  hepatitis B surface antigen 
HBV  hepatitis B virus 
HCA  high content analysis 
HCC  hepatocellular carcinoma 
HCV  hepatitis C virus 
HDAC  histone deacetylase 
Heli helichrysetin 
hi  heat inactivated 
HLM  human liver microsomes 
HMA  human microbiota-associated 
HMBC  heteronuclear multiple bond correlation 
HO-1  heme oxygenase 1 
HPLC  high pressure liquid chromatography 
HPLC–NMR  high pressure liquid chromatography–nuclear magnetic 
resonance spectroscopy 
HPTLC  high performance thin layer chromatography 
HSC  hepatic stellate cells 
HSQC heteronuclear single quantum coherence 
HSRRB  Health Science Research Resources Bank 
HSYA  hydroxysafflor yellow A 
IC50  half maximal inhibitory concentration 
ICAM  intercellular adhesion molecule 
180 9 Abbreviations 
IgG  immunglobuline G 
IKK IκB kinase 
IL  interleukin 
INF  interferon 
iNOS  inducible NO synthase 
IκB  inhibitor of NF-kappaB 
JHSF  Japan Health Science Research Resources Bank 
JNK  c-Jun N-terminal kinase 
K  kawain 
LC–HRESIMS  liquid chromatography–high resolution electrospray ionization 
mass spectrometry 
LC–MS  liquid chromatography–mass spectrometry 
LDH  lactate dehydrogenase 
LPH  lactase phlorizidin hydrolase 
LPS  lipopolysaccharide 
M  methysticin 
MAO  monoamine oxidase 
MAPK  mitogen-activated kinase 
matrix  blank control 
MeCN  acetonitrile 
MEF  myocyte enhancer factor 
MeOH  methanol 
micr  microsomes 
MMP  matrix metalloproteinase 
MPLC  middle pressure liquid chromatography 
mRNA  messenger ribonucleic acid 
MRP2  multidurg resistance-associated protein 2 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NA  noradrenaline 
NADP(H)  (reduced) nicotinamide adenine dinucleotide phosphate 
NAFLD  non-alcoholic fatty liver disease 
NASH  non-alcoholic steatohepatitis 
NAT  N-acetyltransferase 
NEA  non-essential amino acids 
NF-κB  nuclear factor κB 
NMDA  N-methyl-D-aspartate 
NMR  nuclear magnetic resonance (spectroscopy) 
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Nrf2  nuclear factor (erythroid-derived 2)-like 2 
NSAID  non-steroidal anti-inflammatory drug 
ORAC  oxygen radical absorbance capacity 
P  pinostrobin chalcone 
p.a.  pro analysi 
PA  pyrrolizidine alkaloids 
PARP  poly(ADP-ribose)polymerase 
PBO  trans-4-phenyl-3-buten-2-one 
PBS  Dulbecco’s Phosphate Buffered Saline 
PDGF  platelet derived growth factor 
PFA  paraformaldehyde 
PGE2  prostaglandin E2 
Pgp  P-glycoprotein 
PHH  primary human hepatocytes 
PhI  phase I 
PhII  phase II 
PT  prothrombin time 
Rf  retention factor 
ROS  reactive oxygen species 
Rt  retention time 
S  silibinin 
SAR  structure activity relationship 
SD  standard deviation 
SDS  sodium dodecyl sulfate 
SE  standard error 
SGLT1  sodium-dependent glucose transporter 1 
SNMC  stronger neo-minophagen C 
SP  sodium pyruvate 
stabi  stability control 
stock  stock solution 
SULT  sulfotransferase 
T  tacrine 
T3  triiodothyronine 
T4  thyroxine 
TCM  Traditional Chinese Medicine 
TFA  trifluoroacetic acid 
TGF-β  transforming growth factor β 
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THSA  tacrine hemi succinamide 
thXANC tetrahydroxanthohumol C 
TIMP  tissue inhibitor of metalloproteinases 
TLC  thin layer chromatography 
tmax  time to peak concentration 
TMMC  2’,4’,6’-tris(methoxymethoxy)chalcone 
TMS tetramethylsilane 
TNF  tumor necrosis factor 
TOF  time of flight 
TRAIL  TNF-related apoptosis inducing ligand 
TxB2  thromboxane B2 
UDPGA  uridine 5’-diphosphoglucuronic acid 
UGT  UDP-glucuronosyl transferase 
UHPLC ultra high pressure liquid chromatography 
US  United States 
UV  ultraviolet 
VOD  venoocclusive disease 
WHO  World Health Organization 
XAN  xanthohumol 
XANC xanthohumol C 
XANH xanthohumol H 
Y  yangonin 
α-SMA  alpha smooth muscle actin 
 
 10 Appendix 
10.1 Supplementary HCA data of the chalcones 
Figure 10.1: Supplementary HCA data of alpinetin chalcone (A) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.2: Supplementary HCA data of pinostrobin chalcone (P) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.3: Supplementary HCA data of flavokawain A (FKA) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.4: Supplementary HCA data of flavokawain B (FKB) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.5: Supplementary HCA data of flavokawain C (FKC) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.6: Supplementary HCA data of dihydroflavokawain C (dhFKC) (1-50 µM). Cell number 
[%], nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.7: Supplementary HCA data of helichrysetin (Heli) (1-50 µM). Cell number [%], nucleus 
area, actin area, and mitochondrial fluorescence intensity [%] were determined by 
fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c release [%] was 
analyzed by fluorescence microscopy (see chapter 2.2.6.2). Hoechst33342 staining 
of cell nuclei was used to determine the DNA content (see chapter 2.2.6.3) and to 
calculate the ratio 2N/4N. Values are presented as mean ± SD and refer to untreated 
control cells (ctl/n.ctl). Statistical analysis (one-way ANOVA following Dunnett’s 
multi-comparison post-hoc test) was performed using GraphPad Prism 4 software. 
Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.8: Supplementary HCA data of dihydrohelichrysetin (dhHeli) (1-50 µM). Cell number 
[%], nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.9: Supplementary HCA data of 3-hydroxyhelichrysetin (3OHHeli) (1-50 µM). Cell 
number [%], nucleus area, actin area, and mitochondrial fluorescence intensity [%] 
were determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content (see 
chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as mean ± 
SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis (one-way 
ANOVA following Dunnett’s multi-comparison post-hoc test) was performed using 
GraphPad Prism 4 software. Levels of significance *p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.10: Supplementary HCA data of xanthohumol (XAN) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content 
(see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as 
mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis 
(one-way ANOVA following Dunnett’s multi-comparison post-hoc test) was 
performed using GraphPad Prism 4 software. Levels of significance *p < 0.05, 
**p < 0.01 vs ctl/n.ctl. 
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Figure 10.11: Supplementary HCA data of 4-acetylxanthohumol (4AcXAN) (1-50 µM). Cell 
number [%], nucleus area, actin area, and mitochondrial fluorescence intensity 
[%] were determined by fluorescence microscopy (see chapter 2.2.6.1). 
Cytochrome c release [%] was analyzed by fluorescence microscopy (see 
chapter 2.2.6.2). Hoechst33342 staining of cell nuclei was used to determine the 
DNA content (see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are 
presented as mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical 
analysis (one-way ANOVA following Dunnett’s multi-comparison post-hoc test) 
was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.12: Supplementary HCA data of 4-methylxanthohumol (4MeXAN) (1-50 µM). Cell 
number [%], nucleus area, actin area, and mitochondrial fluorescence intensity 
[%] were determined by fluorescence microscopy (see chapter 2.2.6.1). 
Cytochrome c release [%] was analyzed by fluorescence microscopy (see 
chapter 2.2.6.2). Hoechst33342 staining of cell nuclei was used to determine the 
DNA content (see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are 
presented as mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical 
analysis (one-way ANOVA following Dunnett’s multi-comparison post-hoc test) 
was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.13: Supplementary HCA data of 4’-methylxanthohumol (4’MeXAN) (1-50 µM). Cell 
number [%], nucleus area, actin area, and mitochondrial fluorescence intensity 
[%] were determined by fluorescence microscopy (see chapter 2.2.6.1). 
Cytochrome c release [%] was analyzed by fluorescence microscopy (see 
chapter 2.2.6.2). Hoechst33342 staining of cell nuclei was used to determine the 
DNA content (see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are 
presented as mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical 
analysis (one-way ANOVA following Dunnett’s multi-comparison post-hoc test) 
was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.14: Supplementary HCA data of xanthohumol H (XANH) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content 
(see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as 
mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis 
(one-way ANOVA following Dunnett’s multi-comparison post-hoc test) was 
performed using GraphPad Prism 4 software. Levels of significance *p < 0.05, 
**p < 0.01 vs ctl/n.ctl. 
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Figure 10.15: Supplementary HCA data of 3-hydroxyxanthohumol H (3OHXANH) (1-50 µM). 
Cell number [%], nucleus area, actin area, and mitochondrial fluorescence 
intensity [%] were determined by fluorescence microscopy (see chapter 2.2.6.1). 
Cytochrome c release [%] was analyzed by fluorescence microscopy (see 
chapter 2.2.6.2). Hoechst33342 staining of cell nuclei was used to determine the 
DNA content (see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are 
presented as mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical 
analysis (one-way ANOVA following Dunnett’s multi-comparison post-hoc test) 
was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.16: Supplementary HCA data of 3-methoxyxanthohumol H (3OMeXANH) (1-50 µM). 
Cell number [%], nucleus area, actin area, and mitochondrial fluorescence 
intensity [%] were determined by fluorescence microscopy (see chapter 2.2.6.1). 
Cytochrome c release [%] was analyzed by fluorescence microscopy (see 
chapter 2.2.6.2). Hoechst33342 staining of cell nuclei was used to determine the 
DNA content (see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are 
presented as mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical 
analysis (one-way ANOVA following Dunnett’s multi-comparison post-hoc test) 
was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.17: Supplementary HCA data of xanthohumol C (XANC) (1-50 µM). Cell number [%], 
nucleus area, actin area, and mitochondrial fluorescence intensity [%] were 
determined by fluorescence microscopy (see chapter 2.2.6.1). Cytochrome c 
release [%] was analyzed by fluorescence microscopy (see chapter 2.2.6.2). 
Hoechst33342 staining of cell nuclei was used to determine the DNA content 
(see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are presented as 
mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical analysis 
(one-way ANOVA following Dunnett’s multi-comparison post-hoc test) was 
performed using GraphPad Prism 4 software. Levels of significance *p < 0.05, 
**p < 0.01 vs ctl/n.ctl. 
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Figure 10.18: Supplementary HCA data of dihydroxanthohumol C (dhXANC) (1-50 µM). Cell 
number [%], nucleus area, actin area, and mitochondrial fluorescence intensity 
[%] were determined by fluorescence microscopy (see chapter 2.2.6.1). 
Cytochrome c release [%] was analyzed by fluorescence microscopy (see 
chapter 2.2.6.2). Hoechst33342 staining of cell nuclei was used to determine the 
DNA content (see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are 
presented as mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical 
analysis (one-way ANOVA following Dunnett’s multi-comparison post-hoc test) 
was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs ctl/n.ctl. 
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Figure 10.19: Supplementary HCA data of tetrahydroxanthohumol C (thXANC) (1-50 µM). Cell 
number [%], nucleus area, actin area, and mitochondrial fluorescence intensity 
[%] were determined by fluorescence microscopy (see chapter 2.2.6.1). 
Cytochrome c release [%] was analyzed by fluorescence microscopy (see 
chapter 2.2.6.2). Hoechst33342 staining of cell nuclei was used to determine the 
DNA content (see chapter 2.2.6.3) and to calculate the ratio 2N/4N. Values are 
presented as mean ± SD and refer to untreated control cells (ctl/n.ctl). Statistical 
analysis (one-way ANOVA following Dunnett’s multi-comparison post-hoc test) 
was performed using GraphPad Prism 4 software. Levels of significance 
*p < 0.05, **p < 0.01 vs ctl/n.ctl. 
 
 
cell number
ctl 1 10 25 50
0
20
40
60
80
100
120
140
c [µM]
[%
]
nucleus area
ctl 1 10 25 50
0.0
0.5
1.0
1.5
*
c [µM]
actin area
ctl 1 10 25 50
0.0
0.5
1.0
1.5
2.0
c [µM]
DNA
ctl 1 10 25 50
0
1
2
3
4
5
6
*
c [µM]
2
N
/4
N
mito fluorescence intensity
ctl 1 10 25 50
0
20
40
60
80
100
120
140
160
**
**
**
**
c [µM]
[%
]
cytochrome c
p.ctl n.ctl 10 25 50
-20
0
20
40
60
80
100
120
**
**
c [µM]
[%
]
Tetrahydroxanthohumol C
202 10 Appendix 
10.2 Mass spectra of chalcone metabolites 
FKA 
10.2 Mass spectra of chalcone metabolites 203 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
h
 I 
P
h
 II 
204 10 Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
h
 II 
P
h
 I+
II 
10.2 Mass spectra of chalcone metabolites 205 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
h
 I+
II 
P
h
 I+
II 
206 10 Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
h
 I+
II 
P
h
 I+
II 
10.2 Mass spectra of chalcone metabolites 207 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.20:  Mass spectra of FKA and FKA metabolites corresponding to Table 5.4. 
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Figure 10.21:  Mass spectra of FKB and FKB metabolites corresponding to Table 5.5. 
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Figure 10.22:  Mass spectra of FKC and FKC metabolites corresponding to Table 5.6. 
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Figure 10.23:  Mass spectra of A and A metabolites corresponding to Table 5.7. 
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10.3 Supplementary table of the codrug metabolites 
Table 10.1: Detailed information about calculated (calc m/z [M-H]
-
) and actual found (m/z [M-H]
-
) 
substance and metabolite masses in the different incubation systems. Data in the 
table complement HPLC chromatograms of Figure 6.5.  
incubation 
system 
m/z 
[M-H]- 
base formula 
[M] 
calc m/z 
[M-H]- 
compounds/ 
metabolites 
a) w/o micr 860.3404 C48H51N3O12 860.3400 codrug 
b) w/o cof 860.3402 
481.1144 
396.2295 
C48H51N3O12 
C25H22O10 
C23H31N3O3 
860.3400 
481.1140 
396.2293 
codrug 
silibinin 
tacrine hemi succinamide 
c) Ph I 860.3401 
481.1143 
396.2295 
C48H51N3O12 
C25H22O10 
C23H31N3O3 
860.3400 
481.1140 
396.2293 
codrug 
silibinin 
tacrine hemi succinamide 
d) Ph II 860.3404 
1036.3720 
1036.3721 
481.1142 
1212.4029 
396.2296 
657.1465 
657.1463 
C48H51N3O12 
C54H59N3O18 
C54H59N3O18 
C25H22O10 
C60H67N3O24 
C23H31N3O3 
C31H30O16 
C31H30O16 
860.3400 
1036.3721 
1036.3721 
481.1140 
1212.4042 
396.2293 
657.1461 
657.1461 
codrug 
codrug glucuronide 
codrug glucuronide 
silibinin 
codrug diglucuronide 
tacrine hemi succinamide 
silibinin glucuronide 
silibinin glucuronide 
e) Ph I+II 1036.3716 
1036.3722 
481.1141 
1212.403 
396.2295 
657.1463 
657.1467 
C54H59N3O18 
C54H59N3O18 
C25H22O10 
C60H67N3O24 
C23H31N3O3 
C31H30O16 
C31H30O16 
1036.3721 
1036.3721 
481.1140 
1212.4042 
396.2293 
657.1461 
657.1461 
codrug glucuronide 
codrug glucuronide 
silibinin 
codrug diglucuronide 
tacrine hemi succinamide 
silibinin glucuronide 
silibinin glucuronide 
 
 
 
 
 
 
 
 
 
 
 
228 10 Appendix 
10.4 List of publications 
Poster presentations and conference abstracts 
Zenger, K., Kraus, B., Untersuchung der zyto- und mitotoxischen Wirkung von Xanthohumol 
und Strukturderivaten auf hepatische Sternzellen, 2012, Phytotherapeutika, May 17-19, Wien 
(Austria) 
Hild, W., Zenger, K., Rose, C., Hezinger, A., Tessmar, J., Goepferich, A., 2008, Towards the 
optimization of quantum dot preparation for use in biological systems, 2008, NaNaX 3, May 
21-23, Lecce (Italy) 
Hild, W., Zenger, K., Caporale, A., Cabrele, C., Breunig, M., Teßmar, J., und Göpferich, A., 
2008, Towards peptide-modified nanocrystals for drug targeting applications, Controlled 
Release Society, Local Chapter, Braunschweig (Germany) 
 
Publications 
Wolff, H., Zenger, K., Kraus, B., Progress in live-cell imaging and screening applications 
using Definite Focus, 2009, BioTechniques, 47 (5), pp. 976–978 
Chen, X., Zenger, K., Lupp, A., Kling, B., Heilmann, J., Fleck, C., Kraus, B., Decker, M., 
Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive 
and hepatoprotective effects in vivo, 2012, Journal of Medicinal Chemistry, 55 (11), pp. 
5231–5242 
Zenger, K., Chen, X., Decker, M., Kraus, B., In vitro stability and metabolism of a tacrine-
silibinin codrug, 2013, Journal of Pharmacy and Pharmacology, accepted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.5 Curriculum Vitae 229 
10.5 Curriculum Vitae 
Name Katharina Julia Zenger 
Geburtsdatum 7. März 1983 
Geburtsort Heidenheim a. d. Brenz 
Saatsangehörigkeit deutsch 
 
09/89 bis 08/93 Volksschule Duggendorf 
09/93 bis 06/02 Johann-Michael-Fischer Gymnasium, Burglengenfeld 
06/02 Erwerb der allgemeinen Hochschulreife 
10/02 bis 04/07 Studium der Pharmazie an der Universität Regensburg 
04/05 Erster Abschnitt der Pharmazeutischen Prüfung 
09/05 bis 02/06 Forschungsaufenthalt am Lehrstuhl Pharmacotechnie Industrielle, 
Université de Lille 2 (Frankreich) 
04/07 Zweiter Abschnitt der Pharmazeutischen Prüfung 
05/07 bis 10/07 Pharmaziepraktikantin in der Wolfgang Apotheke, Regensburg 
11/07 bis 04/08 Pharmaziepraktikantin am Lehrstuhl Pharmazeutische Technologie, 
Universität Regensburg 
 Dritter Abschnitt der Pharmazeutischen Prüfung 
 Approbation als Apothekerin 
08/08 bis 01/09 Anstellung als Apothekerin in der Wolfgang Apotheke, Regensburg 
02/09 bis 02/13 Promotion am Lehrstuhl Pharmazeutische Biologie, Universität 
Regensburg 
 
